|
G |
ABAT |
4-aminobutyrate aminotransferase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ABAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575
|
|
G |
ABCA5 |
ATP binding cassette subfamily A member 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA panobinostat results in decreased expression of ABCA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:69,244,311...69,327,133
Ensembl chr17:69,244,311...69,327,244
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABHD14A |
abhydrolase domain containing 14A |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ABHD14A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:51,975,064...51,981,196
Ensembl chr 3:51,971,426...51,981,196
|
|
G |
ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:130,713,043...130,887,675
Ensembl chr 9:130,713,043...130,887,675
|
|
G |
AC024940.1 |
ovostatin 2 |
decreases expression |
EXP |
Panobinostat results in decreased expression of OVOS2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:31,111,652...31,201,235
Ensembl chr12:31,111,652...31,201,235
|
|
G |
ACAD11 |
acyl-CoA dehydrogenase family member 11 |
increases expression |
EXP |
panobinostat results in increased expression of ACAD11 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:132,558,141...132,659,809
Ensembl chr 3:132,558,138...132,660,082
|
|
G |
ACKR3 |
atypical chemokine receptor 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ACKR3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:236,537,122...236,582,354
Ensembl chr 2:236,567,787...236,582,354
|
|
G |
ACP3 |
acid phosphatase 3 |
increases expression multiple interactions |
EXP |
Panobinostat results in increased expression of ACP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:132,317,407...132,368,302
Ensembl chr 3:132,317,369...132,368,302
|
|
G |
ACSL1 |
acyl-CoA synthetase long chain family member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA panobinostat results in increased expression of ACSL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
|
|
G |
ACSM3 |
acyl-CoA synthetase medium chain family member 3 |
increases expression |
EXP |
panobinostat results in increased expression of ACSM3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:20,674,405...20,797,581
Ensembl chr16:20,610,243...20,797,581
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Panobinostat results in decreased expression of ACTA2 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
ADA |
adenosine deaminase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA panobinostat results in decreased expression of ADA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252
|
|
G |
ADAM12 |
ADAM metallopeptidase domain 12 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ADAM12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:126,012,391...126,388,477
Ensembl chr10:126,012,381...126,388,477
|
|
G |
ADAM22 |
ADAM metallopeptidase domain 22 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA panobinostat results in decreased expression of ADAM22 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:87,934,251...88,202,889
Ensembl chr 7:87,934,143...88,202,889
|
|
G |
ADAM28 |
ADAM metallopeptidase domain 28 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA panobinostat results in increased expression of ADAM28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:24,294,069...24,359,014
Ensembl chr 8:24,294,069...24,359,014
|
|
G |
ADAMTS15 |
ADAM metallopeptidase with thrombospondin type 1 motif 15 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA panobinostat results in increased expression of ADAMTS15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:130,448,645...130,476,645
Ensembl chr11:130,448,645...130,476,645
|
|
G |
ADAMTS17 |
ADAM metallopeptidase with thrombospondin type 1 motif 17 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:99,971,437...100,341,975
Ensembl chr15:99,971,437...100,342,005
|
|
G |
ADAMTS19 |
ADAM metallopeptidase with thrombospondin type 1 motif 19 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA panobinostat results in increased expression of ADAMTS19 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:129,460,298...129,738,683
Ensembl chr 5:129,460,281...129,738,683
|
|
G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ADCYAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:904,411...912,172
Ensembl chr18:904,871...912,172
|
|
G |
ADCYAP1R1 |
ADCYAP receptor type I |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA panobinostat results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:31,052,308...31,111,474
Ensembl chr 7:31,052,308...31,111,474
|
|
G |
ADGRG1 |
adhesion G protein-coupled receptor G1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA panobinostat results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
|
|
G |
ADGRG6 |
adhesion G protein-coupled receptor G6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:142,302,007...142,446,261
Ensembl chr 6:142,301,854...142,446,266
|
|
G |
ADGRL3 |
adhesion G protein-coupled receptor L3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ADGRL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:61,200,326...62,078,335
Ensembl chr 4:61,200,326...62,078,335
|
|
G |
ADGRV1 |
adhesion G protein-coupled receptor V1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA panobinostat results in decreased expression of ADGRV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:90,558,797...91,164,437
Ensembl chr 5:90,529,344...91,164,437
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907
|
|
G |
AFAP1L1 |
actin filament associated protein 1 like 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of AFAP1L1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:149,271,859...149,343,637
Ensembl chr 5:149,271,859...149,343,637
|
|
G |
AFDN-DT |
AFDN divergent transcript |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of AFDN-DT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:167,823,890...167,826,796
Ensembl chr 6:167,822,103...167,826,833
|
|
G |
AHNAK |
AHNAK nucleoprotein |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of AHNAK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:62,433,544...62,546,806
Ensembl chr11:62,433,542...62,556,235
|
|
G |
AJAP1 |
adherens junctions associated protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA panobinostat results in increased expression of AJAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:4,654,609...4,792,534
Ensembl chr 1:4,654,609...4,792,534
|
|
G |
AKAP12 |
A-kinase anchoring protein 12 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA panobinostat results in decreased expression of AKAP12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein |
CTD |
PMID:18445700 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
ALCAM |
activated leukocyte cell adhesion molecule |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ALCAM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:105,366,909...105,576,900
Ensembl chr 3:105,366,909...105,576,900
|
|
G |
ALDH1A2 |
aldehyde dehydrogenase 1 family member A2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ALDH1A2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:57,953,429...58,065,711
Ensembl chr15:57,953,424...58,497,866
|
|
G |
ALDH1A3 |
aldehyde dehydrogenase 1 family member A3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ALDH1A3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:100,879,831...100,916,626
Ensembl chr15:100,877,714...100,916,626
|
|
G |
ALDH1L2 |
aldehyde dehydrogenase 1 family member L2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ALDH1L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:105,019,790...105,084,458
Ensembl chr12:105,019,784...105,107,643
|
|
G |
ALKAL2 |
ALK and LTK ligand 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA panobinostat results in increased expression of ALKAL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:279,558...288,091
Ensembl chr 2:279,558...288,851
|
|
G |
ALX1 |
ALX homeobox 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ALX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:85,280,220...85,301,784
Ensembl chr12:85,280,220...85,301,784
|
|
G |
AMER2 |
APC membrane recruitment protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of AMER2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:25,161,679...25,172,288
Ensembl chr13:25,161,679...25,172,288
|
|
G |
AMIGO2 |
adhesion molecule with Ig like domain 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA panobinostat results in increased expression of AMIGO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:47,075,707...47,079,959
Ensembl chr12:47,075,707...47,079,959
|
|
G |
ANG |
angiogenin |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:20,684,177...20,694,186
Ensembl chr14:20,684,177...20,698,971
|
|
G |
ANGPT1 |
angiopoietin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA panobinostat results in increased expression of ANGPT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055
|
|
G |
ANGPT2 |
angiopoietin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA panobinostat results in increased expression of ANGPT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:6,499,632...6,563,245
Ensembl chr 8:6,499,632...6,563,409
|
|
G |
ANKH |
ANKH inorganic pyrophosphate transport regulator |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA panobinostat results in increased expression of ANKH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:14,704,800...14,871,778
Ensembl chr 5:14,704,800...14,871,778
|
|
G |
ANKRD1 |
ankyrin repeat domain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA panobinostat results in increased expression of ANKRD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087
|
|
G |
ANKRD22 |
ankyrin repeat domain 22 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:88,819,896...88,851,844
Ensembl chr10:88,819,896...88,851,844
|
|
G |
ANKS1B |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:98,734,786...99,984,936
Ensembl chr12:98,726,457...99,984,936
|
|
G |
ANO3 |
anoctamin 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:26,188,808...26,663,289
Ensembl chr11:26,188,842...26,663,289
|
|
G |
ANOS1 |
anosmin 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA panobinostat results in decreased expression of KAL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:8,528,874...8,732,137
Ensembl chr X:8,528,874...8,732,137
|
|
G |
ANXA1 |
annexin A1 |
increases expression |
EXP |
panobinostat results in increased expression of ANXA1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393
|
|
G |
ANXA2 |
annexin A2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ANXA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883
|
|
G |
ANXA2P2 |
annexin A2 pseudogene 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ANXA2P2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:33,624,225...33,625,534
Ensembl chr 9:33,624,274...33,625,293
|
|
G |
ANXA2P3 |
annexin A2 pseudogene 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ANXA2P3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:64,825,528...64,826,877
Ensembl chr10:64,825,572...64,826,579
|
|
G |
ANXA3 |
annexin A3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA panobinostat results in increased expression of ANXA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:78,551,770...78,610,447
Ensembl chr 4:78,551,747...78,610,451
|
|
G |
ANXA9 |
annexin A9 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:150,977,306...150,995,634
Ensembl chr 1:150,982,249...150,995,634
|
|
G |
AOX1 |
aldehyde oxidase 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of AOX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:200,586,014...200,682,241
Ensembl chr 2:200,586,014...200,677,064
|
|
G |
AP1M2 |
adaptor related protein complex 1 subunit mu 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA panobinostat results in increased expression of AP1M2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,572,671...10,587,312
Ensembl chr19:10,572,671...10,587,315
|
|
G |
AP5S1 |
adaptor related protein complex 5 subunit sigma 1 |
decreases expression |
EXP |
Panobinostat results in decreased expression of AP5S1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr20:3,820,547...3,828,838
Ensembl chr20:3,820,524...3,828,838
|
|
G |
APELA |
apelin receptor early endogenous ligand |
increases expression |
EXP |
panobinostat results in increased expression of APELA mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:164,877,178...164,899,007
Ensembl chr 4:164,877,178...164,898,965
|
|
G |
APOBEC3B |
apolipoprotein B mRNA editing enzyme catalytic subunit 3B |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr22:38,982,347...38,992,779
Ensembl chr22:38,982,347...38,992,804
|
|
G |
ARAP2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ARAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:36,005,404...36,244,784
Ensembl chr 4:35,948,221...36,244,514
|
|
G |
ARFGEF3 |
ARFGEF family member 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA panobinostat results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:138,161,939...138,344,663
Ensembl chr 6:138,161,939...138,344,663
|
|
G |
ARHGAP15 |
Rho GTPase activating protein 15 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA panobinostat results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:143,129,419...143,768,352
Ensembl chr 2:143,091,362...143,768,352
|
|
G |
ARHGAP18 |
Rho GTPase activating protein 18 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA panobinostat results in increased expression of ARHGAP18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:129,576,132...129,710,177
Ensembl chr 6:129,576,132...129,710,177
|
|
G |
ARHGAP24 |
Rho GTPase activating protein 24 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:85,475,150...86,002,666
Ensembl chr 4:85,475,150...86,002,668
|
|
G |
ARHGAP31 |
Rho GTPase activating protein 31 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 3:119,294,383...119,420,714
Ensembl chr 3:119,294,383...119,420,714
|
|
G |
ARHGAP5 |
Rho GTPase activating protein 5 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ARHGAP5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:32,077,304...32,159,728
Ensembl chr14:32,076,114...32,159,728
|
|
G |
ARHGAP6 |
Rho GTPase activating protein 6 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ARHGAP6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:11,137,544...11,665,920
Ensembl chr X:11,117,651...11,665,920
|
|
G |
ARID2 |
AT-rich interaction domain 2 |
affects expression multiple interactions |
EXP |
panobinostat affects the expression of ARID2 mRNA (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of ARID2 mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr12:45,729,706...45,908,037
Ensembl chr12:45,729,706...45,908,040
|
|
G |
ARID5B |
AT-rich interaction domain 5B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA panobinostat results in increased expression of ARID5B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:61,901,699...62,096,944
Ensembl chr10:61,901,684...62,096,944
|
|
G |
ARMH4 |
armadillo like helical domain containing 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA panobinostat results in decreased expression of ARMH4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:58,000,761...58,152,213
Ensembl chr14:57,999,735...58,298,139
|
|
G |
ARNT2 |
aryl hydrocarbon receptor nuclear translocator 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ARNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:80,404,382...80,597,933
Ensembl chr15:80,404,350...80,597,933
|
|
G |
ARRB1 |
arrestin beta 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ARRB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:75,260,122...75,351,661
Ensembl chr11:75,260,122...75,351,705
|
|
G |
ARX |
aristaless related homeobox |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ARX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:25,003,694...25,015,965
Ensembl chr X:25,003,694...25,016,420
|
|
G |
AS3MT |
arsenite methyltransferase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA |
CTD |
PMID:21791302 |
|
NCBI chr10:102,869,470...102,901,899
Ensembl chr10:102,869,470...102,901,899
|
|
G |
ASB9 |
ankyrin repeat and SOCS box containing 9 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:15,243,987...15,270,467
Ensembl chr X:15,235,288...15,270,467
|
|
G |
ASCL1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:102,957,674...102,960,513
Ensembl chr12:102,957,674...102,960,513
|
|
G |
ASIC1 |
acid sensing ion channel subunit 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:50,057,596...50,083,622
Ensembl chr12:50,057,548...50,083,611
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ASNS mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ASS1 |
argininosuccinate synthase 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ASS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274
|
|
G |
ASTN1 |
astrotactin 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ASTN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:176,857,321...177,164,712
Ensembl chr 1:176,857,302...177,164,973
|
|
G |
ASTN2 |
astrotactin 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ASTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:116,423,112...117,415,057
Ensembl chr 9:116,423,112...117,415,070
|
|
G |
ATF3 |
activating transcription factor 3 |
increases expression |
EXP |
panobinostat results in increased expression of ATF3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
ATP13A4 |
ATPase 13A4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:193,398,967...193,593,119
Ensembl chr 3:193,398,967...193,593,111
|
|
G |
ATP23 |
ATP23 metallopeptidase and ATP synthase assembly factor homolog |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ATP23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:57,941,567...57,959,148
Ensembl chr12:57,906,039...57,959,148
|
|
G |
ATP2C2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA panobinostat results in increased expression of ATP2C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:84,368,538...84,464,187
Ensembl chr16:84,368,527...84,464,187
|
|
G |
ATP6V0A2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA panobinostat results in decreased expression of ATP6V0A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:123,712,353...123,761,755
Ensembl chr12:123,712,353...123,761,755
|
|
G |
ATP6V0A4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA panobinostat results in increased expression of ATP6V0A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:138,706,294...138,798,196
Ensembl chr 7:138,706,294...138,799,560
|
|
G |
ATP6V0D2 |
ATPase H+ transporting V0 subunit d2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA panobinostat results in increased expression of ATP6V0D2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:86,098,910...86,154,225
Ensembl chr 8:85,987,323...86,154,225
|
|
G |
ATP8B1 |
ATPase phospholipid transporting 8B1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA panobinostat results in increased expression of ATP8B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
|
|
G |
ATP8B3 |
ATPase phospholipid transporting 8B3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA panobinostat results in increased expression of ATP8B3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:1,782,075...1,812,276
Ensembl chr19:1,782,075...1,812,276
|
|
G |
ATP9A |
ATPase phospholipid transporting 9A (putative) |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA panobinostat results in decreased expression of ATP9A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:51,596,514...51,768,390
Ensembl chr20:51,596,514...51,768,390
|
|
G |
AXIN2 |
axin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA panobinostat results in increased expression of AXIN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648
|
|
G |
B3GNT7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA panobinostat results in increased expression of B3GNT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:231,395,710...231,401,164
Ensembl chr 2:231,395,671...231,408,799
|
|
G |
BACE2 |
beta-secretase 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BACE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:41,168,160...41,282,530
Ensembl chr21:41,167,801...41,282,530
|
|
G |
BAG2 |
BAG cochaperone 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA panobinostat results in increased expression of BAG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:57,172,326...57,189,833
Ensembl chr 6:57,172,326...57,189,833
|
|
G |
BAG5 |
BAG cochaperone 5 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr14:103,556,551...103,562,657
Ensembl chr14:103,556,545...103,562,657
|
|
G |
BAMBI |
BMP and activin membrane bound inhibitor |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BAMBI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
|
|
G |
BATF3 |
basic leucine zipper ATF-like transcription factor 3 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:212,686,417...212,699,840
Ensembl chr 1:212,686,417...212,699,840
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] |
CTD |
PMID:18445700 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BAZ1A |
bromodomain adjacent to zinc finger domain 1A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA panobinostat results in increased expression of BAZ1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:34,752,731...34,875,360
Ensembl chr14:34,752,731...34,875,647
|
|
G |
BCL11A |
BCL11 transcription factor A |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BCL11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:60,450,520...60,553,924
Ensembl chr 2:60,450,520...60,554,467
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
affects expression multiple interactions decreases expression |
EXP |
panobinostat affects the expression of BCL2 mRNA (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA] panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein |
CTD |
PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions increases expression decreases expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] panobinostat results in increased expression of BCL2L11 protein panobinostat results in decreased expression of BCL2L11 mRNA |
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
BEGAIN |
brain enriched guanylate kinase associated |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA panobinostat results in decreased expression of BEGAIN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:100,537,147...100,587,417
Ensembl chr14:100,537,147...100,587,417
|
|
G |
BEST4 |
bestrophin 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA panobinostat results in decreased expression of BEST4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:44,781,840...44,792,828
Ensembl chr 1:44,783,585...44,788,170
|
|
G |
BEX5 |
brain expressed X-linked 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA panobinostat results in increased expression of BEX5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:102,153,712...102,155,977
Ensembl chr X:102,153,708...102,155,977
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BHLHE40 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BHLHE41 |
basic helix-loop-helix family member e41 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr12:26,120,030...26,125,037
Ensembl chr12:26,120,030...26,125,037
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
Panobinostat results in decreased expression of BIRC5 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BMAL2 |
basic helix-loop-helix ARNT like 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of BMAL2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr12:27,332,836...27,425,286
Ensembl chr12:27,332,836...27,425,289
|
|
G |
BMF |
Bcl2 modifying factor |
increases expression |
EXP |
Panobinostat results in increased expression of BMF mRNA |
CTD |
PMID:33770205 |
|
NCBI chr15:40,087,890...40,108,879
Ensembl chr15:40,087,890...40,108,892
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA panobinostat results in increased expression of BMP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BMP4 |
bone morphogenetic protein 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA panobinostat results in increased expression of BMP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761
|
|
G |
BMP5 |
bone morphogenetic protein 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA panobinostat results in increased expression of BMP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:55,753,653...55,875,590
Ensembl chr 6:55,753,653...55,875,590
|
|
G |
BMP7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA panobinostat results in increased expression of BMP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641
|
|
G |
BMPER |
BMP binding endothelial regulator |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA panobinostat results in increased expression of BMPER mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:33,904,915...34,156,427
Ensembl chr 7:33,904,308...34,156,427
|
|
G |
BMPR1B |
bone morphogenetic protein receptor type 1B |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 4:94,757,955...95,158,450
Ensembl chr 4:94,757,955...95,158,448
|
|
G |
BNC2 |
basonuclin zinc finger protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BNC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:16,409,503...16,870,670
Ensembl chr 9:16,409,503...16,870,843
|
|
G |
BNIPL |
BCL2 interacting protein like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA panobinostat results in increased expression of BNIPL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:151,036,586...151,047,720
Ensembl chr 1:151,036,321...151,047,720
|
|
G |
BOC |
BOC cell adhesion associated, oncogene regulated |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA panobinostat results in increased expression of BOC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:113,210,926...113,287,459
Ensembl chr 3:113,211,003...113,287,459
|
|
G |
BRI3BP |
BRI3 binding protein |
increases expression |
EXP |
panobinostat results in increased expression of BRI3BP mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:124,993,645...125,051,167
Ensembl chr12:124,993,645...125,031,231
|
|
G |
BRINP1 |
BMP/retinoic acid inducible neural specific 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BRINP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:119,166,629...119,369,435
Ensembl chr 9:119,153,458...119,369,435
|
|
G |
BRIP1 |
BRCA1 interacting helicase 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:61,679,139...61,863,528
Ensembl chr17:61,679,139...61,863,559
|
|
G |
BSPRY |
B-box and SPRY domain containing |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of BSPRY mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:113,349,541...113,371,222
Ensembl chr 9:113,349,541...113,371,233
|
|
G |
C11orf52 |
chromosome 11 open reading frame 52 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:111,918,913...111,926,871
Ensembl chr11:111,918,032...111,926,871
|
|
G |
C11orf96 |
chromosome 11 open reading frame 96 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA panobinostat results in increased expression of C11ORF96 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:43,942,637...43,943,878
Ensembl chr11:43,942,637...43,943,878
|
|
G |
C12orf56 |
chromosome 12 open reading frame 56 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of C12ORF56 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:64,264,762...64,390,758
Ensembl chr12:64,264,762...64,390,758
|
|
G |
C14orf39 |
chromosome 14 open reading frame 39 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA panobinostat results in decreased expression of C14ORF39 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:60,435,956...60,515,544
Ensembl chr14:60,396,469...60,515,543
|
|
G |
C16orf87 |
chromosome 16 open reading frame 87 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:46,796,603...46,831,180
Ensembl chr16:46,796,603...46,831,180
|
|
G |
C19orf33 |
chromosome 19 open reading frame 33 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA panobinostat results in increased expression of C19ORF33 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:38,304,251...38,305,006
Ensembl chr19:38,304,164...38,305,006
|
|
G |
C1GALT1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA panobinostat results in increased expression of C1GALT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:7,157,377...7,248,616
Ensembl chr 7:7,156,934...7,248,616
|
|
G |
C1orf53 |
chromosome 1 open reading frame 53 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA panobinostat results in decreased expression of C1ORF53 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:197,902,630...197,907,362
Ensembl chr 1:197,902,630...197,907,367
|
|
G |
C1QTNF4 |
C1q and TNF related 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA panobinostat results in decreased expression of C1QTNF4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:47,589,667...47,595,304
Ensembl chr11:47,589,667...47,594,411
|
|
G |
C2CD2 |
C2 calcium dependent domain containing 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA panobinostat results in decreased expression of C2CD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:41,885,112...41,954,018
Ensembl chr21:41,885,112...41,954,018
|
|
G |
C2orf68 |
chromosome 2 open reading frame 68 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of C2ORF68 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:85,605,254...85,612,066
Ensembl chr 2:85,605,254...85,612,066
|
|
G |
C3 |
complement C3 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
|
|
G |
C3orf33 |
chromosome 3 open reading frame 33 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of C3ORF33 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:155,762,617...155,806,278
Ensembl chr 3:155,762,617...155,806,278
|
|
G |
C3orf52 |
chromosome 3 open reading frame 52 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of C3ORF52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:112,086,389...112,136,381
Ensembl chr 3:112,086,335...112,131,004
|
|
G |
C4orf19 |
chromosome 4 open reading frame 19 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:37,453,255...37,593,510
Ensembl chr 4:37,453,925...37,623,495
|
|
G |
C6orf141 |
chromosome 6 open reading frame 141 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of C6ORF141 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:49,550,668...49,561,916
Ensembl chr 6:49,550,666...49,561,907
|
|
G |
C8orf34 |
chromosome 8 open reading frame 34 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA panobinostat results in increased expression of C8ORF34 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:68,330,373...68,819,023
Ensembl chr 8:68,330,955...68,819,023
|
|
G |
C8orf34-AS1 |
C8orf34 antisense RNA 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA panobinostat results in increased expression of C8ORF34-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:68,303,468...68,331,491
Ensembl chr 8:68,302,246...68,331,689
|
|
G |
C9orf72 |
C9orf72-SMCR8 complex subunit |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of C9ORF72 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:27,546,546...27,573,866
Ensembl chr 9:27,535,640...27,573,866
|
|
G |
CA12 |
carbonic anhydrase 12 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CA12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:63,321,378...63,381,846
Ensembl chr15:63,321,378...63,381,846
|
|
G |
CA13 |
carbonic anhydrase 13 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:85,245,458...85,284,073
Ensembl chr 8:85,220,587...85,284,073
|
|
G |
CA4 |
carbonic anhydrase 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:60,149,973...60,179,021
Ensembl chr17:60,149,942...60,170,899
|
|
G |
CA8 |
carbonic anhydrase 8 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:60,185,412...60,281,400
Ensembl chr 8:60,185,412...60,281,400
|
|
G |
CACNA2D1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CACNA2D1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:81,946,444...82,443,956
Ensembl chr 7:81,946,444...82,443,956
|
|
G |
CACNB2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CACNB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:18,140,424...18,543,557
Ensembl chr10:18,140,424...18,543,557
|
|
G |
CADM4 |
cell adhesion molecule 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CADM4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:43,622,368...43,641,984
Ensembl chr19:43,622,368...43,639,850
|
|
G |
CALB2 |
calbindin 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CALB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:71,358,723...71,390,433
Ensembl chr16:71,358,713...71,390,436
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CALCA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CAPN6 |
calpain 6 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CAPN6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:111,245,099...111,270,483
Ensembl chr X:111,245,099...111,270,483
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein |
CTD |
PMID:22923501 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein] panobinostat results in increased expression of CASP8 mRNA |
CTD |
PMID:21791302 PMID:22923501 PMID:26272509 PMID:27188386 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein |
CTD |
PMID:22923501 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CBLC |
Cbl proto-oncogene C |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CBLC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:44,777,869...44,800,652
Ensembl chr19:44,777,869...44,800,652
|
|
G |
CC2D2A |
coiled-coil and C2 domain containing 2A |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 4:15,469,865...15,601,557
Ensembl chr 4:15,469,865...15,601,552
|
|
G |
CCDC136 |
coiled-coil domain containing 136 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CCDC136 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:128,790,761...128,822,130
Ensembl chr 7:128,790,757...128,822,132
|
|
G |
CCDC140 |
CCDC140 long non-coding RNA |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CCDC140 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:222,298,147...222,305,217
Ensembl chr 2:222,298,147...222,305,217
|
|
G |
CCDC177 |
coiled-coil domain containing 177 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CCDC177 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:69,569,799...69,574,871
Ensembl chr14:69,569,799...69,574,871
|
|
G |
CCDC69 |
coiled-coil domain containing 69 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA panobinostat results in increased expression of CCDC69 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:151,181,052...151,224,092
Ensembl chr 5:151,181,052...151,224,093
|
|
G |
CCKBR |
cholecystokinin B receptor |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CCKBR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:6,259,838...6,272,127
Ensembl chr11:6,259,806...6,272,127
|
|
G |
CCL26 |
C-C motif chemokine ligand 26 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CCL26 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:75,769,524...75,791,597
Ensembl chr 7:75,769,533...75,789,896
|
|
G |
CCN3 |
cellular communication network factor 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:119,416,446...119,424,434
Ensembl chr 8:119,416,446...119,424,434
|
|
G |
CCNG2 |
cyclin G2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CCNG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
|
|
G |
CCNT2 |
cyclin T2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CCNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:134,918,822...134,959,342
Ensembl chr 2:134,918,235...134,959,342
|
|
G |
CD200 |
CD200 molecule |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 3:112,332,573...112,362,812
Ensembl chr 3:112,332,235...112,363,181
|
|
G |
CD24 |
CD24 molecule |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA panobinostat results in increased expression of CD24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:106,969,831...106,976,855
Ensembl chr 6:106,969,831...106,975,627
|
|
G |
CD274 |
CD274 molecule |
increases expression |
EXP |
Panobinostat results in increased expression of CD274 protein |
CTD |
PMID:26775640 |
|
NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CD44 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD52 |
CD52 molecule |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CD52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,317,958...26,320,523
Ensembl chr 1:26,317,958...26,320,523
|
|
G |
CD55 |
CD55 molecule (Cromer blood group) |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA panobinostat results in increased expression of CD55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804
|
|
G |
CD74 |
CD74 molecule |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA panobinostat results in increased expression of CD74 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969
|
|
G |
CD9 |
CD9 molecule |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA panobinostat results in increased expression of CD9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:6,199,946...6,238,266
Ensembl chr12:6,199,715...6,238,271
|
|
G |
CDC42EP3 |
CDC42 effector protein 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA panobinostat results in decreased expression of CDC42EP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:37,641,944...37,672,949
Ensembl chr 2:37,641,882...37,738,468
|
|
G |
CDC42EP5 |
CDC42 effector protein 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA panobinostat results in increased expression of CDC42EP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:54,465,026...54,473,296
Ensembl chr19:54,465,026...54,473,296
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA panobinostat results in increased expression of CDH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH10 |
cadherin 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA panobinostat results in increased expression of CDH10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:24,487,100...24,644,978
Ensembl chr 5:24,487,100...24,644,978
|
|
G |
CDH18 |
cadherin 18 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CDH18 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:19,471,296...20,575,713
Ensembl chr 5:19,471,296...20,575,873
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA panobinostat results in decreased expression of CDH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDH3 |
cadherin 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CDH3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:68,645,310...68,733,771
Ensembl chr16:68,636,189...68,727,468
|
|
G |
CDH8 |
cadherin 8 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CDH8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:61,647,250...62,036,438
Ensembl chr16:61,647,242...62,037,035
|
|
G |
CDK19 |
cyclin dependent kinase 19 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:110,609,978...110,815,855
Ensembl chr 6:110,609,978...110,815,958
|
|
G |
CDK5R1 |
cyclin dependent kinase 5 regulatory subunit 1 |
decreases expression |
EXP |
Panobinostat results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:32,486,993...32,491,253
Ensembl chr17:32,486,993...32,491,253
|
|
G |
CDK6 |
cyclin dependent kinase 6 |
multiple interactions increases expression |
EXP |
[(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA panobinostat results in increased expression of CDK6 mRNA |
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
panobinostat results in increased expression of CDKN1A protein |
CTD |
PMID:18445700 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
EXP |
panobinostat results in increased expression of CDKN1B protein |
CTD |
PMID:18445700 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDON |
cell adhesion associated, oncogene regulated |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CDON mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:125,956,821...126,063,352
Ensembl chr11:125,955,796...126,063,335
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA panobinostat results in increased expression of CEBPB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668
|
|
G |
CEBPD |
CCAAT enhancer binding protein delta |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CEBPD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164
|
|
G |
CELF5 |
CUGBP Elav-like family member 5 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:3,224,661...3,297,076
Ensembl chr19:3,224,661...3,297,076
|
|
G |
CEP85L |
centrosomal protein 85 like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA panobinostat results in increased expression of CEP85L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:118,460,772...118,710,089
Ensembl chr 6:118,460,772...118,710,075
|
|
G |
CFAP91 |
cilia and flagella associated protein 91 |
decreases expression multiple interactions |
EXP |
Panobinostat results in decreased expression of CFAP91 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:119,703,022...119,767,102
Ensembl chr 3:119,703,022...119,767,102
|
|
G |
CFAP95 |
cilia and flagella associated protein 95 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:69,820,817...69,906,227
Ensembl chr 9:69,820,817...69,906,227
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CGNL1 |
cingulin like 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CGNL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:57,376,505...57,550,717
Ensembl chr15:57,375,967...57,550,717
|
|
G |
CHAC1 |
ChaC glutathione specific gamma-glutamylcyclotransferase 1 |
increases expression |
EXP |
panobinostat results in increased expression of CHAC1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:40,953,471...40,956,512
Ensembl chr15:40,952,962...40,956,512
|
|
G |
CHGA |
chromogranin A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA panobinostat results in increased expression of CHGA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:92,922,664...92,935,285
Ensembl chr14:92,923,150...92,935,285
|
|
G |
CHODL |
chondrolectin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA panobinostat results in increased expression of CHODL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:17,917,340...18,267,370
Ensembl chr21:17,901,263...18,267,373
|
|
G |
CHRM3 |
cholinergic receptor muscarinic 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA panobinostat results in increased expression of CHRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:239,386,568...239,915,450
Ensembl chr 1:239,386,565...239,915,452
|
|
G |
CHRNA3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:78,593,052...78,620,996
Ensembl chr15:78,593,052...78,621,295
|
|
G |
CHST15 |
carbohydrate sulfotransferase 15 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CHST15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:124,007,668...124,093,598
Ensembl chr10:124,007,668...124,093,598
|
|
G |
CHST4 |
carbohydrate sulfotransferase 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA panobinostat results in increased expression of CHST4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:71,526,120...71,538,748
Ensembl chr16:71,525,233...71,538,748
|
|
G |
CHSY1 |
chondroitin sulfate synthase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA panobinostat results in increased expression of CHSY1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:101,175,727...101,252,048
Ensembl chr15:101,175,727...101,252,048
|
|
G |
CIMAP3 |
ciliary microtubule associated protein 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:111,324,663...111,353,017
Ensembl chr 1:111,346,600...111,353,013
|
|
G |
CITED2 |
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA panobinostat results in increased expression of CITED2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:139,371,807...139,374,648
Ensembl chr 6:139,371,807...139,374,648
|
|
G |
CLDN1 |
claudin 1 |
increases expression |
EXP |
panobinostat results in increased expression of CLDN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446
|
|
G |
CLDN23 |
claudin 23 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CLDN23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:8,701,937...8,704,096
Ensembl chr 8:8,701,937...8,704,096
|
|
G |
CLDN4 |
claudin 4 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CLDN4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:73,830,996...73,832,690
Ensembl chr 7:73,799,542...73,832,690
|
|
G |
CLDN6 |
claudin 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA panobinostat results in increased expression of CLDN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:3,014,712...3,018,183
Ensembl chr16:3,014,712...3,020,071
|
|
G |
CLDN7 |
claudin 7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CLDN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983
|
|
G |
CLGN |
calmegin |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CLGN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:140,388,453...140,427,648
Ensembl chr 4:140,388,453...140,427,661
|
|
G |
CLIC6 |
chloride intracellular channel 6 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CLIC6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:34,668,994...34,718,223
Ensembl chr21:34,668,994...34,718,227
|
|
G |
CLP1 |
cleavage factor polyribonucleotide kinase subunit 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:57,657,762...57,661,865
Ensembl chr11:57,648,188...57,661,865
|
|
G |
CLSTN2 |
calsyntenin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA panobinostat results in increased expression of CLSTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:139,935,185...140,577,397
Ensembl chr 3:139,935,185...140,577,397
|
|
G |
CLTRN |
collectrin, amino acid transport regulator |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA panobinostat results in decreased expression of CLTRN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:15,627,318...15,675,644
Ensembl chr X:15,627,318...15,675,012
|
|
G |
CLU |
clusterin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CLU mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700
|
|
G |
CNKSR2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CNKSR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:21,374,418...21,654,689
Ensembl chr X:21,372,801...21,654,695
|
|
G |
CNMD |
chondromodulin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CNMD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:52,703,264...52,739,820
Ensembl chr13:52,703,264...52,739,820
|
|
G |
CNOT4 |
CCR4-NOT transcription complex subunit 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:135,361,795...135,510,102
Ensembl chr 7:135,361,795...135,510,145
|
|
G |
CNRIP1 |
cannabinoid receptor interacting protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA panobinostat results in increased expression of CNRIP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:68,284,171...68,319,949
Ensembl chr 2:68,284,171...68,320,051
|
|
G |
CNTN1 |
contactin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA panobinostat results in increased expression of CNTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:40,692,439...41,072,415
Ensembl chr12:40,692,439...41,072,415
|
|
G |
CNTN2 |
contactin 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CNTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,042,949...205,078,289
Ensembl chr 1:205,042,937...205,078,289
|
|
G |
COA1 |
cytochrome c oxidase assembly factor 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:43,608,457...43,729,523
Ensembl chr 7:43,608,456...43,729,717
|
|
G |
COBL |
cordon-bleu WH2 repeat protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA panobinostat results in increased expression of COBL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:51,016,212...51,316,809
Ensembl chr 7:51,016,212...51,316,818
|
|
G |
COBLL1 |
cordon-bleu WH2 repeat protein like 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA panobinostat results in increased expression of COBLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:164,657,931...164,842,076
Ensembl chr 2:164,653,624...164,843,679
|
|
G |
COL11A1 |
collagen type XI alpha 1 chain |
increases expression |
EXP |
panobinostat results in increased expression of COL11A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872
|
|
G |
COL14A1 |
collagen type XIV alpha 1 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA panobinostat results in increased expression of COL14A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:120,124,454...120,373,573
Ensembl chr 8:120,059,780...120,373,573
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL1A2 |
collagen type I alpha 2 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA panobinostat results in increased expression of COL1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
|
|
G |
COL21A1 |
collagen type XXI alpha 1 chain |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:56,056,590...56,394,128
Ensembl chr 6:56,056,590...56,394,094
|
|
G |
COL23A1 |
collagen type XXIII alpha 1 chain |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of COL23A1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:178,237,618...178,590,393
Ensembl chr 5:178,237,476...178,590,393
|
|
G |
COL5A2 |
collagen type V alpha 2 chain |
increases expression |
EXP |
panobinostat results in increased expression of COL5A2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:189,031,898...189,441,111
Ensembl chr 2:189,031,898...189,225,312
|
|
G |
COL5A3 |
collagen type V alpha 3 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA panobinostat results in increased expression of COL5A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:9,959,561...10,010,504
Ensembl chr19:9,959,561...10,010,504
|
|
G |
COL6A1 |
collagen type VI alpha 1 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA panobinostat results in increased expression of COL6A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:45,981,770...46,005,048
Ensembl chr21:45,981,770...46,005,050
|
|
G |
COL6A3 |
collagen type VI alpha 3 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA panobinostat results in increased expression of COL6A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:237,324,018...237,414,164
Ensembl chr 2:237,324,003...237,414,328
|
|
G |
COL9A3 |
collagen type IX alpha 3 chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA panobinostat results in increased expression of COL9A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:62,816,213...62,841,159
Ensembl chr20:62,816,244...62,841,159
|
|
G |
COLEC12 |
collectin subfamily member 12 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of COLEC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:316,737...500,701
Ensembl chr18:316,737...500,722
|
|
G |
COLGALT2 |
collagen beta(1-O)galactosyltransferase 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of COLGALT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:183,929,662...184,037,728
Ensembl chr 1:183,929,854...184,037,729
|
|
G |
COMTD1 |
catechol-O-methyltransferase domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of COMTD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:75,233,641...75,235,957
Ensembl chr10:75,233,641...75,236,030
|
|
G |
CORO2A |
coronin 2A |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CORO2A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:98,120,975...98,192,637
Ensembl chr 9:98,120,975...98,192,637
|
|
G |
CPE |
carboxypeptidase E |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CPE mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:165,379,008...165,498,547
Ensembl chr 4:165,361,194...165,498,547
|
|
G |
CPED1 |
cadherin like and PC-esterase domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CPED1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:120,988,711...121,297,442
Ensembl chr 7:120,988,697...121,297,442
|
|
G |
CPNE4 |
copine 4 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CPNE4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:131,533,569...132,039,606
Ensembl chr 3:131,533,555...132,285,410
|
|
G |
CPXM2 |
carboxypeptidase X, M14 family member 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CPXM2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:123,745,639...123,944,104
Ensembl chr10:123,706,207...123,940,267
|
|
G |
CR1L |
complement C3b/C4b receptor 1 like |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CR1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:207,645,133...207,723,703
Ensembl chr 1:207,645,113...207,738,416
|
|
G |
CR2 |
complement C3d receptor 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:207,454,328...207,489,892
Ensembl chr 1:207,453,024...207,489,895
|
|
G |
CRABP1 |
cellular retinoic acid binding protein 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:78,340,353...78,348,225
Ensembl chr15:78,340,353...78,348,225
|
|
G |
CRABP2 |
cellular retinoic acid binding protein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA panobinostat results in increased expression of CRABP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:156,699,606...156,705,784
Ensembl chr 1:156,699,606...156,705,816
|
|
G |
CRIP1 |
cysteine rich protein 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:105,486,886...105,488,947
Ensembl chr14:105,486,317...105,488,947
|
|
G |
CRIPTO |
cripto, EGF-CFC family member |
increases expression |
EXP |
Panobinostat results in increased expression of CRIPTO mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:46,574,535...46,582,457
Ensembl chr 3:46,574,534...46,582,457
|
|
G |
CRISPLD1 |
cysteine rich secretory protein LCCL domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CRISPLD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:74,984,505...75,034,558
Ensembl chr 8:74,984,505...75,034,558
|
|
G |
CRYBA1 |
crystallin beta A1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA panobinostat results in decreased expression of CRYBA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:29,246,859...29,254,494
Ensembl chr17:29,246,859...29,254,494
|
|
G |
CRYBA4 |
crystallin beta A4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CRYBA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:26,590,220...26,630,669
Ensembl chr22:26,621,963...26,630,669
|
|
G |
CRYBG1 |
crystallin beta-gamma domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA panobinostat results in increased expression of CRYBG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:106,360,717...106,572,017
Ensembl chr 6:106,360,717...106,572,017
|
|
G |
CSF2RA |
colony stimulating factor 2 receptor subunit alpha |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:1,268,814...1,325,218 NCBI chr Y:1,268,814...1,325,218
Ensembl chr Y:1,268,800...1,310,381 Ensembl chr X:1,268,800...1,310,381
|
|
G |
CSPG5 |
chondroitin sulfate proteoglycan 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA panobinostat results in decreased expression of CSPG5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:47,562,238...47,580,240
Ensembl chr 3:47,562,238...47,580,792
|
|
G |
CSRNP3 |
cysteine and serine rich nuclear protein 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:165,469,698...165,689,407
Ensembl chr 2:165,469,647...165,689,407
|
|
G |
CTHRC1 |
collagen triple helix repeat containing 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:103,371,538...103,382,989
Ensembl chr 8:103,371,538...103,382,989
|
|
G |
CTNND2 |
catenin delta 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA panobinostat results in decreased expression of CTNND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:10,971,836...11,904,446
Ensembl chr 5:10,971,836...11,904,446
|
|
G |
CTSV |
cathepsin V |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:97,029,677...97,039,643
Ensembl chr 9:97,029,677...97,156,556
|
|
G |
CUL3 |
cullin 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of CUL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:224,470,150...224,585,363
Ensembl chr 2:224,470,150...224,585,397
|
|
G |
CX3CL1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA panobinostat results in increased expression of CX3CL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:57,372,490...57,385,044
Ensembl chr16:57,372,477...57,385,044
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA panobinostat results in increased expression of CXCL12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CXCL14 |
C-X-C motif chemokine ligand 14 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA panobinostat results in increased expression of CXCL14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:135,570,679...135,578,991
Ensembl chr 5:135,570,679...135,579,279
|
|
G |
CXCL5 |
C-X-C motif chemokine ligand 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA panobinostat results in increased expression of CXCL5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:73,995,642...73,998,677
Ensembl chr 4:73,995,642...73,998,677
|
|
G |
CXCR4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
|
|
G |
CXXC5 |
CXXC finger protein 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA panobinostat results in increased expression of CXXC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:139,647,299...139,683,882
Ensembl chr 5:139,647,299...139,683,882
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA panobinostat results in increased expression of CYP1A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of CYP1B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYREN |
cell cycle regulator of NHEJ |
decreases expression |
EXP |
panobinostat results in decreased expression of CYREN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:135,092,303...135,172,469
Ensembl chr 7:135,092,363...135,170,795
|
|
G |
CYRIA |
CYFIP related Rac1 interactor A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA Panobinostat results in increased expression of CYRIA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:16,549,459...16,665,834
Ensembl chr 2:16,549,459...16,666,331
|
|
G |
DAB1 |
DAB adaptor protein 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA panobinostat results in decreased expression of DAB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:56,994,778...58,546,726
Ensembl chr 1:56,994,778...58,546,734
|
|
G |
DACH2 |
dachshund family transcription factor 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DACH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:86,148,451...86,832,602
Ensembl chr X:86,148,451...86,832,604
|
|
G |
DACT1 |
dishevelled binding antagonist of beta catenin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA panobinostat results in increased expression of DACT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:58,634,061...58,648,321
Ensembl chr14:58,633,967...58,648,321
|
|
G |
DAZL |
deleted in azoospermia like |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA panobinostat results in decreased expression of DAZL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:16,586,792...16,605,423
Ensembl chr 3:16,586,792...16,670,306
|
|
G |
DCAF12L2 |
DDB1 and CUL4 associated factor 12 like 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA panobinostat results in decreased expression of DCAF12L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:126,163,499...126,166,289
Ensembl chr X:126,163,499...126,166,289
|
|
G |
DCAF4 |
DDB1 and CUL4 associated factor 4 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DCAF4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:72,926,464...72,962,098
Ensembl chr14:72,926,377...72,959,703
|
|
G |
DCC |
DCC netrin 1 receptor |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA panobinostat results in increased expression of DCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:52,340,197...53,535,899
Ensembl chr18:52,340,197...53,535,899
|
|
G |
DCLK1 |
doublecortin like kinase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA panobinostat results in increased expression of DCLK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:35,768,652...36,131,939
Ensembl chr13:35,768,652...36,131,382
|
|
G |
DCLK2 |
doublecortin like kinase 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA panobinostat results in decreased expression of DCLK2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:150,078,445...150,257,438
Ensembl chr 4:150,078,445...150,257,438
|
|
G |
DCUN1D4 |
defective in cullin neddylation 1 domain containing 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:51,833,884...51,916,837
Ensembl chr 4:51,843,000...51,916,837
|
|
G |
DENND1A |
DENN domain containing 1A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA panobinostat results in decreased expression of DENND1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:123,379,658...123,930,126
Ensembl chr 9:123,379,654...123,930,152
|
|
G |
DENND1B |
DENN domain containing 1B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA panobinostat results in decreased expression of DENND1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:197,504,748...197,782,150
Ensembl chr 1:197,504,748...197,775,696
|
|
G |
DENND2A |
DENN domain containing 2A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA panobinostat results in decreased expression of DENND2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:140,518,419...140,641,460
Ensembl chr 7:140,518,420...140,673,993
|
|
G |
DENND4A |
DENN domain containing 4A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA panobinostat results in increased expression of DENND4A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:65,659,123...65,792,293
Ensembl chr15:65,658,046...65,792,293
|
|
G |
DEPDC1B |
DEP domain containing 1B |
decreases expression |
EXP |
panobinostat results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:60,596,912...60,700,166
Ensembl chr 5:60,596,912...60,700,190
|
|
G |
DEPDC7 |
DEP domain containing 7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DEPDC7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:33,015,878...33,033,582
Ensembl chr11:33,015,876...33,033,582
|
|
G |
DEPTOR |
DEP domain containing MTOR interacting protein |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DEPTOR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:119,873,722...120,050,918
Ensembl chr 8:119,873,717...120,050,918
|
|
G |
DHRS3 |
dehydrogenase/reductase 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DHRS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:12,567,910...12,618,210
Ensembl chr 1:12,567,909...12,620,133
|
|
G |
DIAPH2 |
diaphanous related formin 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DIAPH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:96,684,842...97,604,997
Ensembl chr X:96,684,712...97,604,997
|
|
G |
DIPK1C |
divergent protein kinase domain 1C |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of DIPK1C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:74,434,775...74,464,648
Ensembl chr18:74,434,775...74,457,944
|
|
G |
DLC1 |
DLC1 Rho GTPase activating protein |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DLC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:13,083,361...13,604,620
Ensembl chr 8:13,083,361...13,604,610
|
|
G |
DLK1 |
delta like non-canonical Notch ligand 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of DLK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:100,726,892...100,738,224
Ensembl chr14:100,725,705...100,738,224
|
|
G |
DLX3 |
distal-less homeobox 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DLX3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:49,990,005...49,995,224
Ensembl chr17:49,990,005...49,995,224
|
|
G |
DLX6 |
distal-less homeobox 6 |
decreases expression |
EXP |
panobinostat results in decreased expression of DLX6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:97,005,553...97,011,040
Ensembl chr 7:97,005,553...97,011,040
|
|
G |
DMRTA2 |
DMRT like family A2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA panobinostat results in increased expression of DMRTA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:50,417,550...50,423,443
Ensembl chr 1:50,417,550...50,423,443
|
|
G |
DMXL1 |
Dmx like 1 |
increases expression |
EXP |
Panobinostat results in increased expression of DMXL1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:119,071,027...119,249,127
Ensembl chr 5:119,037,772...119,249,138
|
|
G |
DNER |
delta/notch like EGF repeat containing |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:229,357,629...229,714,555
Ensembl chr 2:229,357,629...229,714,555
|
|
G |
DOCK5 |
dedicator of cytokinesis 5 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DOCK5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:25,184,689...25,415,711
Ensembl chr 8:25,184,689...25,418,082
|
|
G |
DOCK9 |
dedicator of cytokinesis 9 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DOCK9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:98,793,429...99,088,619
Ensembl chr13:98,793,429...99,086,625
|
|
G |
DOK5 |
docking protein 5 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:54,475,593...54,651,169
Ensembl chr20:54,475,593...54,651,169
|
|
G |
DPPA5 |
developmental pluripotency associated 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA panobinostat results in increased expression of DPPA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:73,353,063...73,354,276
Ensembl chr 6:73,353,063...73,354,276
|
|
G |
DPY19L2P2 |
DPY19L2 pseudogene 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of DPY19L2P2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:103,175,013...103,280,466
Ensembl chr 7:103,175,133...103,280,410 Ensembl chr 7:103,175,133...103,280,410
|
|
G |
DSC2 |
desmocollin 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DSC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:31,058,840...31,102,421
Ensembl chr18:31,058,545...31,102,600
|
|
G |
DST |
dystonin |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of DST mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:56,457,996...56,954,830
Ensembl chr 6:56,457,987...56,954,830
|
|
G |
DTWD1 |
DTW domain containing 1 |
decreases expression |
EXP |
Panobinostat results in decreased expression of DTWD1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr15:49,621,048...49,656,232
Ensembl chr15:49,621,037...49,656,232
|
|
G |
DUSP10 |
dual specificity phosphatase 10 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of DUSP10 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:221,701,424...221,742,089
Ensembl chr 1:221,701,424...221,742,089
|
|
G |
DUSP23 |
dual specificity phosphatase 23 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:159,780,962...159,782,543
Ensembl chr 1:159,780,932...159,782,543
|
|
G |
DUSP4 |
dual specificity phosphatase 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of DUSP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:29,333,064...29,350,684
Ensembl chr 8:29,333,064...29,350,684
|
|
G |
DUSP5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA panobinostat results in increased expression of DUSP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:110,497,907...110,511,533
Ensembl chr10:110,497,907...110,511,533
|
|
G |
DYNC1I1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA panobinostat results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:95,772,554...96,110,322
Ensembl chr 7:95,772,506...96,110,322
|
|
G |
DYRK3 |
dual specificity tyrosine phosphorylation regulated kinase 3 |
increases expression |
EXP |
Panobinostat results in increased expression of DYRK3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:206,635,536...206,655,158
Ensembl chr 1:206,635,536...206,684,419
|
|
G |
E2F2 |
E2F transcription factor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA panobinostat results in decreased expression of E2F2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:23,505,212...23,531,233
Ensembl chr 1:23,506,438...23,531,233
|
|
G |
EAF2 |
ELL associated factor 2 |
increases expression |
EXP |
Panobinostat results in increased expression of EAF2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:121,835,209...121,886,526
Ensembl chr 3:121,835,183...121,886,526
|
|
G |
EBF1 |
EBF transcription factor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA panobinostat results in increased expression of EBF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:158,695,920...159,099,916
Ensembl chr 5:158,695,920...159,099,916
|
|
G |
EBI3 |
Epstein-Barr virus induced 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:4,229,523...4,237,528
Ensembl chr19:4,229,523...4,237,528
|
|
G |
ECPAS |
Ecm29 proteasome adaptor and scaffold |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA panobinostat results in decreased expression of ECPAS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:111,360,685...111,484,383
Ensembl chr 9:111,360,685...111,484,745
|
|
G |
EDN1 |
endothelin 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EDN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDNRA |
endothelin receptor type A |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EDNRA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EDNRB |
endothelin receptor type B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA panobinostat results in increased expression of EDNRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
|
|
G |
EFNA1 |
ephrin A1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA panobinostat results in increased expression of EFNA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899
|
|
G |
EFNA5 |
ephrin A5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA panobinostat results in decreased expression of EFNA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:107,376,894...107,670,937
Ensembl chr 5:107,376,894...107,670,937
|
|
G |
EGF |
epidermal growth factor |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA panobinostat results in decreased expression of EGF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFL8 |
EGF like domain multiple 8 |
increases expression |
EXP |
panobinostat results in increased expression of EGFL8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 6:32,164,595...32,168,281
Ensembl chr 6:32,164,595...32,168,281
|
|
G |
EIF3M |
eukaryotic translation initiation factor 3 subunit M |
decreases expression |
EXP |
panobinostat results in decreased expression of EIF3M mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:32,583,831...32,606,264
Ensembl chr11:32,583,798...32,606,264
|
|
G |
EIF4E3 |
eukaryotic translation initiation factor 4E family member 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of EIF4E3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:71,659,363...71,754,773
Ensembl chr 3:71,675,414...71,754,773
|
|
G |
ELF1 |
E74 like ETS transcription factor 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ELF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:40,931,919...41,061,386
Ensembl chr13:40,931,924...41,061,440
|
|
G |
ELF3 |
E74 like ETS transcription factor 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ELF3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:202,010,587...202,017,183
Ensembl chr 1:202,007,945...202,017,183
|
|
G |
ELF5 |
E74 like ETS transcription factor 5 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:34,478,791...34,513,794
Ensembl chr11:34,478,791...34,525,193
|
|
G |
ELK3 |
ETS transcription factor ELK3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ELK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:96,194,375...96,269,824
Ensembl chr12:96,194,375...96,269,824
|
|
G |
ELMOD1 |
ELMO domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ELMOD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:107,591,147...107,666,779
Ensembl chr11:107,591,091...107,666,779
|
|
G |
ELOVL2 |
ELOVL fatty acid elongase 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ELOVL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:10,980,759...11,044,305
Ensembl chr 6:10,980,759...11,044,305
|
|
G |
ELP4 |
elongator acetyltransferase complex subunit 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ELP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:31,509,767...31,790,324
Ensembl chr11:31,509,755...31,790,324
|
|
G |
EMILIN3 |
elastin microfibril interfacer 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of EMILIN3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:41,359,962...41,366,818
Ensembl chr20:41,359,962...41,366,818
|
|
G |
EMP1 |
epithelial membrane protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EMP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:13,196,726...13,219,941
Ensembl chr12:13,196,723...13,219,941
|
|
G |
ENOX1 |
ecto-NOX disulfide-thiol exchanger 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:43,213,130...43,786,972
Ensembl chr13:43,213,130...43,786,972
|
|
G |
ENPP2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA panobinostat results in increased expression of ENPP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:119,557,086...119,673,390
Ensembl chr 8:119,557,086...119,673,453
|
|
G |
EOGT |
EGF domain specific O-linked N-acetylglucosamine transferase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA panobinostat results in increased expression of EOGT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:68,975,225...69,013,684
Ensembl chr 3:68,975,217...69,013,684
|
|
G |
EPAS1 |
endothelial PAS domain protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EPAS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:46,297,407...46,386,697
Ensembl chr 2:46,293,667...46,386,697
|
|
G |
EPB41L3 |
erythrocyte membrane protein band 4.1 like 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EPB41L3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:5,392,386...5,630,663
Ensembl chr18:5,392,381...5,630,700
|
|
G |
EPB41L5 |
erythrocyte membrane protein band 4.1 like 5 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EPB41L5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:120,013,077...120,179,119
Ensembl chr 2:120,013,077...120,179,119
|
|
G |
EPCAM |
epithelial cell adhesion molecule |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA panobinostat results in increased expression of EPCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:47,369,311...47,387,020
Ensembl chr 2:47,345,158...47,387,601
|
|
G |
EPHA1 |
EPH receptor A1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:143,391,129...143,408,856
Ensembl chr 7:143,390,289...143,408,856
|
|
G |
EPHA3 |
EPH receptor A3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA panobinostat results in increased expression of EPHA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:89,107,621...89,482,134
Ensembl chr 3:89,107,621...89,482,134
|
|
G |
EPHA4 |
EPH receptor A4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA panobinostat results in decreased expression of EPHA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:221,418,027...221,574,202
Ensembl chr 2:221,418,027...221,574,202
|
|
G |
EPHA7 |
EPH receptor A7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of EPHA7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:93,240,020...93,419,559
Ensembl chr 6:93,240,020...93,419,687
|
|
G |
EPHB2 |
EPH receptor B2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of EPHB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:22,710,838...22,921,500
Ensembl chr 1:22,710,839...22,921,500
|
|
G |
EPN3 |
epsin 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:50,532,735...50,543,750
Ensembl chr17:50,532,682...50,543,750
|
|
G |
EPS8L2 |
EPS8 signaling adaptor L2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:706,231...727,727
Ensembl chr11:694,438...727,727
|
|
G |
EPSTI1 |
epithelial stromal interaction 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA panobinostat results in increased expression of EPSTI1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:42,886,388...42,992,241
Ensembl chr13:42,886,388...42,992,271
|
|
G |
ERAP1 |
endoplasmic reticulum aminopeptidase 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA panobinostat results in decreased expression of ERAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:96,760,813...96,935,854
Ensembl chr 5:96,760,810...96,808,100
|
|
G |
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA panobinostat results in increased expression of ERBB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505
|
|
G |
ERLEC1P1 |
endoplasmic reticulum lectin 1 pseudogene 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr21:14,078,974...14,144,467
Ensembl chr21:14,143,581...14,144,158
|
|
G |
ERP27 |
endoplasmic reticulum protein 27 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA panobinostat results in increased expression of ERP27 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:14,914,039...14,938,537
Ensembl chr12:14,914,039...14,938,537
|
|
G |
ERVH-1 |
endogenous retrovirus group H member 1 |
increases expression |
EXP |
Panobinostat results in increased expression of ERVH-1 mRNA |
CTD |
PMID:26272509 |
|
Ensembl chr 4:23,723,262...23,733,579
|
|
G |
ERVH48-1 |
endogenous retrovirus group 48 member 1, envelope |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA panobinostat results in increased expression of ERVH48-1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:42,916,803...42,925,630
Ensembl chr21:42,916,803...42,925,630
|
|
G |
ESRG |
embryonic stem cell related |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA panobinostat results in increased expression of ESRG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:54,632,124...54,639,857
Ensembl chr 3:54,632,122...54,639,857
|
|
G |
ESRP1 |
epithelial splicing regulatory protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ESRP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:94,641,174...94,707,466
Ensembl chr 8:94,641,074...94,707,466
|
|
G |
ESRP2 |
epithelial splicing regulatory protein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA panobinostat results in increased expression of ESRP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:68,229,033...68,236,127
Ensembl chr16:68,229,033...68,238,102
|
|
G |
ETNK1 |
ethanolamine kinase 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ETNK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:22,625,171...22,690,665
Ensembl chr12:22,625,075...22,690,665
|
|
G |
ETS1 |
ETS proto-oncogene 1, transcription factor |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ETS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558
|
|
G |
ETV1 |
ETS variant transcription factor 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA panobinostat results in decreased expression of ETV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:13,891,229...13,991,425
Ensembl chr 7:13,891,229...13,991,425
|
|
G |
EXT1 |
exostosin glycosyltransferase 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA panobinostat results in decreased expression of EXT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:117,794,490...118,111,826
Ensembl chr 8:117,794,490...118,111,826
|
|
G |
EZR |
ezrin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA panobinostat results in increased expression of EZR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:158,765,748...158,819,368
Ensembl chr 6:158,765,741...158,819,368
|
|
G |
F2RL1 |
F2R like trypsin receptor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA panobinostat results in increased expression of F2RL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315
|
|
G |
F2RL2 |
coagulation factor II thrombin receptor like 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA panobinostat results in decreased expression of F2RL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:76,615,482...76,623,403
Ensembl chr 5:76,615,482...76,623,413
|
|
G |
FABP3 |
fatty acid binding protein 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA panobinostat results in increased expression of FABP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:31,359,588...31,373,076
Ensembl chr 1:31,365,253...31,376,850
|
|
G |
FAM110B |
family with sequence similarity 110 member B |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:57,994,523...58,148,784
Ensembl chr 8:57,994,523...58,204,279
|
|
G |
FAM124A |
family with sequence similarity 124 member A |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FAM124A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:51,222,398...51,284,239
Ensembl chr13:51,222,334...51,284,239
|
|
G |
FAM13C |
family with sequence similarity 13 member C |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA panobinostat results in increased expression of FAM13C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:59,246,129...59,363,181
Ensembl chr10:59,246,130...59,363,181
|
|
G |
FAM149A |
family with sequence similarity 149 member A |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FAM149A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:186,104,704...186,175,337
Ensembl chr 4:186,104,419...186,175,337
|
|
G |
FAM162B |
family with sequence similarity 162 member B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA panobinostat results in increased expression of FAM162B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:116,752,197...116,765,719
Ensembl chr 6:116,752,197...116,765,719
|
|
G |
FAM163A |
family with sequence similarity 163 member A |
affects expression multiple interactions |
EXP |
panobinostat affects the expression of FAM163A mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 1:179,727,776...179,816,198
Ensembl chr 1:179,743,291...179,816,198
|
|
G |
FAM168A |
family with sequence similarity 168 member A |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FAM168A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:73,400,487...73,598,112
Ensembl chr11:73,400,487...73,598,189
|
|
G |
FAM200B |
family with sequence similarity 200 member B |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FAM200B mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:15,636,791...15,690,447
Ensembl chr 4:15,681,662...15,690,447
|
|
G |
FAM226B |
family with sequence similarity 226 member B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA panobinostat results in decreased expression of FAM226B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:72,777,073...72,779,095
Ensembl chr X:72,777,608...72,779,097
|
|
G |
FAM241A |
family with sequence similarity 241 member A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:112,145,454...112,195,256
Ensembl chr 4:112,145,454...112,195,256
|
|
G |
FAM43A |
family with sequence similarity 43 member A |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FAM43A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:194,685,883...194,689,037
Ensembl chr 3:194,685,883...194,689,037
|
|
G |
FAM89A |
family with sequence similarity 89 member A |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FAM89A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:231,018,958...231,040,254
Ensembl chr 1:231,018,958...231,040,254
|
|
G |
FANK1 |
fibronectin type III and ankyrin repeat domains 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA panobinostat results in decreased expression of FANK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:125,896,564...126,009,592
Ensembl chr10:125,896,564...126,009,592
|
|
G |
FAT3 |
FAT atypical cadherin 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FAT3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:92,224,818...92,896,473
Ensembl chr11:92,224,818...92,896,473
|
|
G |
FAXC |
failed axon connections homolog, metaxin like GST domain containing |
affects expression multiple interactions |
EXP |
panobinostat affects the expression of FAXC mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 6:99,271,161...99,350,056
Ensembl chr 6:99,271,168...99,350,062
|
|
G |
FBLN7 |
fibulin 7 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FBLN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:112,138,385...112,244,708
Ensembl chr 2:112,138,385...112,188,218
|
|
G |
FBN1 |
fibrillin 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA panobinostat results in decreased expression of FBN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:48,408,313...48,645,709
Ensembl chr15:48,408,313...48,645,721
|
|
G |
FBXL13 |
F-box and leucine rich repeat protein 13 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:102,811,189...103,074,796
Ensembl chr 7:102,811,189...103,074,839
|
|
G |
FBXO2 |
F-box protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FBXO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:11,648,387...11,654,429
Ensembl chr 1:11,637,018...11,655,785
|
|
G |
FBXO8 |
F-box protein 8 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 4:174,236,658...174,283,667
Ensembl chr 4:174,236,658...174,283,667
|
|
G |
FBXO9 |
F-box protein 9 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:53,064,998...53,100,873
Ensembl chr 6:53,051,991...53,100,873
|
|
G |
FERMT1 |
FERM domain containing kindlin 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FERMT1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:6,074,845...6,123,030
Ensembl chr20:6,074,845...6,123,214
|
|
G |
FEZ1 |
fasciculation and elongation protein zeta 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA panobinostat results in decreased expression of FEZ1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:125,442,881...125,496,265
Ensembl chr11:125,442,881...125,592,568
|
|
G |
FEZF2 |
FEZ family zinc finger 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA panobinostat results in decreased expression of FEZF2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:62,369,681...62,373,550
Ensembl chr 3:62,369,681...62,374,324
|
|
G |
FGD5 |
FYVE, RhoGEF and PH domain containing 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA panobinostat results in increased expression of FGD5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:14,810,688...14,934,571
Ensembl chr 3:14,810,853...14,934,571
|
|
G |
FGF18 |
fibroblast growth factor 18 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:171,419,647...171,457,626
Ensembl chr 5:171,419,647...171,457,626
|
|
G |
FGF19 |
fibroblast growth factor 19 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FGF19 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
|
|
G |
FGF8 |
fibroblast growth factor 8 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FGF8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:101,770,109...101,780,369
Ensembl chr10:101,770,109...101,780,371
|
|
G |
FGF9 |
fibroblast growth factor 9 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of FGF9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498
|
|
G |
FGFBP3 |
fibroblast growth factor binding protein 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FGFBP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:91,906,584...91,909,486
Ensembl chr10:91,906,584...91,909,486
|
|
G |
FGFR3 |
fibroblast growth factor receptor 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA panobinostat results in increased expression of FGFR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872
|
|
G |
FHOD3 |
formin homology 2 domain containing 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA panobinostat results in decreased expression of FHOD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:36,297,713...36,780,220
Ensembl chr18:36,297,713...36,780,220
|
|
G |
FIGN |
fidgetin, microtubule severing factor |
affects expression multiple interactions |
EXP |
panobinostat affects the expression of FIGN mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 2:163,602,611...163,736,008
Ensembl chr 2:163,593,396...163,736,012
|
|
G |
FJX1 |
four-jointed box kinase 1 |
decreases expression |
EXP |
panobinostat results in decreased expression of FJX1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:35,618,460...35,620,865
Ensembl chr11:35,618,460...35,620,865
|
|
G |
FLNB |
filamin B |
increases expression |
EXP |
panobinostat results in increased expression of FLNB mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:58,008,422...58,172,251
Ensembl chr 3:58,008,398...58,172,251
|
|
G |
FLRT2 |
fibronectin leucine rich transmembrane protein 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA panobinostat results in decreased expression of FLRT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:85,530,144...85,654,428
Ensembl chr14:85,530,144...85,654,428
|
|
G |
FLT1 |
fms related receptor tyrosine kinase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA panobinostat results in increased expression of FLT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
|
|
G |
FNDC5 |
fibronectin type III domain containing 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA panobinostat results in decreased expression of FNDC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:32,862,268...32,872,484
Ensembl chr 1:32,862,268...32,872,482
|
|
G |
FOXC1 |
forkhead box C1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FOXC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:1,609,915...1,613,897
Ensembl chr 6:1,609,915...1,613,897
|
|
G |
FOXC2 |
forkhead box C2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FOXC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:86,566,829...86,569,728
Ensembl chr16:86,566,829...86,569,728
|
|
G |
FOXD3 |
forkhead box D3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FOXD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:63,322,567...63,325,128
Ensembl chr 1:63,322,567...63,325,128
|
|
G |
FOXH1 |
forkhead box H1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FOXH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:144,473,412...144,475,849
Ensembl chr 8:144,473,412...144,475,849
|
|
G |
FOXO1 |
forkhead box O1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of FOXO1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FRAS1 |
Fraser extracellular matrix complex subunit 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 4:78,057,323...78,544,269
Ensembl chr 4:78,057,323...78,544,269
|
|
G |
FREM1 |
FRAS1 related extracellular matrix 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA panobinostat results in increased expression of FREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:14,737,152...14,910,995
Ensembl chr 9:14,737,152...14,910,995
|
|
G |
FRRS1L |
ferric chelate reductase 1 like |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA panobinostat results in decreased expression of FRRS1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:109,130,293...109,167,249
Ensembl chr 9:109,130,293...109,167,249
|
|
G |
FRZB |
frizzled related protein |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA panobinostat results in decreased expression of FRZB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:182,833,275...182,866,637
Ensembl chr 2:182,833,275...182,866,637
|
|
G |
FUT4 |
fucosyltransferase 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA panobinostat results in increased expression of FUT4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:94,543,921...94,549,895
Ensembl chr11:94,543,921...94,549,895
|
|
G |
FUT9 |
fucosyltransferase 9 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA panobinostat results in decreased expression of FUT9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:96,015,974...96,215,612
Ensembl chr 6:96,015,974...96,215,612
|
|
G |
FZD10 |
frizzled class receptor 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA panobinostat results in increased expression of FZD10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:130,162,464...130,165,740
Ensembl chr12:130,162,459...130,165,740
|
|
G |
FZD2 |
frizzled class receptor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA panobinostat results in decreased expression of FZD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:44,557,484...44,561,262
Ensembl chr17:44,557,484...44,561,262
|
|
G |
FZD3 |
frizzled class receptor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA panobinostat results in decreased expression of FZD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:28,494,212...28,574,258
Ensembl chr 8:28,494,205...28,574,267
|
|
G |
FZD5 |
frizzled class receptor 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA panobinostat results in decreased expression of FZD5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:207,762,598...207,769,906
Ensembl chr 2:207,762,598...207,769,906
|
|
G |
FZD7 |
frizzled class receptor 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA panobinostat results in increased expression of FZD7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:202,033,855...202,038,441
Ensembl chr 2:202,033,855...202,038,441
|
|
G |
FZD8 |
frizzled class receptor 8 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:35,638,247...35,642,296
Ensembl chr10:35,638,247...35,642,296
|
|
G |
GABRB2 |
gamma-aminobutyric acid type A receptor subunit beta2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA panobinostat results in increased expression of GABRB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:161,288,436...161,548,404
Ensembl chr 5:161,288,429...161,549,044
|
|
G |
GABRB3 |
gamma-aminobutyric acid type A receptor subunit beta3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA panobinostat results in increased expression of GABRB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:26,543,552...26,773,763
Ensembl chr15:26,543,552...26,939,539
|
|
G |
GABRP |
gamma-aminobutyric acid type A receptor subunit pi |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:170,782,720...170,814,047
Ensembl chr 5:170,763,350...170,814,047
|
|
G |
GAD1 |
glutamate decarboxylase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA panobinostat results in increased expression of GAD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:170,813,210...170,861,151
Ensembl chr 2:170,813,213...170,861,151
|
|
G |
GAD2 |
glutamate decarboxylase 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:26,216,372...26,304,558
Ensembl chr10:26,216,665...26,304,558
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA] panobinostat results in increased expression of GADD45A mRNA |
CTD |
PMID:23681230 PMID:26272509 PMID:27188386 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GADD45B mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:2,476,127...2,478,257
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GADD45G |
growth arrest and DNA damage inducible gamma |
multiple interactions increases expression |
EXP |
GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA] |
CTD |
PMID:23681230 |
|
NCBI chr 9:89,605,012...89,606,555
Ensembl chr 9:89,605,012...89,606,555
|
|
G |
GALNT18 |
polypeptide N-acetylgalactosaminyltransferase 18 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA panobinostat results in increased expression of GALNT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:11,270,877...11,622,005
Ensembl chr11:11,270,877...11,622,005
|
|
G |
GALNT3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA panobinostat results in increased expression of GALNT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:165,747,588...165,794,692
Ensembl chr 2:165,747,588...165,846,201
|
|
G |
GAP43 |
growth associated protein 43 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA panobinostat results in increased expression of GAP43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:115,623,510...115,721,483
Ensembl chr 3:115,623,510...115,721,490
|
|
G |
GARIN1B |
golgi associated RAB2 interactor 1B |
decreases expression |
EXP |
Panobinostat results in decreased expression of GARIN1B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:128,709,061...128,731,743
Ensembl chr 7:128,709,061...128,731,743
|
|
G |
GAS7 |
growth arrest specific 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA panobinostat results in increased expression of GAS7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:9,910,606...10,198,606
Ensembl chr17:9,910,606...10,198,606
|
|
G |
GATA2 |
GATA binding protein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA panobinostat results in increased expression of GATA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201
|
|
G |
GATA3 |
GATA binding protein 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA panobinostat results in increased expression of GATA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA panobinostat results in decreased expression of GATA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002
|
|
G |
GATA6 |
GATA binding protein 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:22,169,589...22,202,528
Ensembl chr18:22,169,589...22,202,528
|
|
G |
GBX2 |
gastrulation brain homeobox 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GBX2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:236,161,340...236,168,386
Ensembl chr 2:236,165,236...236,168,386
|
|
G |
GCHFR |
GTP cyclohydrolase I feedback regulator |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GCHFR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:40,764,068...40,767,708
Ensembl chr15:40,764,068...40,767,708
|
|
G |
GDF10 |
growth differentiation factor 10 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:47,300,197...47,313,577
Ensembl chr10:47,300,197...47,313,577
|
|
G |
GJA3 |
gap junction protein alpha 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GJA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:20,138,255...20,161,565
Ensembl chr13:20,138,255...20,161,052
|
|
G |
GJB2 |
gap junction protein beta 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
|
|
G |
GJE1 |
gap junction protein epsilon 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:142,132,925...142,135,358
Ensembl chr 6:142,132,925...142,135,358
|
|
G |
GKAP1 |
G kinase anchoring protein 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA panobinostat results in decreased expression of GKAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:83,739,425...83,817,769
Ensembl chr 9:83,739,425...83,829,516
|
|
G |
GLB1L |
galactosidase beta 1 like |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 2:219,236,598...219,245,444
Ensembl chr 2:219,236,598...219,245,478
|
|
G |
GLCCI1 |
glucocorticoid induced 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GLCCI1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:7,968,796...8,089,080
Ensembl chr 7:7,968,796...8,094,272
|
|
G |
GLIS3 |
GLIS family zinc finger 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GLIS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:3,824,127...4,490,465
Ensembl chr 9:3,824,127...4,348,392
|
|
G |
GLRX2 |
glutaredoxin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA panobinostat results in increased expression of GLRX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:193,096,465...193,106,114
Ensembl chr 1:193,090,866...193,106,114
|
|
G |
GLS |
glutaminase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA panobinostat results in increased expression of GLS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552
|
|
G |
GNAS |
GNAS complex locus |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA panobinostat results in increased expression of GNAS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:58,839,748...58,911,192
Ensembl chr20:58,839,718...58,911,192
|
|
G |
GNG11 |
G protein subunit gamma 11 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA panobinostat results in increased expression of GNG11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:93,921,735...93,928,610
Ensembl chr 7:93,921,735...93,928,610
|
|
G |
GNG8 |
G protein subunit gamma 8 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA panobinostat results in decreased expression of GNG8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:46,633,953...46,639,326
Ensembl chr19:46,633,953...46,636,541
|
|
G |
GNL3L |
G protein nucleolar 3 like |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA |
CTD |
PMID:21791302 |
|
NCBI chr X:54,530,219...54,645,854
Ensembl chr X:54,530,183...54,621,521
|
|
G |
GPC3 |
glypican 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GPC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:133,535,745...133,985,594
Ensembl chr X:133,535,745...133,987,100
|
|
G |
GPC4 |
glypican 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GPC4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:133,300,103...133,415,489
Ensembl chr X:133,300,103...133,415,489
|
|
G |
GPC6 |
glypican 6 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA panobinostat results in decreased expression of GPC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:93,216,529...94,408,020
Ensembl chr13:93,226,807...94,408,020
|
|
G |
GPD1L |
glycerol-3-phosphate dehydrogenase 1 like |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GPD1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:32,106,620...32,168,709
Ensembl chr 3:32,105,689...32,168,709
|
|
G |
GPR173 |
G protein-coupled receptor 173 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GPR173 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:53,048,789...53,080,615
Ensembl chr X:53,048,789...53,080,615
|
|
G |
GPR183 |
G protein-coupled receptor 183 |
decreases expression |
EXP |
Panobinostat results in decreased expression of GPR183 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr13:99,294,539...99,307,399
Ensembl chr13:99,294,539...99,307,399
|
|
G |
GPR27 |
G protein-coupled receptor 27 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GPR27 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:71,753,855...71,756,496
Ensembl chr 3:71,753,855...71,756,496
|
|
G |
GPR37 |
G protein-coupled receptor 37 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GPR37 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:124,743,885...124,765,792
Ensembl chr 7:124,743,885...124,765,792
|
|
G |
GREM1 |
gremlin 1, DAN family BMP antagonist |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GREM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:32,718,004...32,745,106
Ensembl chr15:32,718,004...32,745,106
|
|
G |
GRHL1 |
grainyhead like transcription factor 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:9,951,693...10,002,277
Ensembl chr 2:9,951,693...10,002,277
|
|
G |
GRHL2 |
grainyhead like transcription factor 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:101,492,439...101,681,200
Ensembl chr 8:101,492,439...101,669,726
|
|
G |
GRHL3 |
grainyhead like transcription factor 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GRHL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:24,319,357...24,364,482
Ensembl chr 1:24,199,558...24,364,482
|
|
G |
GRIA1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:153,489,615...153,813,869
Ensembl chr 5:153,489,615...153,813,869
|
|
G |
GRIA3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GRIA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:123,184,278...123,490,915
Ensembl chr X:123,184,153...123,490,915
|
|
G |
GRIK3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of GRIK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:36,795,527...37,034,515
Ensembl chr 1:36,795,527...37,034,515
|
|
G |
GRIN2A |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928
|
|
G |
GRM3 |
glutamate metabotropic receptor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA panobinostat results in decreased expression of GRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,643,909...86,864,879
Ensembl chr 7:86,643,909...86,864,879
|
|
G |
GSEC |
G-quadruplex forming sequence containing lncRNA |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA panobinostat results in decreased expression of GSEC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:126,341,716...126,355,587
Ensembl chr11:126,340,882...126,355,587
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
GSTA2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:52,750,087...52,763,475
Ensembl chr 6:52,750,087...52,763,475
|
|
G |
GSTA5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:52,831,692...52,846,245
Ensembl chr 6:52,831,655...52,840,843
|
|
G |
GUCY1A1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 4:155,666,848...155,737,059
Ensembl chr 4:155,666,726...155,737,059
|
|
G |
GYPC |
glycophorin C (Gerbich blood group) |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of GYPC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:126,656,158...126,696,667
Ensembl chr 2:126,656,133...126,696,667
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions increases expression |
EXP |
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein] |
CTD |
PMID:22923501 PMID:23681230 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
H2BC12 |
H2B clustered histone 12 |
decreases expression multiple interactions |
EXP |
Panobinostat results in decreased expression of H2BC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:27,138,293...27,146,858
Ensembl chr 6:27,146,361...27,146,855
|
|
G |
H2BW4P |
H2B.W histone 4, pseudogene |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA Panobinostat results in decreased expression of H2BW4P mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:103,975,924...103,978,357
|
|
G |
H3-4 |
H3.4 histone, cluster member |
increases acetylation |
EXP |
Panobinostat results in increased acetylation of H3-4 protein |
CTD |
PMID:19215824 |
|
NCBI chr 1:228,424,845...228,425,360
Ensembl chr 1:228,424,845...228,425,360
|
|
G |
H4C16 |
H4 histone 16 |
increases acetylation |
EXP |
Panobinostat results in increased acetylation of H4C16 protein |
CTD |
PMID:19215824 |
|
NCBI chr12:14,770,720...14,771,131
Ensembl chr12:14,767,999...14,771,131
|
|
G |
HACD1 |
3-hydroxyacyl-CoA dehydratase 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HACD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:17,589,032...17,617,374
Ensembl chr10:17,589,032...17,617,374
|
|
G |
HAND1 |
heart and neural crest derivatives expressed 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:154,474,972...154,478,227
Ensembl chr 5:154,474,972...154,478,227
|
|
G |
HAPLN1 |
hyaluronan and proteoglycan link protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA panobinostat results in increased expression of HAPLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:83,637,805...83,720,855
Ensembl chr 5:83,637,805...83,720,855
|
|
G |
HAS2 |
hyaluronan synthase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA panobinostat results in increased expression of HAS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:121,612,116...121,641,440
Ensembl chr 8:121,612,116...121,641,440
|
|
G |
HCK |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:32,052,242...32,101,856
Ensembl chr20:32,052,197...32,101,856
|
|
G |
HDAC8 |
histone deacetylase 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA panobinostat results in increased expression of HDAC8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:72,329,516...72,572,843
Ensembl chr X:72,329,516...72,573,101
|
|
G |
HDAC9 |
histone deacetylase 9 |
decreases expression |
EXP |
Panobinostat results in decreased expression of HDAC9 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr 7:18,086,825...19,002,416
Ensembl chr 7:18,086,949...19,002,416
|
|
G |
HEG1 |
heart development protein with EGF like domains 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA panobinostat results in decreased expression of HEG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:124,965,710...125,055,997
Ensembl chr 3:124,965,710...125,055,997
|
|
G |
HERC5 |
HECT and RLD domain containing E3 ubiquitin protein ligase 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA panobinostat results in increased expression of HERC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:88,457,119...88,506,163
Ensembl chr 4:88,457,119...88,506,163
|
|
G |
HES2 |
hes family bHLH transcription factor 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HES2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:6,415,232...6,419,919
Ensembl chr 1:6,412,418...6,424,670
|
|
G |
HES5 |
hes family bHLH transcription factor 5 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of HES5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:2,528,745...2,530,263
Ensembl chr 1:2,528,745...2,530,263
|
|
G |
HESX1 |
HESX homeobox 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of HESX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:57,197,838...57,227,615
Ensembl chr 3:57,197,838...57,227,606
|
|
G |
HEY2 |
hes related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA panobinostat results in increased expression of HEY2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:125,749,632...125,761,269
Ensembl chr 6:125,747,664...125,761,269
|
|
G |
HHIP |
hedgehog interacting protein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:144,646,156...144,745,271
Ensembl chr 4:144,646,156...144,745,271
|
|
G |
HIP1 |
huntingtin interacting protein 1 |
increases expression |
EXP |
Panobinostat results in increased expression of HIP1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:75,533,298...75,738,941
Ensembl chr 7:75,533,298...75,738,962
|
|
G |
HK1 |
hexokinase 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:69,270,000...69,401,882
Ensembl chr10:69,269,984...69,401,884
|
|
G |
HLA-DMA |
major histocompatibility complex, class II, DM alpha |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA panobinostat results in increased expression of HLA-DMA mRNA |
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 6:32,948,618...32,953,097
Ensembl chr 6:32,948,613...32,969,094
|
|
G |
HLA-DMB |
major histocompatibility complex, class II, DM beta |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of HLA-DMB mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:32,934,636...32,941,028
Ensembl chr 6:32,934,629...32,941,028
|
|
G |
HLA-DPA1 |
major histocompatibility complex, class II, DP alpha 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of HLA-DPA1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:33,064,569...33,080,748
Ensembl chr 6:33,064,569...33,080,775
|
|
G |
HLA-DPB2 |
major histocompatibility complex, class II, DP beta 2 (pseudogene) |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA panobinostat results in increased expression of HLA-DPB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:33,112,516...33,129,113
Ensembl chr 6:33,112,516...33,129,084
|
|
G |
HLA-DQB1 |
major histocompatibility complex, class II, DQ beta 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383
|
|
G |
HLA-DRB5 |
major histocompatibility complex, class II, DR beta 5 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of HLA-DRB5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:32,517,353...32,530,287
Ensembl chr 6:32,517,353...32,530,287
|
|
G |
HMCES |
5-hydroxymethylcytosine binding, ES cell specific |
increases expression |
EXP |
Panobinostat results in increased expression of HMCES mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:129,278,832...129,306,186
Ensembl chr 3:129,278,828...129,306,186
|
|
G |
HMGCLL1 |
3-hydroxy-3-methylglutaryl-CoA lyase like 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of HMGCLL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:55,434,373...55,678,919
Ensembl chr 6:55,434,373...55,579,197
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA panobinostat results in increased expression of HMOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HMX2 |
H6 family homeobox 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:123,148,136...123,150,672
Ensembl chr10:123,148,136...123,150,672
|
|
G |
HNMT |
histamine N-methyltransferase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HNMT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:137,964,473...138,016,364
Ensembl chr 2:137,964,020...138,016,364
|
|
G |
HNRNPCL1 |
heterogeneous nuclear ribonucleoprotein C like 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of HNRNPCL1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:12,847,377...12,848,720
Ensembl chr 1:12,847,377...12,848,720
|
|
G |
HNRNPR |
heterogeneous nuclear ribonucleoprotein R |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:23,304,688...23,344,284
Ensembl chr 1:23,303,771...23,344,336
|
|
G |
HOMEZ |
homeobox and leucine zipper encoding |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:23,272,422...23,286,132
Ensembl chr14:23,272,422...23,299,796
|
|
G |
HOXA1 |
homeobox A1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:27,092,993...27,096,000
Ensembl chr 7:27,092,993...27,096,000
|
|
G |
HPDL |
4-hydroxyphenylpyruvate dioxygenase like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA panobinostat results in increased expression of HPDL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:45,326,895...45,328,710
Ensembl chr 1:45,326,895...45,328,710
|
|
G |
HPGD |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:174,490,175...174,522,893
Ensembl chr 4:174,490,175...174,523,154
|
|
G |
HPS1 |
HPS1 biogenesis of lysosomal organelles complex 3 subunit 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA panobinostat results in increased expression of HPS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:98,413,948...98,446,935
Ensembl chr10:98,410,939...98,446,963
|
|
G |
HRK |
harakiri, BCL2 interacting protein |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HRK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:116,856,144...116,881,441
Ensembl chr12:116,856,144...116,881,441
|
|
G |
HS3ST3B1 |
heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of HS3ST3B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:14,301,081...14,349,404
Ensembl chr17:14,301,081...14,349,404
|
|
G |
HSPA4L |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of HSPA4L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:127,781,796...127,840,733
Ensembl chr 4:127,781,821...127,840,733
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ICAM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
ICAM3 |
intercellular adhesion molecule 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA panobinostat results in increased expression of ICAM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,333,776...10,339,624
Ensembl chr19:10,333,776...10,339,661
|
|
G |
ID4 |
inhibitor of DNA binding 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA panobinostat results in increased expression of ID4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:19,837,370...19,842,197
Ensembl chr 6:19,837,370...19,842,197
|
|
G |
IDH3A |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA panobinostat results in increased expression of IDH3A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:78,149,362...78,171,945
Ensembl chr15:78,131,498...78,171,945
|
|
G |
IER3 |
immediate early response 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IER3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548
|
|
G |
IFI16 |
interferon gamma inducible protein 16 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IFI16 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
|
|
G |
IFI30 |
IFI30 lysosomal thiol reductase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA panobinostat results in increased expression of IFI30 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:18,173,813...18,178,117
Ensembl chr19:18,173,162...18,178,117
|
|
G |
IFITM1 |
interferon induced transmembrane protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IFITM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:314,040...315,272
Ensembl chr11:310,041...315,272
|
|
G |
IFNAR2 |
interferon alpha and beta receptor subunit 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr21:33,229,938...33,265,664
Ensembl chr21:33,205,282...33,265,675
|
|
G |
IFT25 |
intraflagellar transport 25 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA Panobinostat results in decreased expression of IFT25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:53,911,576...53,946,305
Ensembl chr 1:53,916,574...53,945,699
|
|
G |
IGDCC3 |
immunoglobulin superfamily DCC subclass member 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IGDCC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:65,327,127...65,378,002
Ensembl chr15:65,327,127...65,378,002
|
|
G |
IGF2 |
insulin like growth factor 2 |
increases expression |
EXP |
panobinostat results in increased expression of IGF2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391
|
|
G |
IGFBP3 |
insulin like growth factor binding protein 3 |
decreases expression |
EXP |
panobinostat results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
|
|
G |
IGFBP7 |
insulin like growth factor binding protein 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA panobinostat results in increased expression of IGFBP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:57,030,773...57,110,385
Ensembl chr 4:57,030,773...57,110,385
|
|
G |
IGSF21 |
immunoglobin superfamily member 21 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:18,107,798...18,378,483
Ensembl chr 1:18,107,798...18,378,483
|
|
G |
IL17RD |
interleukin 17 receptor D |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of IL17RD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:57,089,982...57,170,317
Ensembl chr 3:57,089,982...57,170,306
|
|
G |
IL1RAPL1 |
interleukin 1 receptor accessory protein like 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of IL1RAPL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:28,587,446...29,956,718
Ensembl chr X:28,587,446...29,956,718
|
|
G |
IL20RB |
interleukin 20 receptor subunit beta |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IL20RB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:136,957,983...137,011,085
Ensembl chr 3:136,946,230...137,011,085
|
|
G |
IL27RA |
interleukin 27 receptor subunit alpha |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IL27RA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:14,031,762...14,053,218
Ensembl chr19:14,031,762...14,053,218
|
|
G |
IL3RA |
interleukin 3 receptor subunit alpha |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA Panobinostat results in increased expression of IL3RA mRNA |
CTD |
PMID:21791302 PMID:33770205 |
|
NCBI chr X:1,336,785...1,382,689 NCBI chr Y:1,336,785...1,382,689
Ensembl chr Y:1,336,616...1,382,689 Ensembl chr X:1,336,616...1,382,689
|
|
G |
INF2 |
inverted formin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA panobinostat results in increased expression of INF2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:104,689,618...104,722,535
Ensembl chr14:104,681,146...104,722,535
|
|
G |
INHBE |
inhibin subunit beta E |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA panobinostat results in increased expression of INHBE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
|
|
G |
INPP4B |
inositol polyphosphate-4-phosphatase type II B |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:142,023,160...142,846,535
Ensembl chr 4:142,023,160...142,847,432
|
|
G |
INPP5D |
inositol polyphosphate-5-phosphatase D |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:233,060,342...233,207,903
Ensembl chr 2:233,059,967...233,207,903
|
|
G |
INPP5F |
inositol polyphosphate-5-phosphatase F |
increases expression |
EXP |
Panobinostat results in increased expression of INPP5F mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:119,726,050...119,829,147
Ensembl chr10:119,726,042...119,829,147
|
|
G |
INSC |
INSC spindle orientation adaptor protein |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of INSC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:15,111,416...15,269,676
Ensembl chr11:15,112,424...15,247,208
|
|
G |
IPW |
imprinted in Prader-Willi syndrome |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:25,116,545...25,122,476
|
|
G |
IQCA1 |
IQ motif containing with AAA domain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA panobinostat results in increased expression of IQCA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:236,306,685...236,507,476
Ensembl chr 2:236,324,147...236,507,535
|
|
G |
IQGAP1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA panobinostat results in increased expression of IQGAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:90,388,242...90,502,239
Ensembl chr15:90,388,242...90,502,239
|
|
G |
IRF6 |
interferon regulatory factor 6 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of IRF6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:209,785,617...209,806,142
Ensembl chr 1:209,785,617...209,806,175
|
|
G |
IRX1 |
iroquois homeobox 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA panobinostat results in increased expression of IRX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:3,595,832...3,601,403
Ensembl chr 5:3,595,832...3,601,403
|
|
G |
IRX2 |
iroquois homeobox 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA panobinostat results in increased expression of IRX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:2,735,635...2,751,677
Ensembl chr 5:2,745,845...2,751,677
|
|
G |
IRX3 |
iroquois homeobox 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA panobinostat results in increased expression of IRX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:54,283,304...54,286,787
Ensembl chr16:54,283,304...54,286,787
|
|
G |
ISL1 |
ISL LIM homeobox 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:51,383,448...51,394,730
Ensembl chr 5:51,383,448...51,394,730
|
|
G |
ITGA8 |
integrin subunit alpha 8 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ITGA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:15,513,954...15,719,922
Ensembl chr10:15,513,954...15,719,922
|
|
G |
ITGA9 |
integrin subunit alpha 9 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ITGA9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:37,452,141...37,823,507
Ensembl chr 3:37,452,115...37,823,507
|
|
G |
ITGB5 |
integrin subunit beta 5 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ITGB5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:124,761,948...124,901,418
Ensembl chr 3:124,761,948...124,901,418
|
|
G |
ITIH5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ITIH5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:7,559,270...7,666,966
Ensembl chr10:7,559,270...7,666,998
|
|
G |
ITM2A |
integral membrane protein 2A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:79,360,384...79,367,334
Ensembl chr X:79,360,384...79,367,667
|
|
G |
ITPR2 |
inositol 1,4,5-trisphosphate receptor type 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA panobinostat results in increased expression of ITPR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:26,335,352...26,833,194
Ensembl chr12:26,335,352...26,833,194
|
|
G |
JADE2 |
jade family PHD finger 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of JADE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:134,523,952...134,583,227
Ensembl chr 5:134,524,312...134,583,230
|
|
G |
JARID2 |
jumonji and AT-rich interaction domain containing 2 |
increases expression |
EXP |
Panobinostat results in increased expression of JARID2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:15,246,069...15,522,042
Ensembl chr 6:15,246,069...15,522,042
|
|
G |
JAZF1 |
JAZF zinc finger 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of JAZF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:27,830,577...28,180,795
Ensembl chr 7:27,830,573...28,180,795
|
|
G |
JCAD |
junctional cadherin 5 associated |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of JCAD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:30,012,803...30,115,494
Ensembl chr10:30,012,803...30,115,494
|
|
G |
JDP2 |
Jun dimerization protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of JDP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:75,426,943...75,474,107
Ensembl chr14:75,427,716...75,474,111
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
panobinostat results in increased expression of JUN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KANK4 |
KN motif and ankyrin repeat domains 4 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KANK4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:62,236,165...62,319,434
Ensembl chr 1:62,236,165...62,319,434
|
|
G |
KAT2B |
lysine acetyltransferase 2B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA panobinostat results in decreased expression of KAT2B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:20,040,446...20,154,404
Ensembl chr 3:20,040,446...20,154,404
|
|
G |
KAT6A |
lysine acetyltransferase 6A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:41,929,479...42,051,987
Ensembl chr 8:41,929,479...42,051,994
|
|
G |
KAT7 |
lysine acetyltransferase 7 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA panobinostat results in decreased expression of KAT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:49,788,681...49,835,026
Ensembl chr17:49,788,624...49,835,026
|
|
G |
KBTBD11 |
kelch repeat and BTB domain containing 11 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of KBTBD11 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:1,973,677...2,006,936
Ensembl chr 8:1,973,677...2,006,936
|
|
G |
KCNA7 |
potassium voltage-gated channel subfamily A member 7 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr19:49,067,397...49,072,699
Ensembl chr19:49,067,397...49,072,699
|
|
G |
KCNC1 |
potassium voltage-gated channel subfamily C member 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA panobinostat results in decreased expression of KCNC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:17,734,781...17,783,057
Ensembl chr11:17,734,774...17,856,804
|
|
G |
KCND2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA panobinostat results in decreased expression of KCND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:120,272,908...120,750,337
Ensembl chr 7:120,273,175...120,750,337
|
|
G |
KCNG1 |
potassium voltage-gated channel modifier subfamily G member 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KCNG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:51,003,656...51,023,107
Ensembl chr20:51,003,656...51,023,107
|
|
G |
KCNH5 |
potassium voltage-gated channel subfamily H member 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA panobinostat results in decreased expression of KCNH5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:62,699,464...63,045,458
Ensembl chr14:62,699,464...63,102,037
|
|
G |
KCNJ13 |
potassium inwardly rectifying channel subfamily J member 13 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA panobinostat results in decreased expression of KCNJ13 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:232,765,802...232,776,565
Ensembl chr 2:232,765,802...232,776,565
|
|
G |
KCNJ3 |
potassium inwardly rectifying channel subfamily J member 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:154,698,695...154,858,354
Ensembl chr 2:154,697,855...154,858,354
|
|
G |
KCNK1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:233,614,106...233,672,514
Ensembl chr 1:233,614,106...233,672,514
|
|
G |
KCNK10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA panobinostat results in decreased expression of KCNK10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:88,180,108...88,326,912
Ensembl chr14:88,180,103...88,326,907
|
|
G |
KCNMB4 |
potassium calcium-activated channel subfamily M regulatory beta subunit 4 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr12:70,366,290...70,434,292
Ensembl chr12:70,366,290...70,434,292
|
|
G |
KCNN3 |
potassium calcium-activated channel subfamily N member 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA panobinostat results in decreased expression of KCNN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:154,697,455...154,870,281
Ensembl chr 1:154,697,455...154,870,281
|
|
G |
KCNV1 |
potassium voltage-gated channel modifier subfamily V member 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:109,963,636...109,975,771
Ensembl chr 8:109,963,636...109,975,771
|
|
G |
KCTD1 |
potassium channel tetramerization domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA panobinostat results in increased expression of KCTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:26,454,910...26,657,473
Ensembl chr18:26,454,910...26,657,401
|
|
G |
KCTD12 |
potassium channel tetramerization domain containing 12 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA panobinostat results in increased expression of KCTD12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:76,880,175...76,886,405
Ensembl chr13:76,880,175...76,886,405
|
|
G |
KDR |
kinase insert domain receptor |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595
|
|
G |
KIAA0040 |
KIAA0040 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA panobinostat results in increased expression of KIAA0040 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:175,156,986...175,192,987
Ensembl chr 1:175,156,986...175,192,999
|
|
G |
KIAA1549 |
KIAA1549 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of KIAA1549 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:138,831,381...138,981,389
Ensembl chr 7:138,831,381...138,981,389
|
|
G |
KIAA1755 |
KIAA1755 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KIAA1755 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:38,210,503...38,260,735
Ensembl chr20:38,210,503...38,260,772
|
|
G |
KIF13A |
kinesin family member 13A |
decreases expression |
EXP |
panobinostat results in decreased expression of KIF13A mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 6:17,759,126...17,987,635
Ensembl chr 6:17,759,183...17,987,635
|
|
G |
KIF28P |
kinesin family member 28, pseudogene |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:246,771,878...246,784,760
Ensembl chr 1:246,771,837...246,839,611
|
|
G |
KIF5C |
kinesin family member 5C |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 2:148,875,227...149,026,759
Ensembl chr 2:148,875,227...149,026,759
|
|
G |
KIFAP3 |
kinesin associated protein 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KIFAP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:169,921,329...170,085,184
Ensembl chr 1:169,921,326...170,085,208
|
|
G |
KISS1R |
KISS1 receptor |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:917,333...921,005
Ensembl chr19:917,287...921,005
|
|
G |
KIT |
KIT proto-oncogene, receptor tyrosine kinase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KIT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783
|
|
G |
KITLG |
KIT ligand |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KITLG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851
|
|
G |
KIZ |
kizuna centrosomal protein |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of KIZ mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:21,125,975...21,246,622
Ensembl chr20:21,125,983...21,246,622
|
|
G |
KLF15 |
KLF transcription factor 15 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KLF15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:126,288,125...126,357,408
Ensembl chr 3:126,342,635...126,357,408
|
|
G |
KLF3-AS1 |
KLF3 antisense RNA 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA panobinostat results in decreased expression of KLF3-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:38,599,093...38,664,893
Ensembl chr 4:38,602,438...38,664,926
|
|
G |
KLF4 |
KLF transcription factor 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
|
|
G |
KLF5 |
KLF transcription factor 5 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KLF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
|
|
G |
KLF6 |
KLF transcription factor 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA panobinostat results in increased expression of KLF6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KLHL14 |
kelch like family member 14 |
increases expression |
EXP |
panobinostat results in increased expression of KLHL14 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:32,672,673...32,773,023
Ensembl chr18:32,672,673...32,773,023
|
|
G |
KLK10 |
kallikrein related peptidase 10 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr19:51,012,739...51,020,097
Ensembl chr19:51,012,739...51,020,175
|
|
G |
KLK8 |
kallikrein related peptidase 8 |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA panobinostat results in increased expression of KLK8 mRNA |
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr19:50,996,008...51,001,604
Ensembl chr19:50,996,007...51,002,711
|
|
G |
KLRG2 |
killer cell lectin like receptor G2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KLRG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:139,427,098...139,483,673
Ensembl chr 7:139,452,690...139,483,673
|
|
G |
KREMEN1 |
kringle containing transmembrane protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of KREMEN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:29,073,035...29,168,333
Ensembl chr22:29,073,035...29,168,333
|
|
G |
KRT18 |
keratin 18 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA panobinostat results in increased expression of KRT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
|
|
G |
KRT19 |
keratin 19 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:41,523,617...41,528,308
Ensembl chr17:41,523,617...41,528,308
|
|
G |
KRT8 |
keratin 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA panobinostat results in increased expression of KRT8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954
|
|
G |
L1CAM |
L1 cell adhesion molecule |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA panobinostat results in increased expression of L1CAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:153,861,514...153,886,173
Ensembl chr X:153,861,514...153,886,173
|
|
G |
L1TD1 |
LINE1 type transposase domain containing 1 |
increases expression |
EXP |
panobinostat results in increased expression of L1TD1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:62,194,849...62,212,328
Ensembl chr 1:62,194,849...62,212,328
|
|
G |
LACC1 |
laccase domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LACC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:43,879,178...43,893,932
Ensembl chr13:43,879,284...43,893,932
|
|
G |
LACTB |
lactamase beta |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LACTB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:63,121,861...63,142,061
Ensembl chr15:63,121,833...63,142,061
|
|
G |
LAMA2 |
laminin subunit alpha 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LAMA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:128,883,138...129,516,566
Ensembl chr 6:128,883,138...129,516,566
|
|
G |
LAMA4 |
laminin subunit alpha 4 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LAMA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:112,107,931...112,254,985
Ensembl chr 6:112,107,931...112,254,939
|
|
G |
LAMC2 |
laminin subunit gamma 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LAMC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:183,186,264...183,258,968
Ensembl chr 1:183,186,238...183,245,127
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LAMP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:120,426,148...120,469,349
Ensembl chr X:120,426,148...120,469,365
|
|
G |
LAYN |
layilin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LAYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:111,540,280...111,561,745
Ensembl chr11:111,540,280...111,561,745
|
|
G |
LCTL |
lactase like |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LCTL mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:66,547,532...66,565,998
Ensembl chr15:66,547,179...66,565,998
|
|
G |
LDHD |
lactate dehydrogenase D |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LDHD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:75,111,864...75,116,780
Ensembl chr16:75,111,860...75,116,780
|
|
G |
LEMD1 |
LEM domain containing 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:205,381,378...205,449,966
Ensembl chr 1:205,381,378...205,455,954
|
|
G |
LGALS1 |
galectin 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr22:37,675,636...37,679,802
Ensembl chr22:37,675,636...37,679,802
|
|
G |
LGALS3 |
galectin 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LGALS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
|
|
G |
LHFPL6 |
LHFPL tetraspan subfamily member 6 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LHFPL6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:39,342,892...39,603,193
Ensembl chr13:39,209,116...39,603,528
|
|
G |
LHX2 |
LIM homeobox 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA panobinostat results in decreased expression of LHX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:124,011,768...124,033,301
Ensembl chr 9:124,001,670...124,033,301
|
|
G |
LHX8 |
LIM homeobox 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA panobinostat results in increased expression of LHX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:75,128,434...75,199,454
Ensembl chr 1:75,128,434...75,161,533
|
|
G |
LIFR |
LIF receptor subunit alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA panobinostat results in increased expression of LIFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:38,474,668...38,608,403
Ensembl chr 5:38,474,668...38,608,354
|
|
G |
LIM2 |
lens intrinsic membrane protein 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:51,379,909...51,387,974
Ensembl chr19:51,379,909...51,387,974
|
|
G |
LIMCH1 |
LIM and calponin homology domains 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LIMCH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:41,359,607...41,700,044
Ensembl chr 4:41,359,607...41,700,044
|
|
G |
LIN28B |
lin-28 homolog B |
multiple interactions decreases expression affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein] panobinostat results in decreased expression of LIN28B protein panobinostat affects the expression of LIN28B mRNA |
CTD |
PMID:26733615 |
|
NCBI chr 6:104,937,026...105,083,332
Ensembl chr 6:104,936,616...105,083,332
|
|
G |
LINC00458 |
long intergenic non-protein coding RNA 458 |
increases expression |
EXP |
panobinostat results in increased expression of LINC00458 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:54,124,324...54,132,871
Ensembl chr13:53,950,255...54,270,397
|
|
G |
LINC00472 |
long intergenic non-protein coding RNA 472 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00472 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:71,407,864...71,420,745
Ensembl chr 6:71,187,161...71,420,745
|
|
G |
LINC00491 |
long intergenic non-protein coding RNA 491 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LINC00491 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:102,608,492...102,671,464
Ensembl chr 5:102,604,220...102,671,765
|
|
G |
LINC00515 |
long intergenic non-protein coding RNA 515 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA panobinostat results in decreased expression of LINC00515 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:25,582,775...25,583,224
Ensembl chr21:25,582,770...25,583,326
|
|
G |
LINC00540 |
long intergenic non-protein coding RNA 540 |
increases expression |
EXP |
panobinostat results in increased expression of LINC00540 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:22,210,285...22,276,521
Ensembl chr13:22,040,972...22,276,526
|
|
G |
LINC00545 |
long intergenic non-protein coding RNA 545 |
increases expression |
EXP |
panobinostat results in increased expression of LINC00545 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:30,882,562...30,883,395
Ensembl chr13:30,803,206...30,883,424
|
|
G |
LINC00698 |
long intergenic non-protein coding RNA 698 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LINC00698 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:63,102,688...63,125,062
Ensembl chr 3:62,950,430...63,125,062
|
|
G |
LINC01003 |
long intergenic non-protein coding RNA 1003 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LINC01003 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:152,464,124...152,465,545
Ensembl chr 7:152,463,786...152,465,549
|
|
G |
LINC01405 |
long intergenic non-protein coding RNA 1405 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LINC01405 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01405 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:110,936,602...110,937,448
Ensembl chr12:110,934,590...110,959,093
|
|
G |
LINC03124 |
long intergenic non-protein coding RNA 3124 |
decreases expression |
EXP |
Panobinostat results in decreased expression of LINC03124 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:131,682,499...131,767,404
Ensembl chr 2:131,647,990...131,767,404
|
|
G |
LINGO2 |
leucine rich repeat and Ig domain containing 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LINGO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:27,937,617...29,213,601
Ensembl chr 9:27,937,617...29,213,601
|
|
G |
LIX1 |
limb and CNS expressed 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LIX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:97,091,867...97,142,611
Ensembl chr 5:97,091,867...97,142,753
|
|
G |
LMAN1 |
lectin, mannose binding 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LMAN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:59,327,823...59,359,265
Ensembl chr18:59,327,823...59,359,265
|
|
G |
LMF1 |
lipase maturation factor 1 |
increases expression |
EXP |
panobinostat results in increased expression of LMF1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:853,634...981,613
Ensembl chr16:853,634...981,318
|
|
G |
LMO2 |
LIM domain only 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA panobinostat results in decreased expression of LMO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:33,858,576...33,892,076
Ensembl chr11:33,858,576...33,892,076
|
|
G |
LMO3 |
LIM domain only 3 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LMO3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:16,548,372...16,610,174
Ensembl chr12:16,548,372...16,610,594
|
|
G |
LMO7 |
LIM domain 7 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:75,620,434...75,859,870
Ensembl chr13:75,620,434...75,859,870
|
|
G |
LNX1 |
ligand of numb-protein X 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA panobinostat results in increased expression of LNX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:53,459,301...53,652,477
Ensembl chr 4:53,459,301...53,701,405
|
|
G |
LPAR6 |
lysophosphatidic acid receptor 6 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LPAR6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:48,389,571...48,444,669
Ensembl chr13:48,389,567...48,444,704
|
|
G |
LRIG1 |
leucine rich repeats and immunoglobulin like domains 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LRIG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:66,378,797...66,501,121
Ensembl chr 3:66,378,797...66,501,263
|
|
G |
LRP12 |
LDL receptor related protein 12 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LRP12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:104,489,236...104,589,258
Ensembl chr 8:104,489,231...104,589,258
|
|
G |
LRP2 |
LDL receptor related protein 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA panobinostat results in decreased expression of LRP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:169,127,109...169,362,534
Ensembl chr 2:169,127,109...169,362,534
|
|
G |
LRP8 |
LDL receptor related protein 8 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:53,242,364...53,328,070
Ensembl chr 1:53,242,364...53,328,469
|
|
G |
LRRC17 |
leucine rich repeat containing 17 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA panobinostat results in increased expression of LRRC17 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:102,913,000...102,945,111
Ensembl chr 7:102,913,000...102,945,111
|
|
G |
LRRC3B |
leucine rich repeat containing 3B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA panobinostat results in decreased expression of LRRC3B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:26,622,772...26,710,776
Ensembl chr 3:26,622,772...26,717,537
|
|
G |
LRRC55 |
leucine rich repeat containing 55 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of LRRC55 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:57,181,953...57,191,717
Ensembl chr11:57,181,747...57,191,717
|
|
G |
LRRC8B |
leucine rich repeat containing 8 VRAC subunit B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA panobinostat results in decreased expression of LRRC8B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:89,524,829...89,597,861
Ensembl chr 1:89,524,829...89,597,861
|
|
G |
LRRC8E |
leucine rich repeat containing 8 VRAC subunit E |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA panobinostat results in increased expression of LRRC8E mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:7,888,510...7,902,016
Ensembl chr19:7,888,505...7,902,021
|
|
G |
LRRFIP1 |
LRR binding FLII interacting protein 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:237,627,587...237,781,643
Ensembl chr 2:237,627,587...237,813,682
|
|
G |
LRRN3 |
leucine rich repeat neuronal 3 |
multiple interactions increases expression affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA] panobinostat results in increased expression of LRRN3 mRNA panobinostat affects the expression of LRRN3 mRNA |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 7:111,091,127...111,125,454
Ensembl chr 7:111,091,006...111,125,454
|
|
G |
LRRN4 |
leucine rich repeat neuronal 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:6,040,546...6,054,060
Ensembl chr20:6,040,546...6,054,060
|
|
G |
LRRTM1 |
leucine rich repeat transmembrane neuronal 1 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA] panobinostat affects the expression of LRRTM1 mRNA |
CTD |
PMID:26733615 PMID:27188386 |
|
NCBI chr 2:80,288,356...80,304,752
Ensembl chr 2:80,288,351...80,304,752
|
|
G |
LY75 |
lymphocyte antigen 75 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LY75 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:159,803,355...159,904,756
Ensembl chr 2:159,803,355...159,904,756
|
|
G |
LYN |
LYN proto-oncogene, Src family tyrosine kinase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:55,879,835...56,014,169
Ensembl chr 8:55,879,835...56,014,169
|
|
G |
LYPD3 |
LY6/PLAUR domain containing 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LYPD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:43,460,787...43,465,608
Ensembl chr19:43,460,787...43,465,608
|
|
G |
LYSMD2 |
LysM domain containing 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LYSMD2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:51,723,011...51,751,451
Ensembl chr15:51,723,011...51,751,585
|
|
G |
LYZL6 |
lysozyme like 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA panobinostat results in increased expression of LYZL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:35,934,518...35,943,713
Ensembl chr17:35,934,518...35,943,713
|
|
G |
LZTS1 |
leucine zipper tumor suppressor 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of LZTS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:20,246,165...20,303,963
Ensembl chr 8:20,246,165...20,303,963
|
|
G |
MAB21L2 |
mab-21 like 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of MAB21L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:150,582,151...150,584,693
Ensembl chr 4:150,582,151...150,584,693
|
|
G |
MACC1 |
MET transcriptional regulator MACC1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA panobinostat results in increased expression of MACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:20,134,655...20,217,384
Ensembl chr 7:20,134,655...20,217,404
|
|
G |
MACROD2 |
mono-ADP ribosylhydrolase 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of MACROD2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:13,995,516...16,053,197
Ensembl chr20:13,995,369...16,053,197
|
|
G |
MACROH2A1 |
macroH2A.1 histone |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA Panobinostat results in decreased expression of MACROH2A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:135,334,381...135,399,887
Ensembl chr 5:135,334,381...135,399,914
|
|
G |
MAFB |
MAF bZIP transcription factor B |
increases expression |
EXP |
panobinostat results in increased expression of MAFB mRNA |
CTD |
PMID:26272509 |
|
NCBI chr20:40,685,848...40,689,236
Ensembl chr20:40,685,848...40,689,236
|
|
G |
MAGI2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA panobinostat results in increased expression of MAGI2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:78,017,055...79,453,667
Ensembl chr 7:78,017,055...79,453,667
|
|
G |
MAILR |
macrophage interferon regulatory lncRNA |
decreases expression |
EXP |
Panobinostat results in decreased expression of MAILR mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:102,864,271...102,977,876
Ensembl chr 8:102,864,271...103,002,424
|
|
G |
MAK |
male germ cell associated kinase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA panobinostat results in decreased expression of MAK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:10,762,723...10,838,539
Ensembl chr 6:10,762,723...10,838,553
|
|
G |
MAN1A1 |
mannosidase alpha class 1A member 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MAN1A1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:119,177,205...119,350,605
Ensembl chr 6:119,177,205...119,349,761
|
|
G |
MANEAL |
mannosidase endo-alpha like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA panobinostat results in increased expression of MANEAL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:37,793,847...37,801,133
Ensembl chr 1:37,793,847...37,801,137
|
|
G |
MAP1LC3C |
microtubule associated protein 1 light chain 3 gamma |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1LC3C mRNA panobinostat results in increased expression of MAP1LC3C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:241,995,490...242,001,393
Ensembl chr 1:241,995,490...241,999,098
|
|
G |
MAP2 |
microtubule associated protein 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147
|
|
G |
MAP2K6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
|
|
G |
MAP6 |
microtubule associated protein 6 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA panobinostat results in decreased expression of MAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:75,586,918...75,669,038
Ensembl chr11:75,586,918...75,669,038
|
|
G |
MAP7D2 |
MAP7 domain containing 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:20,006,713...20,116,907
Ensembl chr X:20,006,713...20,116,907
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein |
CTD |
PMID:18445700 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of MAPK10 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625
|
|
G |
MAPK13 |
mitogen-activated protein kinase 13 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA panobinostat results in increased expression of MAPK13 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:36,130,513...36,144,521
Ensembl chr 6:36,127,809...36,144,524
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
[Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein |
CTD |
PMID:18445700 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAT1A |
methionine adenosyltransferase 1A |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of MAT1A mRNA |
CTD |
PMID:21791302 |
|
NCBI chr10:80,271,820...80,289,658
Ensembl chr10:80,271,820...80,289,658
|
|
G |
MBNL3 |
muscleblind like splicing regulator 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MBNL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:132,369,320...132,490,035
Ensembl chr X:132,369,320...132,489,968
|
|
G |
MBOAT1 |
membrane bound O-acyltransferase domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA panobinostat results in increased expression of MBOAT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:20,099,684...20,212,469
Ensembl chr 6:20,099,684...20,212,469
|
|
G |
MCC |
MCC regulator of WNT signaling pathway |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA panobinostat results in increased expression of MCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:113,022,106...113,488,453
Ensembl chr 5:113,022,106...113,488,823
|
|
G |
MCOLN3 |
mucolipin TRP cation channel 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MCOLN3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:85,018,082...85,048,500
Ensembl chr 1:85,018,082...85,048,500
|
|
G |
MCUB |
mitochondrial calcium uniporter dominant negative subunit beta |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of MCUB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:109,560,246...109,688,719
Ensembl chr 4:109,560,209...109,688,719
|
|
G |
MDFIC |
MyoD family inhibitor domain containing |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA panobinostat results in increased expression of MDFIC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:114,922,094...115,019,917
Ensembl chr 7:114,922,094...115,019,917
|
|
G |
ME3 |
malic enzyme 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA panobinostat results in decreased expression of ME3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:86,434,930...86,672,616
Ensembl chr11:86,441,108...86,672,636
|
|
G |
MECOM |
MDS1 and EVI1 complex locus |
decreases expression |
EXP |
panobinostat results in decreased expression of MECOM mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:169,083,507...169,663,712
Ensembl chr 3:169,083,499...169,663,775
|
|
G |
MED13L |
mediator complex subunit 13L |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MED13L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:115,958,576...116,277,693
Ensembl chr12:115,957,905...116,277,693
|
|
G |
MEF2C |
myocyte enhancer factor 2C |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MEF2C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:88,717,117...88,904,105
Ensembl chr 5:88,717,117...88,904,257
|
|
G |
MEIS2 |
Meis homeobox 2 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MEIS2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MEIS2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr15:36,889,204...37,101,311
Ensembl chr15:36,889,204...37,101,299
|
|
G |
MEOX1 |
mesenchyme homeobox 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA panobinostat results in increased expression of MEOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:43,640,389...43,661,922
Ensembl chr17:43,640,389...43,661,922
|
|
G |
METRNL |
meteorin like, glial cell differentiation regulator |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA panobinostat results in increased expression of METRNL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:83,079,609...83,095,122
Ensembl chr17:83,079,609...83,095,122
|
|
G |
METTL21A |
methyltransferase 21A, HSPA lysine |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:207,580,635...207,626,053
Ensembl chr 2:207,580,631...207,625,928
|
|
G |
MFAP3L |
microfibril associated protein 3 like |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA panobinostat results in decreased expression of MFAP3L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:169,986,602...170,027,277
Ensembl chr 4:169,986,597...170,033,031
|
|
G |
MFNG |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA panobinostat results in decreased expression of MFNG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:37,469,063...37,486,384
Ensembl chr22:37,469,063...37,486,393
|
|
G |
MGAT3 |
beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of MGAT3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr22:39,457,012...39,492,194
Ensembl chr22:39,457,012...39,492,194
|
|
G |
MIA |
MIA SH3 domain containing |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MIA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:40,775,160...40,777,490
Ensembl chr19:40,771,648...40,777,490
|
|
G |
MIAT |
myocardial infarction associated transcript |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of MIAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:26,646,429...26,676,478
Ensembl chr22:26,646,411...26,676,475
|
|
G |
MICALL1 |
MICAL like 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MICALL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:37,906,297...37,942,822
Ensembl chr22:37,905,657...37,942,822
|
|
G |
MICB |
MHC class I polypeptide-related sequence B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA panobinostat results in increased expression of MICB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:31,494,918...31,511,124
Ensembl chr 6:31,494,881...31,511,124
|
|
G |
MID1IP1 |
MID1 interacting protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MID1IP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:38,801,459...38,806,532
Ensembl chr X:38,801,440...38,806,537
|
|
G |
MIR124-2HG |
MIR124-2 host gene |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:64,373,218...64,387,504
Ensembl chr 8:64,373,105...64,383,919
|
|
G |
MIR22HG |
MIR22 host gene |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MIR22HG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:1,711,504...1,716,272
Ensembl chr17:1,711,447...1,717,174
|
|
G |
MMP14 |
matrix metallopeptidase 14 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MMP14 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041
|
|
G |
MNX1 |
motor neuron and pancreas homeobox 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MNX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:157,004,854...157,010,663
Ensembl chr 7:156,994,051...157,010,663
|
|
G |
MPPED2 |
metallophosphoesterase domain containing 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA panobinostat results in decreased expression of MPPED2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:30,384,079...30,586,993
Ensembl chr11:30,384,493...30,586,872
|
|
G |
MPZ |
myelin protein zero |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MPZ mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:161,303,600...161,309,968
Ensembl chr 1:161,304,735...161,309,968
|
|
G |
MSL1 |
MSL complex subunit 1 |
affects expression decreases expression multiple interactions |
EXP |
panobinostat affects the expression of MSL1 mRNA Panobinostat results in decreased expression of MSL1 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of MSL1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of MSL1 mRNA] |
CTD |
PMID:26733615 PMID:33770205 |
|
NCBI chr17:40,121,971...40,136,917
Ensembl chr17:40,121,971...40,136,917
|
|
G |
MSX1 |
msh homeobox 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA panobinostat results in increased expression of MSX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:4,859,665...4,863,936
Ensembl chr 4:4,859,665...4,863,936
|
|
G |
MSX2 |
msh homeobox 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA panobinostat results in increased expression of MSX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:174,724,582...174,730,896
Ensembl chr 5:174,724,582...174,730,896
|
|
G |
MTARC2 |
mitochondrial amidoxime reducing component 2 |
increases expression multiple interactions |
EXP |
Panobinostat results in increased expression of MTARC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:220,748,322...220,784,815
Ensembl chr 1:220,748,225...220,784,815
|
|
G |
MTHFD2L |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 like |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MTHFD2L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:74,114,560...74,303,099
Ensembl chr 4:74,114,174...74,303,099
|
|
G |
MUC15 |
mucin 15, cell surface associated |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MUC15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:26,559,032...26,572,263
Ensembl chr11:26,559,032...26,572,263
|
|
G |
MUC3A |
mucin 3A, cell surface associated |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:100,949,534...100,968,347
Ensembl chr 7:100,949,534...100,968,347
|
|
G |
MUC4 |
mucin 4, cell surface associated |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA panobinostat results in increased expression of MUC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:195,746,771...195,811,929
Ensembl chr 3:195,746,765...195,811,973
|
|
G |
MUSTN1 |
musculoskeletal, embryonic nuclear protein 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:52,833,121...52,835,019
Ensembl chr 3:52,833,114...52,835,019
|
|
G |
MVB12A |
multivesicular body subunit 12A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA panobinostat results in decreased expression of MVB12A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:17,405,741...17,425,332
Ensembl chr19:17,405,722...17,433,724
|
|
G |
MXRA7 |
matrix remodeling associated 7 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA panobinostat results in decreased expression of MXRA7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:76,672,551...76,710,965
Ensembl chr17:76,672,551...76,711,004
|
|
G |
MYBL1 |
MYB proto-oncogene like 1 |
increases expression |
EXP |
Panobinostat results in increased expression of MYBL1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:66,562,175...66,613,218
Ensembl chr 8:66,562,175...66,614,247
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat results in decreased expression of MYC protein]; [panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of MYC protein; panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]; panobinostat promotes the reaction [SRT2183 results in decreased expression of MYC protein] |
CTD |
PMID:23681230 PMID:24435446 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions increases expression decreases expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of MYCN protein]; [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; Panobinostat inhibits the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of MYCN protein] panobinostat results in increased expression of MYCN mRNA panobinostat results in decreased expression of MYCN protein |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007
|
|
G |
MYCT1 |
MYC target 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:152,697,897...152,747,181
Ensembl chr 6:152,697,897...152,724,569
|
|
G |
MYF5 |
myogenic factor 5 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:80,716,912...80,719,671
Ensembl chr12:80,716,912...80,719,671
|
|
G |
MYLIP |
myosin regulatory light chain interacting protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA panobinostat results in increased expression of MYLIP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:16,129,086...16,163,887
Ensembl chr 6:16,129,086...16,148,248
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA panobinostat results in decreased expression of MYLK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
|
|
G |
MYO1D |
myosin ID |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA panobinostat results in increased expression of MYO1D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:32,492,522...32,877,124
Ensembl chr17:32,492,522...32,877,177
|
|
G |
MYO1E |
myosin IE |
increases expression |
EXP |
Panobinostat results in increased expression of MYO1E mRNA |
CTD |
PMID:33770205 |
|
NCBI chr15:59,132,434...59,372,871
Ensembl chr15:59,132,434...59,372,871
|
|
G |
MYO5B |
myosin VB |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:49,822,789...50,195,147
Ensembl chr18:49,822,789...50,195,164
|
|
G |
MYOCD |
myocardin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MYOCD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:12,665,890...12,768,949
Ensembl chr17:12,665,890...12,768,949
|
|
G |
MYOF |
myoferlin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of MYOF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:93,306,429...93,482,334
Ensembl chr10:93,306,429...93,482,334
|
|
G |
NABP1 |
nucleic acid binding protein 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NABP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:191,678,136...191,686,943
Ensembl chr 2:191,678,068...191,741,097
|
|
G |
NALF1 |
NALCN channel auxiliary factor 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA Panobinostat results in decreased expression of NALF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:107,163,510...107,867,496
Ensembl chr13:107,163,510...107,867,496
|
|
G |
NANOG |
Nanog homeobox |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NANOG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
|
|
G |
NANOS1 |
nanos C2HC-type zinc finger 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA panobinostat results in decreased expression of NANOS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:119,029,714...119,033,730
Ensembl chr10:119,029,714...119,033,730
|
|
G |
NANS |
N-acetylneuraminate synthase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA panobinostat results in increased expression of NANS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:98,056,732...98,083,077
Ensembl chr 9:98,056,732...98,083,077
|
|
G |
NAV1 |
neuron navigator 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA panobinostat results in decreased expression of NAV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:201,539,127...201,826,969
Ensembl chr 1:201,539,127...201,826,969
|
|
G |
NAV3 |
neuron navigator 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA panobinostat results in increased expression of NAV3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:77,571,862...78,213,010
Ensembl chr12:77,324,641...78,213,010
|
|
G |
NCALD |
neurocalcin delta |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA panobinostat results in decreased expression of NCALD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:101,686,542...102,124,907
Ensembl chr 8:101,686,542...102,124,907
|
|
G |
NCOA7 |
nuclear receptor coactivator 7 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA panobinostat results in decreased expression of NCOA7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:125,781,115...125,932,034
Ensembl chr 6:125,781,161...125,932,034
|
|
G |
NDP |
norrin cystine knot growth factor NDP |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA panobinostat results in decreased expression of NDP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:43,948,776...43,973,390
Ensembl chr X:43,948,776...43,973,395
|
|
G |
NDUFB1 |
NADH:ubiquinone oxidoreductase subunit B1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of NDUFB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:92,116,123...92,121,706
Ensembl chr14:92,116,122...92,121,917
|
|
G |
NEAT1 |
nuclear paraspeckle assembly transcript 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NEAT1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:65,422,798...65,445,540
Ensembl chr11:65,422,774...65,445,540
|
|
G |
NEFL |
neurofilament light chain |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NEFL mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:24,950,955...24,956,612
Ensembl chr 8:24,950,955...24,956,721
|
|
G |
NEFM |
neurofilament medium chain |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA panobinostat results in increased expression of NEFM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:24,913,761...24,919,093
Ensembl chr 8:24,913,758...24,919,098
|
|
G |
NEGR1 |
neuronal growth regulator 1 |
increases expression |
EXP |
panobinostat results in increased expression of NEGR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:71,395,943...72,282,539
Ensembl chr 1:71,395,943...72,282,539
|
|
G |
NELL1 |
neural EGFL like 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NELL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:20,669,551...21,575,686
Ensembl chr11:20,669,551...21,575,686
|
|
G |
NELL2 |
neural EGFL like 2 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of NELL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,508,275...44,921,848
Ensembl chr12:44,508,275...44,921,848
|
|
G |
NEU1 |
neuraminidase 1 |
increases expression |
EXP |
Panobinostat results in increased expression of NEU1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:31,857,659...31,862,821
Ensembl chr 6:31,857,659...31,862,905
|
|
G |
NEURL3 |
neuralized E3 ubiquitin protein ligase 3 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of LINCR mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 2:96,497,646...96,508,109
Ensembl chr 2:96,497,646...96,508,109
|
|
G |
NEXMIF |
neurite extension and migration factor |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA panobinostat results in decreased expression of NEXMIF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:74,732,856...74,925,452
Ensembl chr X:74,732,856...74,925,472
|
|
G |
NF1 |
neurofibromin 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of NF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,094,927...31,377,677
Ensembl chr17:31,094,927...31,382,116
|
|
G |
NFASC |
neurofascin |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA panobinostat results in decreased expression of NFASC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:204,828,652...205,022,822
Ensembl chr 1:204,828,651...205,022,822
|
|
G |
NFATC4 |
nuclear factor of activated T cells 4 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of NFATC4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:24,366,911...24,379,604
Ensembl chr14:24,365,673...24,379,604
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NFE2L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFIB |
nuclear factor I B |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NFIB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:14,081,843...14,532,077
Ensembl chr 9:14,081,843...14,398,983
|
|
G |
NFIC |
nuclear factor I C |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NFIC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NFIC mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr19:3,359,630...3,469,217
Ensembl chr19:3,314,403...3,469,217
|
|
G |
NGEF |
neuronal guanine nucleotide exchange factor |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NGEF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:232,878,701...233,013,256
Ensembl chr 2:232,878,701...233,013,256
|
|
G |
NGFR |
nerve growth factor receptor |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NGFR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:49,495,293...49,515,008
Ensembl chr17:49,495,293...49,515,008
|
|
G |
NHSL2 |
NHS like 2 |
affects expression multiple interactions |
EXP |
panobinostat affects the expression of NHSL2 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NHSL2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NHSL2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr X:71,910,845...72,153,286
Ensembl chr X:71,910,845...72,161,750
|
|
G |
NIFK-AS1 |
NIFK antisense RNA 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA panobinostat results in decreased expression of NIFK-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:121,649,654...121,728,560
Ensembl chr 2:121,649,320...121,728,563
|
|
G |
NIPAL2 |
NIPA like domain containing 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NIPAL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:98,189,826...98,294,235
Ensembl chr 8:98,189,826...98,294,393
|
|
G |
NKAIN3 |
sodium/potassium transporting ATPase interacting 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA Panobinostat results in decreased expression of NKAIN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:62,248,854...62,999,652
Ensembl chr 8:62,248,591...63,014,000
|
|
G |
NKD1 |
NKD inhibitor of WNT signaling pathway 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NKD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:50,548,396...50,649,249
Ensembl chr16:50,548,396...50,649,249
|
|
G |
NLGN1 |
neuroligin 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of NLGN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:173,395,952...174,294,372
Ensembl chr 3:173,396,284...174,294,372
|
|
G |
NLRP1 |
NLR family pyrin domain containing 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of NLRP1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr17:5,501,396...5,584,509
Ensembl chr17:5,499,415...5,619,424
|
|
G |
NME8 |
NME/NM23 family member 8 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NME8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:37,848,597...37,900,397
Ensembl chr 7:37,848,597...37,900,397
|
|
G |
NMI |
N-myc and STAT interactor |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of NMI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:151,270,470...151,289,668
Ensembl chr 2:151,270,470...151,289,894
|
|
G |
NMNAT2 |
nicotinamide nucleotide adenylyltransferase 2 |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA panobinostat results in increased expression of NMNAT2 mRNA |
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 1:183,248,237...183,418,380
Ensembl chr 1:183,248,237...183,418,380
|
|
G |
NOCT |
nocturnin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA panobinostat results in increased expression of NOCT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:139,015,781...139,045,939
Ensembl chr 4:139,015,781...139,045,939
|
|
G |
NOG |
noggin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DPY19L2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM200B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NANOS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DQB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00472 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01405 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MANEAL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1LC3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDFIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METRNL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUSTN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYF5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOCD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NELL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGFR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NKD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMNAT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOG mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA panobinostat results in increased expression of NOG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:56,593,699...56,595,611
Ensembl chr17:56,593,699...56,595,611
|
|
G |
NOL4 |
nucleolar protein 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA panobinostat results in decreased expression of NOL4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:33,851,100...34,224,913
Ensembl chr18:33,851,100...34,224,952
|
|
G |
NPFFR2 |
neuropeptide FF receptor 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA panobinostat results in increased expression of NPFFR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:72,032,000...72,148,305
Ensembl chr 4:72,031,902...72,148,305
|
|
G |
NPNT |
nephronectin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA panobinostat results in increased expression of NPNT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:105,895,471...105,971,671
Ensembl chr 4:105,894,775...106,004,027
|
|
G |
NPR3 |
natriuretic peptide receptor 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA panobinostat results in increased expression of NPR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:32,690,872...32,791,720
Ensembl chr 5:32,689,070...32,791,724
|
|
G |
NPY |
neuropeptide Y |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA panobinostat results in increased expression of NPY mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862
|
|
G |
NPY1R |
neuropeptide Y receptor Y1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY1R mRNA panobinostat results in decreased expression of NPY1R mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:163,323,962...163,344,689
Ensembl chr 4:163,323,962...163,344,832
|
|
G |
NPY2R |
neuropeptide Y receptor Y2 |
multiple interactions decreases expression affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of NPY2R mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA] panobinostat results in decreased expression of NPY2R mRNA panobinostat affects the expression of NPY2R mRNA |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 4:155,173,723...155,217,076
Ensembl chr 4:155,208,636...155,217,078
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA panobinostat results in increased expression of NQO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NQO2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA panobinostat results in increased expression of NQO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,019,755
|
|
G |
NR2F1 |
nuclear receptor subfamily 2 group F member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR2F1 mRNA panobinostat results in increased expression of NR2F1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:93,583,222...93,594,611
Ensembl chr 5:93,583,222...93,594,611
|
|
G |
NR2F2 |
nuclear receptor subfamily 2 group F member 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA panobinostat results in decreased expression of NR2F2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:96,326,046...96,340,263
Ensembl chr15:96,325,938...96,340,263
|
|
G |
NRG1 |
neuregulin 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA panobinostat results in decreased expression of NRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666
|
|
G |
NRIP1 |
nuclear receptor interacting protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRIP1 mRNA panobinostat results in increased expression of NRIP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:14,961,235...15,065,936
Ensembl chr21:14,961,235...15,065,936
|
|
G |
NRIP3 |
nuclear receptor interacting protein 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA panobinostat results in decreased expression of NRIP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:8,980,576...9,004,505
Ensembl chr11:8,965,682...9,005,288
|
|
G |
NRK |
Nik related kinase |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:105,821,786...105,958,610
Ensembl chr X:105,822,539...105,958,610
|
|
G |
NRP1 |
neuropilin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA panobinostat results in increased expression of NRP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:33,177,493...33,334,667
Ensembl chr10:33,177,492...33,336,262
|
|
G |
NRP2 |
neuropilin 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:205,682,501...205,798,131
Ensembl chr 2:205,681,990...205,798,133
|
|
G |
NRROS |
negative regulator of reactive oxygen species |
decreases expression |
EXP |
Panobinostat results in decreased expression of NRROS mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:196,639,694...196,662,004
Ensembl chr 3:196,639,694...196,662,004
|
|
G |
NRXN2 |
neurexin 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:64,606,174...64,723,197
Ensembl chr11:64,606,174...64,723,197
|
|
G |
NSD2 |
nuclear receptor binding SET domain protein 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA panobinostat results in decreased expression of NSD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:1,871,393...1,982,192
Ensembl chr 4:1,871,393...1,982,207
|
|
G |
NSMAF |
neutral sphingomyelinase activation associated factor |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NSMAF mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NSMAF mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 8:58,583,504...58,659,853
Ensembl chr 8:58,583,508...58,659,853
|
|
G |
NTN4 |
netrin 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA panobinostat results in decreased expression of NTN4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:95,657,807...95,791,155
Ensembl chr12:95,657,807...95,791,189
|
|
G |
NUAK2 |
NUAK family kinase 2 |
decreases expression |
EXP |
panobinostat results in decreased expression of NUAK2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:205,302,063...205,321,745
Ensembl chr 1:205,302,063...205,321,745
|
|
G |
NUDT4 |
nudix hydrolase 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NUDT4 mRNA panobinostat results in increased expression of NUDT4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:93,377,925...93,408,146
Ensembl chr12:93,377,883...93,408,146
|
|
G |
NWD2 |
NACHT and WD repeat domain containing 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA panobinostat results in increased expression of NWD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:37,244,743...37,449,463
Ensembl chr 4:37,244,743...37,449,463
|
|
G |
OAT |
ornithine aminotransferase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA panobinostat results in increased expression of OAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976
|
|
G |
OLA1 |
Obg like ATPase 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLA1 mRNA panobinostat results in decreased expression of OLA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,072,447...174,248,532
Ensembl chr 2:174,072,447...174,248,599
|
|
G |
OLFM3 |
olfactomedin 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA panobinostat results in increased expression of OLFM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:101,802,560...101,996,926
Ensembl chr 1:101,802,560...101,996,926
|
|
G |
OLFML3 |
olfactomedin like 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA panobinostat results in increased expression of OLFML3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:113,979,474...113,982,253
Ensembl chr 1:113,979,391...114,035,572
|
|
G |
OLIG3 |
oligodendrocyte transcription factor 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:137,492,199...137,494,394
Ensembl chr 6:137,492,199...137,494,394
|
|
G |
ONECUT2 |
one cut homeobox 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of ONECUT2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr18:57,435,374...57,491,298
Ensembl chr18:57,435,374...57,491,298
|
|
G |
OPCML |
opioid binding protein/cell adhesion molecule like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA panobinostat results in increased expression of OPCML mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:132,414,981...133,532,501
Ensembl chr11:132,414,977...133,532,501
|
|
G |
OPRK1 |
opioid receptor kappa 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA panobinostat results in decreased expression of OPRK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:53,225,724...53,251,637
Ensembl chr 8:53,225,724...53,251,637
|
|
G |
ORM1 |
orosomucoid 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA panobinostat results in decreased expression of ORM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479
|
|
G |
ORM2 |
orosomucoid 2 |
decreases expression |
EXP |
panobinostat results in decreased expression of ORM2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 9:114,329,869...114,333,251
Ensembl chr 9:114,329,869...114,333,251
|
|
G |
OSBPL10 |
oxysterol binding protein like 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA panobinostat results in increased expression of OSBPL10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:31,660,825...32,077,692
Ensembl chr 3:31,657,912...32,077,580
|
|
G |
OTX2 |
orthodenticle homeobox 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTX2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:56,799,905...56,810,479
Ensembl chr14:56,799,905...56,816,693
|
|
G |
OVOL1 |
ovo like transcriptional repressor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA panobinostat results in increased expression of OVOL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:65,787,063...65,797,214
Ensembl chr11:65,787,063...65,797,214
|
|
G |
OVOL2 |
ovo like zinc finger 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:18,024,152...18,059,188
Ensembl chr20:17,956,979...18,059,188
|
|
G |
PABPC4L |
poly(A) binding protein cytoplasmic 4 like |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PABPC4L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PABPC4L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:133,948,459...134,201,901
Ensembl chr 4:134,196,333...134,201,789
|
|
G |
PABPC5 |
poly(A) binding protein cytoplasmic 5 |
increases expression |
EXP |
panobinostat results in increased expression of PABPC5 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr X:91,434,839...91,438,584
Ensembl chr X:91,434,595...91,438,584
|
|
G |
PAK3 |
p21 (RAC1) activated kinase 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK3 mRNA panobinostat results in decreased expression of PAK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:110,944,397...111,227,361
Ensembl chr X:110,944,285...111,227,361
|
|
G |
PAMR1 |
peptidase domain containing associated with muscle regeneration 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA panobinostat results in decreased expression of PAMR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:35,431,827...35,530,300
Ensembl chr11:35,431,823...35,530,300
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
[resveratrol co-treated with panobinostat] results in increased cleavage of PARP1 protein |
CTD |
PMID:22923501 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PATJ |
PATJ crumbs cell polarity complex component |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:61,742,480...62,163,915
Ensembl chr 1:61,742,477...62,178,675
|
|
G |
PAX2 |
paired box 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA panobinostat results in increased expression of PAX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:100,735,396...100,829,944
Ensembl chr10:100,735,396...100,829,944
|
|
G |
PAX3 |
paired box 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA panobinostat results in increased expression of PAX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:222,199,887...222,298,998
Ensembl chr 2:222,199,887...222,298,998
|
|
G |
PAX6 |
paired box 6 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of PAX6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:31,789,026...31,817,961
Ensembl chr11:31,784,779...31,817,961
|
|
G |
PAX7 |
paired box 7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PAX7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:18,630,846...18,748,866
Ensembl chr 1:18,630,846...18,748,866
|
|
G |
PBX2 |
PBX homeobox 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of PBX2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:32,184,733...32,190,202
Ensembl chr 6:32,184,733...32,190,202
|
|
G |
PCDH10 |
protocadherin 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA panobinostat results in increased expression of PCDH10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:133,149,294...133,208,606
Ensembl chr 4:133,149,294...133,208,606
|
|
G |
PCDH20 |
protocadherin 20 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA panobinostat results in increased expression of PCDH20 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:61,409,685...61,415,849
Ensembl chr13:61,409,685...61,415,849
|
|
G |
PCDH7 |
protocadherin 7 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA panobinostat results in increased expression of PCDH7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:30,720,369...31,146,800
Ensembl chr 4:30,720,369...31,146,805
|
|
G |
PCDH8 |
protocadherin 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA panobinostat results in increased expression of PCDH8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:52,842,889...52,848,640
Ensembl chr13:52,842,889...52,848,641
|
|
G |
PCDHB14 |
protocadherin beta 14 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA panobinostat results in decreased expression of PCDHB14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:141,223,343...141,227,759
Ensembl chr 5:141,223,343...141,227,759
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCK1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PCM1 |
pericentriolar material 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:17,922,988...18,029,948
Ensembl chr 8:17,922,842...18,029,948
|
|
G |
PCMTD1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:51,817,575...51,899,186
Ensembl chr 8:51,817,575...51,899,186
|
|
G |
PCOLCE |
procollagen C-endopeptidase enhancer |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:100,602,363...100,608,175
Ensembl chr 7:100,602,363...100,608,175
|
|
G |
PCOLCE2 |
procollagen C-endopeptidase enhancer 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE2 mRNA panobinostat results in increased expression of PCOLCE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:142,817,874...142,889,083
Ensembl chr 3:142,815,922...142,889,206
|
|
G |
PCP4L1 |
Purkinje cell protein 4 like 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCP4L1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:161,258,745...161,285,450
Ensembl chr 1:161,258,745...161,285,450
|
|
G |
PDE10A |
phosphodiesterase 10A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA panobinostat results in decreased expression of PDE10A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:165,327,289...165,988,052
Ensembl chr 6:165,327,287...165,988,117
|
|
G |
PDE11A |
phosphodiesterase 11A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE11A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:177,623,244...178,108,339
Ensembl chr 2:177,623,244...178,108,339
|
|
G |
PDE3A |
phosphodiesterase 3A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA panobinostat results in increased expression of PDE3A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:20,368,537...20,688,583
Ensembl chr12:20,368,537...20,688,583
|
|
G |
PDE4C |
phosphodiesterase 4C |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of PDE4C mRNA |
CTD |
PMID:21791302 |
|
NCBI chr19:18,207,965...18,255,362
Ensembl chr19:18,207,965...18,248,200 Ensembl chr19:18,207,965...18,248,200
|
|
G |
PDE4D |
phosphodiesterase 4D |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA panobinostat results in increased expression of PDE4D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:58,969,038...60,522,128
Ensembl chr 5:58,969,038...60,522,120
|
|
G |
PDE4DIP |
phosphodiesterase 4D interacting protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4DIP mRNA panobinostat results in increased expression of PDE4DIP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:148,808,434...149,033,016
Ensembl chr 1:148,808,140...149,048,286
|
|
G |
PDGFA |
platelet derived growth factor subunit A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA panobinostat results in increased expression of PDGFA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296
|
|
G |
PDGFC |
platelet derived growth factor C |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PDGFC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:156,760,454...156,971,799
Ensembl chr 4:156,760,454...156,971,799
|
|
G |
PDGFRA |
platelet derived growth factor receptor alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFRA mRNA panobinostat results in increased expression of PDGFRA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245
|
|
G |
PDIA5 |
protein disulfide isomerase family A member 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA panobinostat results in increased expression of PDIA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:123,067,025...123,162,104
Ensembl chr 3:123,067,025...123,225,227
|
|
G |
PDLIM1 |
PDZ and LIM domain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA panobinostat results in increased expression of PDLIM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:95,237,572...95,291,003
Ensembl chr10:95,237,572...95,291,012
|
|
G |
PDPN |
podoplanin |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PDPN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:13,583,757...13,617,957
Ensembl chr 1:13,583,465...13,617,957
|
|
G |
PDYN |
prodynorphin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA panobinostat results in increased expression of PDYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:1,978,756...1,994,285
Ensembl chr20:1,978,757...1,994,285
|
|
G |
PFKP |
phosphofructokinase, platelet |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PFKP mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:3,067,548...3,136,805
Ensembl chr10:3,066,333...3,137,718
|
|
G |
PGM1 |
phosphoglucomutase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA panobinostat results in increased expression of PGM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:63,593,411...63,660,245
Ensembl chr 1:63,593,411...63,660,245
|
|
G |
PHIP |
pleckstrin homology domain interacting protein |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHIP mRNA panobinostat results in decreased expression of PHIP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:78,934,419...79,078,254
Ensembl chr 6:78,934,419...79,078,287
|
|
G |
PHLDA1 |
pleckstrin homology like domain family A member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA panobinostat results in increased expression of PHLDA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776
|
|
G |
PHLDA2 |
pleckstrin homology like domain family A member 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PHLDA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:2,928,273...2,929,420
Ensembl chr11:2,928,273...2,929,420
|
|
G |
PHTF2 |
putative homeodomain transcription factor 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:77,798,773...77,957,504
Ensembl chr 7:77,798,773...77,957,503
|
|
G |
PID1 |
phosphotyrosine interaction domain containing 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:229,023,973...229,271,287
Ensembl chr 2:228,850,526...229,271,287
|
|
G |
PIEZO2 |
piezo type mechanosensitive ion channel component 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIEZO2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:10,670,247...11,149,569
Ensembl chr18:10,666,483...11,149,569
|
|
G |
PIM1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PIM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:37,170,152...37,175,428
Ensembl chr 6:37,170,152...37,175,428
|
|
G |
PIPOX |
pipecolic acid and sarcosine oxidase |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PIPOX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:29,043,141...29,057,216
Ensembl chr17:28,950,513...29,057,216
|
|
G |
PITX2 |
paired like homeodomain 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA panobinostat results in increased expression of PITX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:110,617,423...110,642,123
Ensembl chr 4:110,617,423...110,642,123
|
|
G |
PKDCC |
protein kinase domain containing, cytoplasmic |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PKDCC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:42,048,021...42,058,517
Ensembl chr 2:42,048,021...42,058,517
|
|
G |
PKM |
pyruvate kinase M1/2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of PKM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819
|
|
G |
PKNOX2 |
PBX/knotted 1 homeobox 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKNOX2 mRNA panobinostat results in increased expression of PKNOX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:125,164,751...125,433,389
Ensembl chr11:125,164,687...125,433,389
|
|
G |
PLA2G2A |
phospholipase A2 group IIA |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA panobinostat results in increased expression of PLA2G2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:19,975,431...19,980,434
Ensembl chr 1:19,975,431...19,980,416
|
|
G |
PLA2G4A |
phospholipase A2 group IVA |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA panobinostat results in increased expression of PLA2G4A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981
|
|
G |
PLA2G7 |
phospholipase A2 group VII |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA panobinostat results in increased expression of PLA2G7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:46,704,201...46,735,721
Ensembl chr 6:46,704,201...46,735,693
|
|
G |
PLAAT5 |
phospholipase A and acyltransferase 5 |
increases expression multiple interactions |
EXP |
Panobinostat results in increased expression of PLAAT5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:63,461,404...63,491,167
Ensembl chr11:63,461,404...63,491,194
|
|
G |
PLAT |
plasminogen activator, tissue type |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAT mRNA panobinostat results in increased expression of PLAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PLAU |
plasminogen activator, urokinase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA panobinostat results in increased expression of PLAU mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PLBD1 |
phospholipase B domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA panobinostat results in increased expression of PLBD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:14,503,661...14,567,883
Ensembl chr12:14,503,661...14,567,883
|
|
G |
PLCE1 |
phospholipase C epsilon 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA panobinostat results in increased expression of PLCE1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:93,993,931...94,332,823
Ensembl chr10:93,993,931...94,332,823
|
|
G |
PLEKHA2 |
pleckstrin homology domain containing A2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:38,901,346...38,973,912
Ensembl chr 8:38,901,235...38,973,912
|
|
G |
PLEKHM3 |
pleckstrin homology domain containing M3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:207,821,288...208,025,527
Ensembl chr 2:207,821,288...208,025,527
|
|
G |
PLOD2 |
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA panobinostat results in increased expression of PLOD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:146,069,440...146,161,184
Ensembl chr 3:146,035,139...146,163,725
|
|
G |
PLP1 |
proteolipid protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP1 mRNA panobinostat results in increased expression of PLP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:103,776,506...103,792,619
Ensembl chr X:103,773,718...103,792,619
|
|
G |
PLSCR1 |
phospholipid scramblase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA panobinostat results in increased expression of PLSCR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:146,515,180...146,544,607
Ensembl chr 3:146,515,180...146,544,856
|
|
G |
PLXNA2 |
plexin A2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXNA2 mRNA panobinostat results in increased expression of PLXNA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:208,022,242...208,244,384
Ensembl chr 1:208,022,242...208,244,384
|
|
G |
PLXNC1 |
plexin C1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA panobinostat results in decreased expression of PLXNC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:94,148,577...94,307,675
Ensembl chr12:94,148,577...94,307,675
|
|
G |
PMEPA1 |
prostate transmembrane protein, androgen induced 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA panobinostat results in increased expression of PMEPA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:57,648,396...57,711,472
Ensembl chr20:57,648,392...57,711,536
|
|
G |
PNMT |
phenylethanolamine N-methyltransferase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of PNMT mRNA |
CTD |
PMID:21791302 |
|
NCBI chr17:39,668,019...39,670,475
Ensembl chr17:39,667,981...39,670,475
|
|
G |
PNP |
purine nucleoside phosphorylase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNP mRNA panobinostat results in increased expression of PNP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:20,469,406...20,477,089
Ensembl chr14:20,461,992...20,477,094
|
|
G |
PODXL |
podocalyxin like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA panobinostat results in increased expression of PODXL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:131,500,271...131,556,628
Ensembl chr 7:131,500,262...131,558,217
|
|
G |
POLI |
DNA polymerase iota |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POLI mRNA panobinostat results in decreased expression of POLI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:54,269,479...54,321,266
Ensembl chr18:54,269,517...54,321,266
|
|
G |
POLR2A |
RNA polymerase II subunit A |
multiple interactions decreases phosphorylation |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat results in decreased phosphorylation of POLR2A protein]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of POLR2A protein] panobinostat results in decreased phosphorylation of POLR2A protein |
CTD |
PMID:24435446 |
|
NCBI chr17:7,484,366...7,514,616
Ensembl chr17:7,484,366...7,514,616
|
|
G |
POLR3E |
RNA polymerase III subunit E |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of POLR3E mRNA |
CTD |
PMID:21791302 |
|
NCBI chr16:22,297,409...22,335,096
Ensembl chr16:22,297,375...22,335,101
|
|
G |
POLR3G |
RNA polymerase III subunit G |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA panobinostat results in increased expression of POLR3G mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:90,473,929...90,514,557
Ensembl chr 5:90,471,748...90,514,557
|
|
G |
PON1 |
paraoxonase 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PON1 mRNA panobinostat results in decreased expression of PON1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
POPDC2 |
popeye domain containing 2 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of POPDC2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of POPDC2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 3:119,642,056...119,660,883
Ensembl chr 3:119,636,457...119,665,324
|
|
G |
POPDC3 |
popeye domain containing 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POPDC3 mRNA panobinostat results in decreased expression of POPDC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:105,157,900...105,180,014
Ensembl chr 6:105,157,900...105,180,014
|
|
G |
POU3F1 |
POU class 3 homeobox 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA panobinostat results in decreased expression of POU3F1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:38,043,829...38,046,793
Ensembl chr 1:38,043,829...38,046,793
|
|
G |
POU3F3 |
POU class 3 homeobox 3 |
increases expression |
EXP |
panobinostat results in increased expression of POU3F3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:104,854,115...104,858,574
Ensembl chr 2:104,853,287...104,858,574
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
increases expression |
EXP |
panobinostat results in increased expression of POU5F1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
POU5F1B |
POU class 5 homeobox 1B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA panobinostat results in increased expression of POU5F1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:127,413,447...127,417,224
Ensembl chr 8:127,322,183...127,420,066
|
|
G |
POU5F1P3 |
POU class 5 homeobox 1 pseudogene 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA panobinostat results in increased expression of POU5F1P3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:8,133,769...8,134,852
Ensembl chr12:8,133,772...8,134,849
|
|
G |
POU5F1P4 |
POU class 5 homeobox 1 pseudogene 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA panobinostat results in increased expression of POU5F1P4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:155,433,180...155,434,262
Ensembl chr 1:155,433,178...155,434,262
|
|
G |
PPARGC1B |
PPARG coactivator 1 beta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA panobinostat results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:149,730,310...149,857,959
Ensembl chr 5:149,730,298...149,855,022
|
|
G |
PPIB |
peptidylprolyl isomerase B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIB mRNA panobinostat results in increased expression of PPIB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:64,155,817...64,163,022
Ensembl chr15:64,155,740...64,163,134
|
|
G |
PPIC |
peptidylprolyl isomerase C |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA panobinostat results in increased expression of PPIC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:123,023,250...123,036,725
Ensembl chr 5:123,023,250...123,036,725
|
|
G |
PPL |
periplakin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA panobinostat results in increased expression of PPL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:4,882,507...4,937,148
Ensembl chr16:4,882,507...4,960,741
|
|
G |
PPM1A |
protein phosphatase, Mg2+/Mn2+ dependent 1A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:60,245,750...60,299,087
Ensembl chr14:60,245,752...60,299,087
|
|
G |
PPM1J |
protein phosphatase, Mg2+/Mn2+ dependent 1J |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA panobinostat results in increased expression of PPM1J mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:112,709,998...112,715,332
Ensembl chr 1:112,709,994...112,715,332
|
|
G |
PPM1K |
protein phosphatase, Mg2+/Mn2+ dependent 1K |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA panobinostat results in increased expression of PPM1K mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:88,257,620...88,284,561
Ensembl chr 4:88,257,620...88,284,769
|
|
G |
PPOX |
protoporphyrinogen oxidase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA panobinostat results in decreased expression of PPOX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:161,165,728...161,178,013
Ensembl chr 1:161,166,056...161,178,013
|
|
G |
PPP1R13L |
protein phosphatase 1 regulatory subunit 13 like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA panobinostat results in increased expression of PPP1R13L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:45,379,638...45,406,361
Ensembl chr19:45,379,638...45,406,349
|
|
G |
PPP1R1A |
protein phosphatase 1 regulatory inhibitor subunit 1A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA panobinostat results in increased expression of PPP1R1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:54,579,246...54,588,659
Ensembl chr12:54,575,387...54,588,659
|
|
G |
PPP1R3B |
protein phosphatase 1 regulatory subunit 3B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA panobinostat results in increased expression of PPP1R3B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:9,136,255...9,151,539
Ensembl chr 8:9,136,255...9,151,574
|
|
G |
PPP1R3D |
protein phosphatase 1 regulatory subunit 3D |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA panobinostat results in increased expression of PPP1R3D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:59,936,663...59,940,305
Ensembl chr20:59,936,663...59,940,305
|
|
G |
PPP1R9A |
protein phosphatase 1 regulatory subunit 9A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA panobinostat results in decreased expression of PPP1R9A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:94,907,236...95,296,415
Ensembl chr 7:94,907,202...95,296,415
|
|
G |
PPP2R2B |
protein phosphatase 2 regulatory subunit Bbeta |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA panobinostat results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:146,580,742...147,081,520
Ensembl chr 5:146,580,742...147,084,784
|
|
G |
PRAG1 |
PEAK1 related, kinase-activating pseudokinase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRAG1 mRNA panobinostat results in increased expression of PRAG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:8,317,736...8,386,439
Ensembl chr 8:8,317,736...8,386,439
|
|
G |
PRDM1 |
PR/SET domain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA panobinostat results in increased expression of PRDM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:105,992,690...106,109,938
Ensembl chr 6:105,993,463...106,109,939
|
|
G |
PRDM14 |
PR/SET domain 14 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA panobinostat results in increased expression of PRDM14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:70,051,651...70,071,252
Ensembl chr 8:70,051,651...70,071,693
|
|
G |
PRDM16 |
PR/SET domain 16 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:3,069,203...3,438,621
Ensembl chr 1:3,069,168...3,438,621
|
|
G |
PRELP |
proline and arginine rich end leucine rich repeat protein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRELP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:203,475,806...203,491,352
Ensembl chr 1:203,475,806...203,491,352
|
|
G |
PREX1 |
phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PREX1 mRNA panobinostat results in increased expression of PREX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:48,624,252...48,888,185
Ensembl chr20:48,624,252...48,827,999
|
|
G |
PRKACA |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA panobinostat results in increased expression of PRKACA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:14,091,688...14,117,762
Ensembl chr19:14,091,688...14,118,084
|
|
G |
PRKCA |
protein kinase C alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA panobinostat results in increased expression of PRKCA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
|
|
G |
PRKCB |
protein kinase C beta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA panobinostat results in increased expression of PRKCB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611
|
|
G |
PRKCH |
protein kinase C eta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA panobinostat results in increased expression of PRKCH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:61,187,468...61,550,976
Ensembl chr14:61,187,559...61,550,976
|
|
G |
PRNP |
prion protein (Kanno blood group) |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA panobinostat results in increased expression of PRNP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590
|
|
G |
PRODH |
proline dehydrogenase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA panobinostat results in increased expression of PRODH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:18,912,781...18,936,553
Ensembl chr22:18,912,777...18,936,553
|
|
G |
PROK2 |
prokineticin 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA panobinostat results in decreased expression of PROK2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:71,771,655...71,785,148
Ensembl chr 3:71,771,655...71,785,206
|
|
G |
PRR15 |
proline rich 15 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA panobinostat results in increased expression of PRR15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:29,563,835...29,567,295
Ensembl chr 7:29,563,835...29,567,293
|
|
G |
PRR16 |
proline rich 16 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA panobinostat results in increased expression of PRR16 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:120,464,278...120,794,594
Ensembl chr 5:120,464,300...120,687,332
|
|
G |
PRRG1 |
proline rich and Gla domain 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA panobinostat results in increased expression of PRRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:37,349,364...37,457,291
Ensembl chr X:37,349,309...37,457,292
|
|
G |
PRRX1 |
paired related homeobox 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA panobinostat results in increased expression of PRRX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:170,662,768...170,739,421
Ensembl chr 1:170,662,728...170,739,421
|
|
G |
PRSS12 |
serine protease 12 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA panobinostat results in increased expression of PRSS12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:118,280,038...118,353,003
Ensembl chr 4:118,280,038...118,353,003
|
|
G |
PRSS23 |
serine protease 23 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA panobinostat results in decreased expression of PRSS23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:86,791,071...86,952,910
Ensembl chr11:86,791,059...86,952,910
|
|
G |
PRSS8 |
serine protease 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA panobinostat results in increased expression of PRSS8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:31,131,433...31,135,727
Ensembl chr16:31,131,433...31,135,727
|
|
G |
PRUNE2 |
prune homolog 2 with BCH domain |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA panobinostat results in decreased expression of PRUNE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:76,611,376...76,906,114
Ensembl chr 9:76,611,376...76,906,114
|
|
G |
PTCHD1 |
patched domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA panobinostat results in increased expression of PTCHD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:23,334,396...23,404,374
Ensembl chr X:23,334,849...23,404,374
|
|
G |
PTGER4 |
prostaglandin E receptor 4 |
increases expression |
EXP |
panobinostat results in increased expression of PTGER4 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:40,679,915...40,746,800
Ensembl chr 5:40,679,915...40,693,735
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA panobinostat results in decreased expression of PTGS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703
|
|
G |
PTPN5 |
protein tyrosine phosphatase non-receptor type 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA panobinostat results in decreased expression of PTPN5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:18,727,928...18,792,721
Ensembl chr11:18,727,928...18,792,721
|
|
G |
PTPN9 |
protein tyrosine phosphatase non-receptor type 9 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of PTPN9 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of PTPN9 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr15:75,463,251...75,579,315
Ensembl chr15:75,463,251...75,579,315
|
|
G |
PTPRF |
protein tyrosine phosphatase receptor type F |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of PTPRF mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:43,522,051...43,623,666
Ensembl chr 1:43,525,187...43,623,666
|
|
G |
PTPRN2 |
protein tyrosine phosphatase receptor type N2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRN2 mRNA panobinostat results in decreased expression of PTPRN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:157,539,056...158,587,823
Ensembl chr 7:157,539,056...158,587,823
|
|
G |
PTPRO |
protein tyrosine phosphatase receptor type O |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA panobinostat results in decreased expression of PTPRO mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:15,322,508...15,598,331
Ensembl chr12:15,322,257...15,602,175
|
|
G |
PURG |
purine rich element binding protein G |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA panobinostat results in decreased expression of PURG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:30,995,802...31,033,356
Ensembl chr 8:30,995,802...31,033,715
|
|
G |
PWWP2B |
PWWP domain containing 2B |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:132,397,200...132,417,859
Ensembl chr10:132,397,168...132,417,859
|
|
G |
PXDC1 |
PX domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA panobinostat results in increased expression of PXDC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:3,722,619...3,751,713
Ensembl chr 6:3,722,614...3,751,713
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA panobinostat results in increased expression of PYCARD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
PYM1 |
PYM homolog 1, exon junction complex associated factor |
decreases expression |
EXP |
Panobinostat results in decreased expression of PYM1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr12:55,901,413...55,927,894
Ensembl chr12:55,901,413...55,932,618
|
|
G |
RAB11FIP1 |
RAB11 family interacting protein 1 |
increases expression |
EXP |
Panobinostat results in increased expression of RAB11FIP1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:37,858,618...37,899,497
Ensembl chr 8:37,858,618...37,899,497
|
|
G |
RAB11FIP4 |
RAB11 family interacting protein 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA panobinostat results in increased expression of RAB11FIP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,391,675...31,538,211
Ensembl chr17:31,391,675...31,538,211
|
|
G |
RAB17 |
RAB17, member RAS oncogene family |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA panobinostat results in increased expression of RAB17 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:237,574,326...237,590,734
Ensembl chr 2:237,574,322...237,601,614
|
|
G |
RAB20 |
RAB20, member RAS oncogene family |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA panobinostat results in increased expression of RAB20 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:110,523,066...110,561,722
Ensembl chr13:110,523,066...110,561,722
|
|
G |
RAB31 |
RAB31, member RAS oncogene family |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA panobinostat results in increased expression of RAB31 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:9,708,301...9,862,551
Ensembl chr18:9,708,275...9,862,551
|
|
G |
RAB33A |
RAB33A, member RAS oncogene family |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA panobinostat results in decreased expression of RAB33A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:130,110,623...130,184,870
Ensembl chr X:130,171,962...130,184,870
|
|
G |
RAB3C |
RAB3C, member RAS oncogene family |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA panobinostat results in increased expression of RAB3C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:58,582,152...58,859,394
Ensembl chr 5:58,582,221...58,859,394
|
|
G |
RAB3IP |
RAB3A interacting protein |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA panobinostat results in decreased expression of RAB3IP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:69,738,242...69,823,204
Ensembl chr12:69,738,860...69,823,204
|
|
G |
RAB7B |
RAB7B, member RAS oncogene family |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB7B mRNA panobinostat results in increased expression of RAB7B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,976,740...206,003,395
Ensembl chr 1:205,976,740...206,003,461
|
|
G |
RABGAP1L |
RAB GTPase activating protein 1 like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA panobinostat results in increased expression of RABGAP1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:174,159,520...174,995,308
Ensembl chr 1:174,159,410...174,995,308
|
|
G |
RAC2 |
Rac family small GTPase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA panobinostat results in increased expression of RAC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:37,225,270...37,244,269
Ensembl chr22:37,225,270...37,259,594
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
[Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein |
CTD |
PMID:18445700 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RARB |
retinoic acid receptor beta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA panobinostat results in increased expression of RARB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:24,829,321...25,597,932
Ensembl chr 3:24,687,887...25,597,932
|
|
G |
RARRES2 |
retinoic acid receptor responder 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA panobinostat results in increased expression of RARRES2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:150,338,329...150,341,629
Ensembl chr 7:150,338,317...150,341,662
|
|
G |
RASA2 |
RAS p21 protein activator 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA panobinostat results in decreased expression of RASA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:141,487,027...141,615,344
Ensembl chr 3:141,487,027...141,615,344
|
|
G |
RASEF |
RAS and EF-hand domain containing |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA panobinostat results in increased expression of RASEF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:82,979,590...83,219,224
Ensembl chr 9:82,979,590...83,063,177
|
|
G |
RASGRP2 |
RAS guanyl releasing protein 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:64,726,911...64,745,456
Ensembl chr11:64,726,911...64,745,456
|
|
G |
RASSF1 |
Ras association domain family member 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of RASSF1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:50,329,788...50,340,836
Ensembl chr 3:50,329,782...50,340,980
|
|
G |
RASSF10 |
Ras association domain family member 10 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA panobinostat results in decreased expression of RASSF10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:13,009,316...13,012,119
Ensembl chr11:13,009,316...13,012,119
|
|
G |
RASSF3 |
Ras association domain family member 3 |
increases expression |
EXP |
panobinostat results in increased expression of RASSF3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:64,506,964...64,697,564
Ensembl chr12:64,507,001...64,697,564
|
|
G |
RASSF6 |
Ras association domain family member 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:73,571,550...73,620,631
Ensembl chr 4:73,571,550...73,620,631
|
|
G |
RAX |
retina and anterior neural fold homeobox |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA panobinostat results in decreased expression of RAX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:59,267,038...59,273,454
Ensembl chr18:59,267,035...59,274,086
|
|
G |
RBFOX1 |
RNA binding fox-1 homolog 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA panobinostat results in increased expression of RBFOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:5,239,721...7,713,340
Ensembl chr16:5,239,802...7,713,340
|
|
G |
RBFOX3 |
RNA binding fox-1 homolog 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA panobinostat results in decreased expression of RBFOX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:79,089,345...79,665,571
Ensembl chr17:79,089,345...79,611,051
|
|
G |
RBM22 |
RNA binding motif protein 22 |
decreases expression |
EXP |
Panobinostat results in decreased expression of RBM22 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:150,690,792...150,701,062
Ensembl chr 5:150,690,792...150,701,077
|
|
G |
RBM24 |
RNA binding motif protein 24 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA panobinostat results in decreased expression of RBM24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:17,281,361...17,293,871
Ensembl chr 6:17,281,361...17,293,871
|
|
G |
RBM43 |
RNA binding motif protein 43 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM43 mRNA panobinostat results in increased expression of RBM43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:151,247,940...151,261,863
Ensembl chr 2:151,247,940...151,261,863
|
|
G |
RBM47 |
RNA binding motif protein 47 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:40,423,280...40,630,852
Ensembl chr 4:40,423,267...40,630,875
|
|
G |
RBMS3 |
RNA binding motif single stranded interacting protein 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:29,281,071...30,010,395
Ensembl chr 3:28,574,791...30,010,391
|
|
G |
RBP1 |
retinol binding protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP1 mRNA panobinostat results in increased expression of RBP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:139,517,438...139,539,742
Ensembl chr 3:139,517,434...139,539,829
|
|
G |
RBPMS2 |
RNA binding protein, mRNA processing factor 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA panobinostat results in increased expression of RBPMS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:64,739,891...64,775,589
Ensembl chr15:64,739,891...64,775,589
|
|
G |
RCAN1 |
regulator of calcineurin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RCAN1 mRNA panobinostat results in increased expression of RCAN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:34,516,442...34,615,113
Ensembl chr21:34,513,142...34,615,113
|
|
G |
RDM1 |
RAD52 motif containing 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RDM1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:35,918,080...35,930,773
Ensembl chr17:35,918,066...35,930,773
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
panobinostat results in increased activity of and results in decreased acetylation of RELA protein; resveratrol inhibits the reaction [panobinostat results in increased activity of and results in decreased acetylation of RELA protein] |
CTD |
PMID:22923501 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RELN |
reelin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA panobinostat results in increased expression of RELN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:103,471,789...103,989,658
Ensembl chr 7:103,471,381...103,989,658
|
|
G |
REST |
RE1 silencing transcription factor |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REST mRNA panobinostat results in increased expression of REST mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:56,907,900...56,935,844
Ensembl chr 4:56,907,876...56,966,808
|
|
G |
RFTN2 |
raftlin family member 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFTN2 mRNA panobinostat results in increased expression of RFTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:197,568,224...197,675,587
Ensembl chr 2:197,568,224...197,676,045
|
|
G |
RFX3 |
regulatory factor X3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:3,218,297...3,526,001
Ensembl chr 9:3,218,297...3,526,004
|
|
G |
RFX4 |
regulatory factor X4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RFX4 mRNA panobinostat results in increased expression of RFX4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:106,583,004...106,762,803
Ensembl chr12:106,583,004...106,762,803
|
|
G |
RGL1 |
ral guanine nucleotide dissociation stimulator like 1 |
increases expression |
EXP |
Panobinostat results in increased expression of RGL1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:183,636,109...183,928,532
Ensembl chr 1:183,636,085...183,928,532
|
|
G |
RGMA |
repulsive guidance molecule BMP co-receptor a |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA panobinostat results in decreased expression of RGMA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:93,035,271...93,089,211
Ensembl chr15:93,035,271...93,089,211
|
|
G |
RGS5 |
regulator of G protein signaling 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA panobinostat results in increased expression of RGS5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:163,142,299...163,321,735
Ensembl chr 1:163,111,121...163,321,791
|
|
G |
RHOB |
ras homolog family member B |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of RHOB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
RHOBTB3 |
Rho related BTB domain containing 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA panobinostat results in increased expression of RHOBTB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:95,717,624...95,796,361
Ensembl chr 5:95,713,522...95,824,383
|
|
G |
RHOH |
ras homolog family member H |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:40,191,080...40,246,967
Ensembl chr 4:40,191,011...40,246,967
|
|
G |
RIMS1 |
regulating synaptic membrane exocytosis 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS1 mRNA panobinostat results in increased expression of RIMS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:71,886,550...72,403,145
Ensembl chr 6:71,886,550...72,403,150
|
|
G |
RIPK4 |
receptor interacting serine/threonine kinase 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA panobinostat results in increased expression of RIPK4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:41,739,373...41,767,052
Ensembl chr21:41,739,369...41,767,089
|
|
G |
RMST |
rhabdomyosarcoma 2 associated transcript |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:97,462,804...97,565,035
Ensembl chr12:97,430,884...97,598,415
|
|
G |
RND3 |
Rho family GTPase 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA panobinostat results in increased expression of RND3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:150,468,193...150,487,695
Ensembl chr 2:150,468,195...150,539,011
|
|
G |
RNF144B |
ring finger protein 144B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA panobinostat results in increased expression of RNF144B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:18,387,350...18,468,870
Ensembl chr 6:18,387,350...18,468,870
|
|
G |
RNF150 |
ring finger protein 150 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA panobinostat results in increased expression of RNF150 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:140,859,807...141,212,900
Ensembl chr 4:140,859,807...141,212,877
|
|
G |
RNF175 |
ring finger protein 175 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA panobinostat results in decreased expression of RNF175 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:153,710,160...153,760,024
Ensembl chr 4:153,710,160...153,760,024
|
|
G |
RNF182 |
ring finger protein 182 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF182 mRNA panobinostat results in decreased expression of RNF182 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:13,924,446...13,980,310
Ensembl chr 6:13,924,446...13,980,310
|
|
G |
RNF217 |
ring finger protein 217 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA panobinostat results in increased expression of RNF217 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:124,962,437...125,092,634
Ensembl chr 6:124,962,437...125,092,633
|
|
G |
RNF24 |
ring finger protein 24 |
increases expression |
EXP |
Panobinostat results in increased expression of RNF24 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr20:3,927,311...4,015,558
Ensembl chr20:3,927,309...4,015,558
|
|
G |
RNF43 |
ring finger protein 43 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA panobinostat results in increased expression of RNF43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:58,352,500...58,417,534
Ensembl chr17:58,353,676...58,417,595
|
|
G |
ROBO2 |
roundabout guidance receptor 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:75,906,675...77,649,964
Ensembl chr 3:75,906,695...77,649,964
|
|
G |
ROR1 |
receptor tyrosine kinase like orphan receptor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA panobinostat results in increased expression of ROR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:63,774,017...64,181,498
Ensembl chr 1:63,774,017...64,181,498
|
|
G |
RPL31 |
ribosomal protein L31 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA panobinostat results in decreased expression of RPL31 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:101,002,289...101,019,724
Ensembl chr 2:101,002,229...101,024,032
|
|
G |
RPP25 |
ribonuclease P and MRP subunit p25 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA panobinostat results in increased expression of RPP25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:74,954,418...74,956,772
Ensembl chr15:74,954,418...74,956,772
|
|
G |
RPRM |
reprimo, TP53 dependent G2 arrest mediator homolog |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA panobinostat results in increased expression of RPRM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:153,477,338...153,478,762
Ensembl chr 2:153,477,338...153,478,762
|
|
G |
RPRML |
reprimo like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA panobinostat results in increased expression of RPRML mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:46,978,156...46,979,253
Ensembl chr17:46,978,156...46,979,253
|
|
G |
RPS24 |
ribosomal protein S24 |
increases expression |
EXP |
panobinostat results in increased expression of RPS24 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:78,033,863...78,056,806
Ensembl chr10:78,033,760...78,056,813
|
|
G |
RPS6KA6 |
ribosomal protein S6 kinase A6 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS6KA6 mRNA panobinostat results in decreased expression of RPS6KA6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:84,058,346...84,188,499
Ensembl chr X:84,058,346...84,206,356
|
|
G |
RRAGD |
Ras related GTP binding D |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAGD mRNA panobinostat results in decreased expression of RRAGD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:89,364,616...89,412,273
Ensembl chr 6:89,364,616...89,412,273
|
|
G |
RREB1 |
ras responsive element binding protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RREB1 mRNA panobinostat results in increased expression of RREB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:7,107,743...7,251,980
Ensembl chr 6:7,107,597...7,251,980
|
|
G |
RSPO2 |
R-spondin 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA panobinostat results in decreased expression of RSPO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,899,316...108,083,620
Ensembl chr 8:107,899,316...108,083,642
|
|
G |
RSPO3 |
R-spondin 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RSPO3 mRNA panobinostat results in increased expression of RSPO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:127,118,671...127,199,481
Ensembl chr 6:127,118,671...127,199,481
|
|
G |
RTN1 |
reticulon 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA panobinostat results in decreased expression of RTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:59,595,976...59,870,776
Ensembl chr14:59,595,976...59,870,776
|
|
G |
RTP1 |
receptor transporter protein 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:187,197,486...187,201,462
Ensembl chr 3:187,197,486...187,201,462
|
|
G |
RUNX1T1 |
RUNX1 partner transcriptional co-repressor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA panobinostat results in increased expression of RUNX1T1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:91,954,967...92,103,385
Ensembl chr 8:91,954,972...92,103,385
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
RUNX3 |
RUNX family transcription factor 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA panobinostat results in increased expression of RUNX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:24,899,511...24,965,138
Ensembl chr 1:24,899,511...24,965,121
|
|
G |
RYR3 |
ryanodine receptor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA panobinostat results in decreased expression of RYR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:33,310,967...33,866,102
Ensembl chr15:33,310,962...33,866,121
|
|
G |
S100A10 |
S100 calcium binding protein A10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA panobinostat results in increased expression of S100A10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:151,982,915...151,993,859
Ensembl chr 1:151,982,915...151,993,859
|
|
G |
S100A11 |
S100 calcium binding protein A11 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA panobinostat results in increased expression of S100A11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907
|
|
G |
S100A11P1 |
S100A11 pseudogene 1 |
increases expression |
EXP |
panobinostat results in increased expression of S100A11P1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:103,261,951...103,262,480
Ensembl chr 7:103,262,000...103,262,311
|
|
G |
S100A4 |
S100 calcium binding protein A4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA panobinostat results in increased expression of S100A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136
|
|
G |
S100A6 |
S100 calcium binding protein A6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA panobinostat results in increased expression of S100A6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,534,599...153,535,991
Ensembl chr 1:153,534,599...153,536,244
|
|
G |
S100B |
S100 calcium binding protein B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA panobinostat results in increased expression of S100B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr21:46,598,604...46,605,082
Ensembl chr21:46,598,604...46,605,208
|
|
G |
S1PR3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA panobinostat results in decreased expression of S1PR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:88,990,863...89,005,155
Ensembl chr 9:88,990,863...89,005,155
|
|
G |
S1PR5 |
sphingosine-1-phosphate receptor 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA panobinostat results in increased expression of S1PR5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,512,742...10,517,965
Ensembl chr19:10,512,742...10,517,931
|
|
G |
SALL2 |
spalt like transcription factor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL2 mRNA panobinostat results in decreased expression of SALL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:21,521,080...21,537,121
Ensembl chr14:21,521,080...21,537,216
|
|
G |
SALL3 |
spalt like transcription factor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA panobinostat results in decreased expression of SALL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:78,979,818...78,998,969
Ensembl chr18:78,979,818...79,002,677
|
|
G |
SAT1 |
spermidine/spermine N1-acetyltransferase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA panobinostat results in increased expression of SAT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:23,783,173...23,786,210
Ensembl chr X:23,783,173...23,786,210
|
|
G |
SBF2 |
SET binding factor 2 |
increases expression |
EXP |
panobinostat results in increased expression of SBF2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:9,778,668...10,303,837
Ensembl chr11:9,776,776...10,304,877
|
|
G |
SCCPDH |
saccharopine dehydrogenase (putative) |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of SCCPDH mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCCPDH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:246,724,409...246,768,137
Ensembl chr 1:246,724,409...246,768,137
|
|
G |
SCG3 |
secretogranin III |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA panobinostat results in increased expression of SCG3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:51,681,503...51,721,026
Ensembl chr15:51,681,492...51,721,026
|
|
G |
SCGB3A2 |
secretoglobin family 3A member 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA panobinostat results in increased expression of SCGB3A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,878,711...147,882,191
Ensembl chr 5:147,870,682...147,882,191
|
|
G |
SCGN |
secretagogin, EF-hand calcium binding protein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:25,652,215...25,701,783
Ensembl chr 6:25,652,201...25,701,783
|
|
G |
SCML1 |
Scm polycomb group protein like 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA panobinostat results in increased expression of SCML1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:17,737,128...17,754,985
Ensembl chr X:17,737,449...17,754,988
|
|
G |
SCN2B |
sodium voltage-gated channel beta subunit 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SCN2B mRNA |
CTD |
PMID:21791302 |
|
NCBI chr11:118,162,806...118,176,639
Ensembl chr11:118,162,806...118,176,639
|
|
G |
SCN4B |
sodium voltage-gated channel beta subunit 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN4B mRNA panobinostat results in increased expression of SCN4B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:118,133,377...118,152,823
Ensembl chr11:118,133,377...118,152,888
|
|
G |
SCN7A |
sodium voltage-gated channel alpha subunit 7 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA panobinostat results in decreased expression of SCN7A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:166,403,573...166,494,249
Ensembl chr 2:166,403,573...166,611,482
|
|
G |
SCNN1A |
sodium channel epithelial 1 subunit alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA panobinostat results in increased expression of SCNN1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:6,346,847...6,377,359
Ensembl chr12:6,346,843...6,377,730
|
|
G |
SCNN1G |
sodium channel epithelial 1 subunit gamma |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA panobinostat results in increased expression of SCNN1G mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:23,182,745...23,216,883
Ensembl chr16:23,182,745...23,216,883
|
|
G |
SCRG1 |
stimulator of chondrogenesis 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCRG1 mRNA panobinostat results in increased expression of SCRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:173,384,701...173,519,144
Ensembl chr 4:173,384,701...173,406,380
|
|
G |
SCUBE2 |
signal peptide, CUB domain and EGF like domain containing 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA panobinostat results in decreased expression of SCUBE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:9,019,476...9,091,599
Ensembl chr11:9,019,476...9,138,114
|
|
G |
SDC4 |
syndecan 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDC4 mRNA panobinostat results in increased expression of SDC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:45,325,288...45,348,424
Ensembl chr20:45,325,288...45,348,424
|
|
G |
SEC24D |
SEC24 homolog D, COPII coat complex component |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA panobinostat results in increased expression of SEC24D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:118,722,823...118,836,126
Ensembl chr 4:118,722,823...118,838,683
|
|
G |
SELENOI |
selenoprotein I |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOI mRNA panobinostat results in increased expression of SELENOI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:26,346,143...26,395,885
Ensembl chr 2:26,308,547...26,395,885
|
|
G |
SELENOP |
selenoprotein P |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA panobinostat results in increased expression of SELENOP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:42,799,880...42,811,892
Ensembl chr 5:42,799,880...42,887,392
|
|
G |
SEMA3C |
semaphorin 3C |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA panobinostat results in increased expression of SEMA3C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:80,742,538...80,922,389
Ensembl chr 7:80,742,538...80,922,359
|
|
G |
SEMA3E |
semaphorin 3E |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA panobinostat results in increased expression of SEMA3E mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:83,363,238...83,649,139
Ensembl chr 7:83,363,238...83,649,139
|
|
G |
SEMA5A |
semaphorin 5A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA panobinostat results in decreased expression of SEMA5A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:9,035,033...9,546,075
Ensembl chr 5:9,035,033...9,546,075
|
|
G |
SEMA6D |
semaphorin 6D |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA6D mRNA panobinostat results in decreased expression of SEMA6D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:47,184,089...47,774,228
Ensembl chr15:47,184,101...47,774,228
|
|
G |
SENP6 |
SUMO specific peptidase 6 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of SENP6 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of SENP6 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 6:75,601,880...75,718,281
Ensembl chr 6:75,601,509...75,718,281
|
|
G |
SEPTIN6 |
septin 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA Panobinostat results in increased expression of SEPTIN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:119,615,724...119,693,168
Ensembl chr X:119,615,724...119,693,370
|
|
G |
SERPINB9 |
serpin family B member 9 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA panobinostat results in increased expression of SERPINB9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:2,887,270...2,903,309
Ensembl chr 6:2,887,270...2,903,309
|
|
G |
SERPINF1 |
serpin family F member 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINF1 mRNA panobinostat results in decreased expression of SERPINF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:1,762,060...1,777,565
Ensembl chr17:1,762,029...1,777,565
|
|
G |
SESTD1 |
SEC14 and spectrin domain containing 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA panobinostat results in decreased expression of SESTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:179,101,678...179,264,832
Ensembl chr 2:179,101,678...179,264,832
|
|
G |
SEZ6 |
seizure related 6 homolog |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA panobinostat results in increased expression of SEZ6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:28,954,905...29,006,440
Ensembl chr17:28,954,901...29,006,440
|
|
G |
SFMBT1 |
Scm like with four mbt domains 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFMBT1 mRNA panobinostat results in decreased expression of SFMBT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:52,903,572...53,046,073
Ensembl chr 3:52,903,572...53,046,750
|
|
G |
SFMBT2 |
Scm like with four mbt domains 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA panobinostat results in increased expression of SFMBT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:7,158,624...7,411,490
Ensembl chr10:7,158,624...7,411,488
|
|
G |
SFN |
stratifin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA panobinostat results in increased expression of SFN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SFRP1 |
secreted frizzled related protein 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA panobinostat results in decreased expression of SFRP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:41,261,962...41,309,473
Ensembl chr 8:41,261,962...41,309,473
|
|
G |
SFRP2 |
secreted frizzled related protein 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA panobinostat results in decreased expression of SFRP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:153,780,591...153,789,083
Ensembl chr 4:153,780,591...153,789,083
|
|
G |
SGK3 |
serum/glucocorticoid regulated kinase family member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA panobinostat results in increased expression of SGK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:66,712,781...66,862,022
Ensembl chr 8:66,712,734...66,862,022
|
|
G |
SGPP1 |
sphingosine-1-phosphate phosphatase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP1 mRNA panobinostat results in increased expression of SGPP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:63,684,216...63,728,065
Ensembl chr14:63,684,216...63,728,065
|
|
G |
SGPP2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA panobinostat results in increased expression of SGPP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:222,423,988...222,562,621
Ensembl chr 2:222,424,543...222,562,621
|
|
G |
SH3KBP1 |
SH3 domain containing kinase binding protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA panobinostat results in increased expression of SH3KBP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:19,533,977...19,887,600
Ensembl chr X:19,533,977...19,887,600
|
|
G |
SHB |
SH2 domain containing adaptor protein B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA panobinostat results in increased expression of SHB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:37,915,898...38,069,227
Ensembl chr 9:37,915,898...38,069,227
|
|
G |
SHC3 |
SHC adaptor protein 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:89,005,771...89,178,818
Ensembl chr 9:89,005,771...89,178,818
|
|
G |
SHISA2 |
shisa family member 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:26,044,597...26,052,016
Ensembl chr13:26,044,597...26,052,016
|
|
G |
SHISA6 |
shisa family member 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:11,241,213...11,564,063
Ensembl chr17:11,241,213...11,564,063
|
|
G |
SIK1 |
salt inducible kinase 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIK1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131
|
|
G |
SIX1 |
SIX homeobox 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA panobinostat results in increased expression of SIX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:60,643,421...60,649,477
Ensembl chr14:60,643,421...60,658,259
|
|
G |
SIX3 |
SIX homeobox 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA panobinostat results in decreased expression of SIX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:44,941,702...44,946,071
Ensembl chr 2:44,941,702...44,946,071
|
|
G |
SIX6 |
SIX homeobox 6 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA panobinostat results in decreased expression of SIX6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:60,509,146...60,512,850
Ensembl chr14:60,509,146...60,512,850
|
|
G |
SKAP2 |
src kinase associated phosphoprotein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA panobinostat results in increased expression of SKAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:26,654,770...26,864,590
Ensembl chr 7:26,667,068...26,995,239
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA panobinostat results in increased expression of SLC16A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,593
|
|
G |
SLC16A14 |
solute carrier family 16 member 14 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA panobinostat results in decreased expression of SLC16A14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:230,034,982...230,068,924
Ensembl chr 2:230,034,982...230,068,993
|
|
G |
SLC16A4 |
solute carrier family 16 member 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A4 mRNA panobinostat results in increased expression of SLC16A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:110,362,857...110,391,026
Ensembl chr 1:110,362,851...110,391,082
|
|
G |
SLC17A5 |
solute carrier family 17 member 5 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SLC17A5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:73,593,379...73,653,992
Ensembl chr 6:73,593,379...73,653,992
|
|
G |
SLC18B1 |
solute carrier family 18 member B1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA panobinostat results in increased expression of SLC18B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:132,769,370...132,798,637
Ensembl chr 6:132,769,370...132,813,339
|
|
G |
SLC19A3 |
solute carrier family 19 member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC19A3 mRNA panobinostat results in increased expression of SLC19A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:227,683,763...227,718,028
Ensembl chr 2:227,683,763...227,718,028
|
|
G |
SLC1A1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SLC1A1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:4,490,468...4,587,469
Ensembl chr 9:4,490,468...4,587,469
|
|
G |
SLC1A3 |
solute carrier family 1 member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA panobinostat results in increased expression of SLC1A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:36,606,606...36,688,334
Ensembl chr 5:36,596,588...36,688,334
|
|
G |
SLC24A3 |
solute carrier family 24 member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA panobinostat results in increased expression of SLC24A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:19,212,642...19,722,926
Ensembl chr20:19,212,642...19,722,926
|
|
G |
SLC25A12 |
solute carrier family 25 member 12 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA panobinostat results in increased expression of SLC25A12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:171,783,405...171,894,244
Ensembl chr 2:171,783,405...171,999,859
|
|
G |
SLC25A16 |
solute carrier family 25 member 16 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A16 mRNA panobinostat results in increased expression of SLC25A16 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:68,477,998...68,527,523
Ensembl chr10:68,477,998...68,527,523
|
|
G |
SLC25A25 |
solute carrier family 25 member 25 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SLC25A25 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:128,068,232...128,109,245
Ensembl chr 9:128,068,201...128,109,245
|
|
G |
SLC25A53 |
solute carrier family 25 member 53 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA panobinostat results in decreased expression of SLC25A53 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:104,099,214...104,157,009
Ensembl chr X:104,099,214...104,157,009
|
|
G |
SLC27A2 |
solute carrier family 27 member 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:50,182,196...50,236,385
Ensembl chr15:50,182,196...50,236,385
|
|
G |
SLC2A3 |
solute carrier family 2 member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA panobinostat results in increased expression of SLC2A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007
|
|
G |
SLC30A4 |
solute carrier family 30 member 4 |
increases expression |
EXP |
panobinostat results in increased expression of SLC30A4 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:45,479,606...45,522,755
Ensembl chr15:45,479,606...45,522,755
|
|
G |
SLC35D3 |
solute carrier family 35 member D3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:136,922,301...136,925,660
Ensembl chr 6:136,922,301...136,925,660
|
|
G |
SLC35F2 |
solute carrier family 35 member F2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35F2 mRNA panobinostat results in increased expression of SLC35F2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:107,790,991...107,858,787
Ensembl chr11:107,790,991...107,928,293
|
|
G |
SLC35G2 |
solute carrier family 35 member G2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:136,819,126...136,855,888
Ensembl chr 3:136,818,647...136,855,888
|
|
G |
SLC38A6 |
solute carrier family 38 member 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:60,981,245...61,083,733
Ensembl chr14:60,981,114...61,114,316
|
|
G |
SLC39A6 |
solute carrier family 39 member 6 |
decreases expression |
EXP |
panobinostat results in decreased expression of SLC39A6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:36,108,531...36,129,340
Ensembl chr18:36,108,531...36,129,385
|
|
G |
SLC39A7 |
solute carrier family 39 member 7 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SLC39A7 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:33,200,867...33,204,437
Ensembl chr 6:33,200,305...33,204,439
|
|
G |
SLC39A8 |
solute carrier family 39 member 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA panobinostat results in increased expression of SLC39A8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:102,251,041...102,345,482
Ensembl chr 4:102,251,080...102,431,258
|
|
G |
SLC40A1 |
solute carrier family 40 member 1 |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of SLC40A1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA panobinostat results in increased expression of SLC40A1 mRNA |
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 2:189,560,590...189,580,786
Ensembl chr 2:189,560,590...189,583,758
|
|
G |
SLC43A1 |
solute carrier family 43 member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA panobinostat results in increased expression of SLC43A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:57,484,534...57,515,702
Ensembl chr11:57,484,534...57,515,780
|
|
G |
SLC52A3 |
solute carrier family 52 member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA panobinostat results in increased expression of SLC52A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:760,080...780,033
Ensembl chr20:760,080...776,015
|
|
G |
SLC6A8 |
solute carrier family 6 member 8 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA panobinostat results in decreased expression of SLC6A8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:153,687,926...153,696,593
Ensembl chr X:153,687,926...153,696,588
|
|
G |
SLC7A10 |
solute carrier family 7 member 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA panobinostat results in increased expression of SLC7A10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:33,208,664...33,225,850
Ensembl chr19:33,208,664...33,225,850
|
|
G |
SLC7A11 |
solute carrier family 7 member 11 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA panobinostat results in increased expression of SLC7A11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349
|
|
G |
SLC7A5 |
solute carrier family 7 member 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA panobinostat results in increased expression of SLC7A5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:87,830,023...87,869,507
Ensembl chr16:87,830,023...87,869,507
|
|
G |
SLC9B2 |
solute carrier family 9 member B2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA panobinostat results in decreased expression of SLC9B2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:103,018,029...103,077,319
Ensembl chr 4:103,019,868...103,085,829
|
|
G |
SLCO4C1 |
solute carrier organic anion transporter family member 4C1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA panobinostat results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:102,233,986...102,296,284
Ensembl chr 5:102,233,986...102,296,284
|
|
G |
SLFN5 |
schlafen family member 5 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:35,243,072...35,273,655
Ensembl chr17:35,243,071...35,273,655
|
|
G |
SLIT1 |
slit guidance ligand 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA panobinostat results in increased expression of SLIT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:96,998,038...97,185,959
Ensembl chr10:96,998,038...97,185,959
|
|
G |
SLIT2 |
slit guidance ligand 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA panobinostat results in increased expression of SLIT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:20,251,905...20,620,561
Ensembl chr 4:20,251,905...20,620,561
|
|
G |
SLIT3 |
slit guidance ligand 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA panobinostat results in increased expression of SLIT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:168,661,740...169,301,139
Ensembl chr 5:168,661,740...169,301,139
|
|
G |
SLITRK6 |
SLIT and NTRK like family member 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLITRK6 mRNA panobinostat results in increased expression of SLITRK6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:85,792,790...85,799,419
Ensembl chr13:85,792,790...85,806,683
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA panobinostat results in decreased expression of SMAD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMARCA2 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA panobinostat results in increased expression of SMARCA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:2,015,347...2,193,624
Ensembl chr 9:1,980,290...2,193,624
|
|
G |
SMIM14 |
small integral membrane protein 14 |
increases expression |
EXP |
Panobinostat results in increased expression of SMIM14 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:39,546,336...39,638,865
Ensembl chr 4:39,546,336...39,638,902
|
|
G |
SMOC1 |
SPARC related modular calcium binding 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA panobinostat results in decreased expression of SMOC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:69,879,416...70,032,366
Ensembl chr14:69,854,131...70,032,366
|
|
G |
SMOC2 |
SPARC related modular calcium binding 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:168,441,184...168,667,992
Ensembl chr 6:168,441,151...168,673,445
|
|
G |
SMPDL3A |
sphingomyelin phosphodiesterase acid like 3A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:122,789,258...122,809,720
Ensembl chr 6:122,789,049...122,809,720
|
|
G |
SMYD2 |
SET and MYND domain containing 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMYD2 mRNA panobinostat results in increased expression of SMYD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:214,281,159...214,337,131
Ensembl chr 1:214,281,102...214,337,131
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA panobinostat results in increased expression of SNAI2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740
|
|
G |
SNAP25 |
synaptosome associated protein 25 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA panobinostat results in increased expression of SNAP25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:10,218,830...10,307,418
Ensembl chr20:10,172,395...10,308,258
|
|
G |
SNRK |
SNF related kinase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SNRK mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:43,286,540...43,351,143
Ensembl chr 3:43,286,512...43,424,764
|
|
G |
SNX25 |
sorting nexin 25 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA panobinostat results in decreased expression of SNX25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:185,204,237...185,378,642
Ensembl chr 4:185,204,237...185,370,185
|
|
G |
SOCS1 |
suppressor of cytokine signaling 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA panobinostat results in increased expression of SOCS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:11,254,417...11,256,204
Ensembl chr16:11,254,417...11,256,204
|
|
G |
SOCS2 |
suppressor of cytokine signaling 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA panobinostat results in increased expression of SOCS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:93,569,969...93,626,236
Ensembl chr12:93,569,814...93,583,487
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA panobinostat results in decreased expression of SOCS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SORCS2 |
sortilin related VPS10 domain containing receptor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA panobinostat results in decreased expression of SORCS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:7,192,538...7,742,827
Ensembl chr 4:7,192,538...7,742,827
|
|
G |
SORD |
sorbitol dehydrogenase |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA panobinostat results in decreased expression of SORD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:45,023,195...45,077,185
Ensembl chr15:45,023,147...45,077,185
|
|
G |
SOST |
sclerostin |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:43,753,738...43,758,791
Ensembl chr17:43,753,738...43,758,791
|
|
G |
SOX10 |
SRY-box transcription factor 10 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX10 mRNA panobinostat results in increased expression of SOX10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:37,972,312...37,984,555
Ensembl chr22:37,970,686...37,987,422
|
|
G |
SOX11 |
SRY-box transcription factor 11 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA panobinostat results in decreased expression of SOX11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:5,692,384...5,701,385
Ensembl chr 2:5,692,384...5,701,385
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA panobinostat results in decreased expression of SOX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
|
|
G |
SOX2-OT |
SOX2 overlapping transcript |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA panobinostat results in decreased expression of SOX2-OT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:181,056,680...181,742,228
Ensembl chr 3:180,989,762...181,836,880
|
|
G |
SOX21-AS1 |
SOX21 antisense divergent transcript 1 |
decreases expression |
EXP |
panobinostat results in decreased expression of SOX21-AS1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:94,712,716...94,715,945
Ensembl chr13:94,703,454...94,803,430
|
|
G |
SOX3 |
SRY-box transcription factor 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA panobinostat results in decreased expression of SOX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:140,502,985...140,505,069
Ensembl chr X:140,502,985...140,505,069
|
|
G |
SOX8 |
SRY-box transcription factor 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA panobinostat results in increased expression of SOX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:981,770...986,979
Ensembl chr16:981,444...986,979
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX9 mRNA panobinostat results in increased expression of SOX9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SP140L |
SP140 nuclear body protein like |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA panobinostat results in increased expression of SP140L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:230,327,193...230,403,732
Ensembl chr 2:230,327,184...230,403,732
|
|
G |
SP5 |
Sp5 transcription factor |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA panobinostat results in increased expression of SP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:170,715,337...170,718,078
Ensembl chr 2:170,715,337...170,718,078
|
|
G |
SP6 |
Sp6 transcription factor |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA panobinostat results in increased expression of SP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:47,844,908...47,876,311
Ensembl chr17:47,844,908...47,855,874
|
|
G |
SP8 |
Sp8 transcription factor |
decreases expression |
EXP |
panobinostat results in decreased expression of SP8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:20,782,279...20,786,886
Ensembl chr 7:20,782,279...20,786,886
|
|
G |
SPAG1 |
sperm associated antigen 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:100,158,038...100,241,904
Ensembl chr 8:100,157,906...100,259,278
|
|
G |
SPAG9 |
sperm associated antigen 9 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:50,962,174...51,120,868
Ensembl chr17:50,962,174...51,120,868
|
|
G |
SPHK1 |
sphingosine kinase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPHK1 mRNA panobinostat results in increased expression of SPHK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860
|
|
G |
SPINK1 |
serine peptidase inhibitor Kazal type 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK1 mRNA panobinostat results in increased expression of SPINK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,824,582...147,839,196
Ensembl chr 5:147,824,572...147,831,671
|
|
G |
SPINK2 |
serine peptidase inhibitor Kazal type 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA panobinostat results in increased expression of SPINK2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:56,809,860...56,821,869
Ensembl chr 4:56,809,860...56,821,742
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA panobinostat results in increased expression of SPP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SPRY1 |
sprouty RTK signaling antagonist 1 |
decreases expression |
EXP |
panobinostat results in decreased expression of SPRY1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:123,396,795...123,403,760
Ensembl chr 4:123,396,795...123,403,760
|
|
G |
SPSB4 |
splA/ryanodine receptor domain and SOCS box containing 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA panobinostat results in increased expression of SPSB4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:141,051,347...141,148,611
Ensembl chr 3:141,051,347...141,148,611
|
|
G |
SQOR |
sulfide quinone oxidoreductase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQOR mRNA panobinostat results in increased expression of SQOR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:45,631,148...45,691,281
Ensembl chr15:45,631,148...45,691,281
|
|
G |
SRCIN1 |
SRC kinase signaling inhibitor 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA panobinostat results in decreased expression of SRCIN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:38,530,031...38,607,025
Ensembl chr17:38,530,031...38,605,952
|
|
G |
SSBP2 |
single stranded DNA binding protein 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA panobinostat results in decreased expression of SSBP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:81,412,804...81,751,807
Ensembl chr 5:81,412,804...81,751,797
|
|
G |
SST |
somatostatin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA panobinostat results in increased expression of SST mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:187,668,912...187,670,394
Ensembl chr 3:187,668,912...187,670,394
|
|
G |
ST14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:130,159,782...130,210,362
Ensembl chr11:130,159,782...130,210,362
|
|
G |
ST3GAL1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST3GAL1 mRNA panobinostat results in increased expression of ST3GAL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:133,454,848...133,571,887
Ensembl chr 8:133,454,848...133,571,926
|
|
G |
ST3GAL5 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
increases expression |
EXP |
Panobinostat results in increased expression of ST3GAL5 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:85,837,120...85,889,034
Ensembl chr 2:85,837,120...85,905,199
|
|
G |
ST6GALNAC2 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST6GALNAC2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:76,565,377...76,585,860
Ensembl chr17:76,565,377...76,586,956
|
|
G |
ST6GALNAC5 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA panobinostat results in decreased expression of ST6GALNAC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:76,867,480...77,067,546
Ensembl chr 1:76,867,480...77,067,546
|
|
G |
ST8SIA2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ST8SIA2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr15:92,393,881...92,468,728
Ensembl chr15:92,393,881...92,468,728
|
|
G |
ST8SIA3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ST8SIA3 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ST8SIA3 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr18:57,352,557...57,368,931
Ensembl chr18:57,352,557...57,371,731
|
|
G |
STAM2 |
signal transducing adaptor molecule 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:152,116,801...152,175,763
Ensembl chr 2:152,116,801...152,175,763
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions increases acetylation |
EXP |
panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]] Panobinostat results in increased acetylation of STAT3 protein |
CTD |
PMID:23681230 PMID:26775640 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
STAT6 |
signal transducer and activator of transcription 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA panobinostat results in increased expression of STAT6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:57,095,408...57,111,362
Ensembl chr12:57,095,408...57,132,139
|
|
G |
STC1 |
stanniocalcin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC1 mRNA panobinostat results in increased expression of STC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:23,841,929...23,854,806
Ensembl chr 8:23,841,929...23,854,806
|
|
G |
STEAP1 |
STEAP family member 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with Panobinostat] affects the expression of STEAP1 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA |
CTD |
PMID:21791302 PMID:27188386 |
|
NCBI chr 7:90,154,469...90,164,827
Ensembl chr 7:90,154,456...90,164,829
|
|
G |
STEAP3 |
STEAP3 metalloreductase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA panobinostat results in increased expression of STEAP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:119,223,834...119,265,652
Ensembl chr 2:119,223,831...119,265,652
|
|
G |
STIMATE-MUSTN1 |
STIMATE-MUSTN1 readthrough |
increases expression |
EXP |
Panobinostat results in increased expression of STIMATE-MUSTN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:52,833,121...52,897,548
Ensembl chr 3:52,833,121...52,897,562
|
|
G |
STK32A |
serine/threonine kinase 32A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA panobinostat results in decreased expression of STK32A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,235,026...147,401,990
Ensembl chr 5:147,234,963...147,387,855
|
|
G |
STMN2 |
stathmin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA panobinostat results in increased expression of STMN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:79,611,117...79,666,158
Ensembl chr 8:79,611,117...79,666,158
|
|
G |
STOM |
stomatin |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STOM mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:121,338,987...121,370,250
Ensembl chr 9:121,338,987...121,370,304
|
|
G |
STON1 |
stonin 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of STON1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 2:48,530,154...48,598,513
Ensembl chr 2:48,529,383...48,598,513
|
|
G |
STOX1 |
storkhead box 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:68,827,531...68,895,432
Ensembl chr10:68,827,531...68,895,432
|
|
G |
STRA6 |
signaling receptor and transporter of retinol STRA6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA panobinostat results in increased expression of STRA6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:74,179,466...74,212,259
Ensembl chr15:74,179,466...74,212,267
|
|
G |
STYK1 |
serine/threonine/tyrosine kinase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA panobinostat results in increased expression of STYK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:10,618,923...10,674,052
Ensembl chr12:10,618,923...10,674,318
|
|
G |
SULF2 |
sulfatase 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of SULF2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr20:47,657,406...47,786,627
Ensembl chr20:47,656,197...47,786,616
|
|
G |
SULT1A1 |
sulfotransferase family 1A member 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:28,605,258...28,623,375
Ensembl chr16:28,605,196...28,610,044
|
|
G |
SULT1A2 |
sulfotransferase family 1A member 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA panobinostat results in increased expression of SULT1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:28,591,943...28,597,050
Ensembl chr16:28,591,943...28,597,050
|
|
G |
SULT1C2 |
sulfotransferase family 1C member 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA panobinostat results in increased expression of SULT1C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:108,288,895...108,309,915
Ensembl chr 2:108,288,639...108,309,915
|
|
G |
SUSD2 |
sushi domain containing 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA panobinostat results in increased expression of SUSD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:24,181,487...24,189,106
Ensembl chr22:24,181,487...24,189,106
|
|
G |
SUSD3 |
sushi domain containing 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA panobinostat results in increased expression of SUSD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:93,058,701...93,085,133
Ensembl chr 9:93,058,688...93,085,133
|
|
G |
SV2C |
synaptic vesicle glycoprotein 2C |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA panobinostat results in increased expression of SV2C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:75,847,464...76,353,939
Ensembl chr 5:76,083,383...76,353,939
|
|
G |
SYK |
spleen associated tyrosine kinase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA panobinostat results in increased expression of SYK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,801,600...90,898,549
Ensembl chr 9:90,801,787...90,898,549
|
|
G |
SYNCRIP |
synaptotagmin binding cytoplasmic RNA interacting protein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:85,607,784...85,643,870
Ensembl chr 6:85,607,779...85,644,063
|
|
G |
SYNE1 |
spectrin repeat containing nuclear envelope protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA panobinostat results in increased expression of SYNE1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:152,121,687...152,637,362
Ensembl chr 6:152,121,687...152,637,801
|
|
G |
SYNE3 |
spectrin repeat containing nuclear envelope family member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE3 mRNA panobinostat results in increased expression of SYNE3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:95,407,266...95,516,650
Ensembl chr14:95,407,266...95,516,650
|
|
G |
SYNGR1 |
synaptogyrin 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA panobinostat results in increased expression of SYNGR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:39,349,991...39,385,575
Ensembl chr22:39,349,925...39,385,575
|
|
G |
SYNPR |
synaptoporin |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA panobinostat results in increased expression of SYNPR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:63,200,604...63,616,924
Ensembl chr 3:63,228,315...63,616,924
|
|
G |
SYT11 |
synaptotagmin 11 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA panobinostat results in decreased expression of SYT11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:155,859,567...155,885,199
Ensembl chr 1:155,859,567...155,885,199
|
|
G |
SYT4 |
synaptotagmin 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT4 mRNA panobinostat results in increased expression of SYT4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:43,267,892...43,277,490
Ensembl chr18:43,267,892...43,277,535
|
|
G |
SYT7 |
synaptotagmin 7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of SYT7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:61,513,714...61,588,387
Ensembl chr11:61,513,714...61,581,148
|
|
G |
SYTL2 |
synaptotagmin like 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:85,694,229...85,854,870
Ensembl chr11:85,694,224...85,811,159
|
|
G |
SYTL4 |
synaptotagmin like 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYTL4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:100,674,491...100,732,121
Ensembl chr X:100,671,783...100,732,123
|
|
G |
TAC1 |
tachykinin precursor 1 |
increases expression |
EXP |
panobinostat results in increased expression of TAC1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472
|
|
G |
TACC1 |
transforming acidic coiled-coil containing protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA panobinostat results in increased expression of TACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:38,728,582...38,853,028
Ensembl chr 8:38,728,186...38,853,028
|
|
G |
TACSTD2 |
tumor associated calcium signal transducer 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA panobinostat results in increased expression of TACSTD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:58,575,433...58,577,252
Ensembl chr 1:58,575,433...58,577,252
|
|
G |
TAGLN2 |
transgelin 2 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of TAGLN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAGLN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:159,918,111...159,925,507
Ensembl chr 1:159,918,107...159,925,507
|
|
G |
TANC1 |
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA panobinostat results in increased expression of TANC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:158,968,640...159,232,659
Ensembl chr 2:158,968,640...159,232,659
|
|
G |
TARS1 |
threonyl-tRNA synthetase 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA Panobinostat results in increased expression of TARS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:33,440,696...33,468,091
Ensembl chr 5:33,440,696...33,468,091
|
|
G |
TBC1D16 |
TBC1 domain family member 16 |
increases expression |
EXP |
Panobinostat results in increased expression of TBC1D16 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:79,932,343...80,035,872
Ensembl chr17:79,932,343...80,035,872
|
|
G |
TBC1D30 |
TBC1 domain family member 30 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA panobinostat results in decreased expression of TBC1D30 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:64,759,484...64,881,033
Ensembl chr12:64,759,484...64,881,033
|
|
G |
TBC1D8 |
TBC1 domain family member 8 |
decreases expression |
EXP |
panobinostat results in decreased expression of TBC1D8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:101,007,228...101,151,382
Ensembl chr 2:101,007,228...101,252,866
|
|
G |
TBL1XR1 |
TBL1X/Y related 1 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBL1XR1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBL1XR1 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 3:177,019,344...177,201,800
Ensembl chr 3:177,019,340...177,228,000
|
|
G |
TBX3 |
T-box transcription factor 3 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TBX3 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TBX3 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr12:114,670,255...114,684,175
Ensembl chr12:114,670,255...114,684,175
|
|
G |
TC2N |
tandem C2 domains, nuclear |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:91,779,746...91,867,536
Ensembl chr14:91,779,746...91,867,536
|
|
G |
TDRKH |
tudor and KH domain containing |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TDRKH mRNA panobinostat results in decreased expression of TDRKH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:151,766,486...151,790,534
Ensembl chr 1:151,770,107...151,791,416
|
|
G |
TDRP |
testis development related protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA panobinostat results in increased expression of TDRP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:489,946...545,780
Ensembl chr 8:489,803...545,781
|
|
G |
TENM2 |
teneurin transmembrane protein 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA panobinostat results in increased expression of TENM2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:166,979,029...168,264,157
Ensembl chr 5:166,979,029...168,264,157
|
|
G |
TENT5B |
terminal nucleotidyltransferase 5B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA panobinostat results in increased expression of TENT5B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:27,005,020...27,012,850
Ensembl chr 1:27,005,020...27,012,850
|
|
G |
TEP1 |
telomerase associated protein 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of TEP1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr14:20,365,667...20,413,501
Ensembl chr14:20,365,667...20,413,501
|
|
G |
TES |
testin LIM domain protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA panobinostat results in increased expression of TES mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:116,210,539...116,258,783
Ensembl chr 7:116,210,506...116,258,783
|
|
G |
TFAP2A |
transcription factor AP-2 alpha |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA panobinostat results in increased expression of TFAP2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:10,396,677...10,419,659
Ensembl chr 6:10,393,186...10,419,659
|
|
G |
TFAP2B |
transcription factor AP-2 beta |
multiple interactions increases expression affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of TFAP2B mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TFAP2B mRNA] panobinostat results in increased expression of TFAP2B mRNA panobinostat affects the expression of TFAP2B mRNA |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 6:50,818,355...50,847,619
Ensembl chr 6:50,818,723...50,847,619
|
|
G |
TFAP2C |
transcription factor AP-2 gamma |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA panobinostat results in increased expression of TFAP2C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:56,629,306...56,639,283
Ensembl chr20:56,629,306...56,639,283
|
|
G |
TFCP2L1 |
transcription factor CP2 like 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA panobinostat results in increased expression of TFCP2L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:121,216,587...121,285,202
Ensembl chr 2:121,216,587...121,285,202
|
|
G |
TFPI |
tissue factor pathway inhibitor |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA panobinostat results in increased expression of TFPI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
TFPI2 |
tissue factor pathway inhibitor 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA panobinostat results in increased expression of TFPI2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:93,885,396...93,890,753
Ensembl chr 7:93,885,396...93,890,753
|
|
G |
TGFB1I1 |
transforming growth factor beta 1 induced transcript 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA panobinostat results in increased expression of TGFB1I1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:31,472,152...31,477,960
Ensembl chr16:31,471,585...31,477,960
|
|
G |
TGFBI |
transforming growth factor beta induced |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TGFBI mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:136,028,988...136,063,818
Ensembl chr 5:136,028,988...136,063,818
|
|
G |
TGFBRAP1 |
transforming growth factor beta receptor associated protein 1 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TGFBRAP1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TGFBRAP1 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 2:105,249,404...105,329,735
Ensembl chr 2:105,264,391...105,329,735
|
|
G |
THAP2 |
THAP domain containing 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:71,664,301...71,680,644
Ensembl chr12:71,664,301...71,680,644
|
|
G |
THAP9 |
THAP domain containing 9 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP9 mRNA panobinostat results in decreased expression of THAP9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:82,900,735...82,919,969
Ensembl chr 4:82,900,684...82,919,969
|
|
G |
THBS2 |
thrombospondin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA panobinostat results in increased expression of THBS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:169,215,785...169,253,846
Ensembl chr 6:169,215,780...169,254,050
|
|
G |
THRB |
thyroid hormone receptor beta |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA panobinostat results in increased expression of THRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756
|
|
G |
TKTL1 |
transketolase like 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKTL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:154,295,795...154,330,350
Ensembl chr X:154,295,795...154,330,350
|
|
G |
TLE4 |
TLE family member 4, transcriptional corepressor |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA panobinostat results in decreased expression of TLE4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:79,571,965...79,726,882
Ensembl chr 9:79,571,773...79,726,882
|
|
G |
TMC5 |
transmembrane channel like 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMC5 mRNA panobinostat results in increased expression of TMC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:19,410,539...19,499,113
Ensembl chr16:19,410,496...19,499,113
|
|
G |
TMCC2 |
transmembrane and coiled-coil domain family 2 |
increases expression |
EXP |
Panobinostat results in increased expression of TMCC2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:205,227,946...205,273,343
Ensembl chr 1:205,227,946...205,285,632
|
|
G |
TMED5 |
transmembrane p24 trafficking protein 5 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA panobinostat results in increased expression of TMED5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:93,149,742...93,180,413
Ensembl chr 1:93,149,742...93,180,516
|
|
G |
TMEM125 |
transmembrane protein 125 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA panobinostat results in increased expression of TMEM125 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:43,269,983...43,274,002
Ensembl chr 1:43,269,983...43,274,002
|
|
G |
TMEM144 |
transmembrane protein 144 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA panobinostat results in increased expression of TMEM144 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:158,210,486...158,255,416
Ensembl chr 4:158,201,604...158,255,416
|
|
G |
TMEM154 |
transmembrane protein 154 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA panobinostat results in increased expression of TMEM154 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:152,618,628...152,679,997
Ensembl chr 4:152,618,628...152,680,012
|
|
G |
TMEM163 |
transmembrane protein 163 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA panobinostat results in decreased expression of TMEM163 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:134,455,759...134,719,000
Ensembl chr 2:134,455,759...134,719,000
|
|
G |
TMEM169 |
transmembrane protein 169 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA panobinostat results in decreased expression of TMEM169 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:216,081,919...216,102,783
Ensembl chr 2:216,081,866...216,102,783
|
|
G |
TMEM170B |
transmembrane protein 170B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA panobinostat results in decreased expression of TMEM170B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:11,537,749...11,583,524
Ensembl chr 6:11,537,749...11,583,524
|
|
G |
TMEM178A |
transmembrane protein 178A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA panobinostat results in decreased expression of TMEM178A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:39,665,483...39,735,960
Ensembl chr 2:39,664,982...39,717,963
|
|
G |
TMEM18 |
transmembrane protein 18 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM18 mRNA panobinostat results in decreased expression of TMEM18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:663,877...677,406
Ensembl chr 2:663,877...677,406
|
|
G |
TMEM218 |
transmembrane protein 218 |
decreases expression |
EXP |
panobinostat results in decreased expression of TMEM218 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:125,094,389...125,111,626
Ensembl chr11:125,094,389...125,111,763
|
|
G |
TMEM30B |
transmembrane protein 30B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA panobinostat results in increased expression of TMEM30B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:61,277,370...61,281,338
Ensembl chr14:61,277,370...61,281,761
|
|
G |
TMEM64 |
transmembrane protein 64 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA panobinostat results in increased expression of TMEM64 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:90,621,995...90,646,083
Ensembl chr 8:90,621,995...90,791,632
|
|
G |
TMEM74 |
transmembrane protein 74 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA panobinostat results in decreased expression of TMEM74 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:108,606,850...108,787,594
Ensembl chr 8:108,606,850...108,787,594
|
|
G |
TMEM88 |
transmembrane protein 88 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA panobinostat results in decreased expression of TMEM88 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:7,855,066...7,856,099
Ensembl chr17:7,855,066...7,856,099
|
|
G |
TMOD2 |
tropomodulin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD2 mRNA panobinostat results in increased expression of TMOD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:51,751,597...51,816,363
Ensembl chr15:51,751,597...51,816,363
|
|
G |
TMPRSS11E |
transmembrane serine protease 11E |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:68,447,463...68,497,604
Ensembl chr 4:68,447,463...68,497,604
|
|
G |
TMT1A |
thiol methyltransferase 1A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:50,925,015...50,932,508
Ensembl chr12:50,923,472...50,932,510
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of TNFAIP3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TNFRSF10B |
TNF receptor superfamily member 10b |
multiple interactions |
EXP |
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [panobinostat promotes the reaction [resveratrol results in increased expression of TNFRSF10B protein]]; panobinostat promotes the reaction [resveratrol results in increased expression of TNFRSF10B protein] |
CTD |
PMID:22923501 |
|
NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF11B mRNA panobinostat results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFRSF12A |
TNF receptor superfamily member 12A |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA panobinostat results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383
|
|
G |
TNFRSF19 |
TNF receptor superfamily member 19 |
increases expression |
EXP |
Panobinostat results in increased expression of TNFRSF19 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr13:23,570,412...23,676,093
Ensembl chr13:23,570,370...23,676,104
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of TNFSF10 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA panobinostat results in increased expression of TNFSF11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TNFSF9 |
TNF superfamily member 9 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:6,531,026...6,535,924
Ensembl chr19:6,531,026...6,535,924
|
|
G |
TNIK |
TRAF2 and NCK interacting kinase |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA panobinostat results in increased expression of TNIK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:171,058,414...171,460,408
Ensembl chr 3:171,058,414...171,460,408
|
|
G |
TNN |
tenascin N |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA panobinostat results in increased expression of TNN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:175,067,833...175,148,075
Ensembl chr 1:175,067,833...175,148,075
|
|
G |
TNRC6B |
trinucleotide repeat containing adaptor 6B |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of TNRC6B mRNA |
CTD |
PMID:21791302 |
|
NCBI chr22:40,044,834...40,335,808
Ensembl chr22:40,044,817...40,335,808
|
|
G |
TOX |
thymocyte selection associated high mobility group box |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA panobinostat results in increased expression of TOX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:58,805,412...59,119,147
Ensembl chr 8:58,805,412...59,119,147
|
|
G |
TOX2 |
TOX high mobility group box family member 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA panobinostat results in decreased expression of TOX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:43,914,852...44,069,616
Ensembl chr20:43,914,852...44,069,616
|
|
G |
TOX3 |
TOX high mobility group box family member 3 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA panobinostat results in decreased expression of TOX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:52,436,416...52,547,802
Ensembl chr16:52,436,417...52,547,802
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions increases acetylation |
EXP |
[panobinostat co-treated with SRT2183] results in increased acetylation of TP53 protein panobinostat results in increased acetylation of TP53 protein |
CTD |
PMID:23681230 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TP63 |
tumor protein p63 |
increases expression |
EXP |
panobinostat results in increased expression of TP63 protein alternative form |
CTD |
PMID:20043870 |
|
NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276
|
|
G |
TPBG |
trophoblast glycoprotein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:82,362,983...82,367,420
Ensembl chr 6:82,363,206...82,367,420
|
|
G |
TPD52L1 |
TPD52 like 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA panobinostat results in increased expression of TPD52L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:125,153,773...125,264,407
Ensembl chr 6:125,119,049...125,264,407
|
|
G |
TRABD2B |
TraB domain containing 2B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRABD2B mRNA panobinostat results in increased expression of TRABD2B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:47,760,528...47,997,385
Ensembl chr 1:47,760,528...47,997,385
|
|
G |
TRIM14 |
tripartite motif containing 14 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA panobinostat results in increased expression of TRIM14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:98,035,797...98,119,222
Ensembl chr 9:98,069,275...98,119,222
|
|
G |
TRIM38 |
tripartite motif containing 38 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA panobinostat results in increased expression of TRIM38 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:25,962,802...25,991,231
Ensembl chr 6:25,962,802...25,991,231
|
|
G |
TRIM6 |
tripartite motif containing 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA panobinostat results in increased expression of TRIM6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:5,596,111...5,612,952
Ensembl chr11:5,596,109...5,612,958
|
|
G |
TRIM69 |
tripartite motif containing 69 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA panobinostat results in increased expression of TRIM69 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:44,736,528...44,767,827
Ensembl chr15:44,728,988...44,767,829
|
|
G |
TRIM8 |
tripartite motif containing 8 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of TRIM8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of TRIM8 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr10:102,644,479...102,658,319
Ensembl chr10:102,642,503...102,658,318
|
|
G |
TRIM9 |
tripartite motif containing 9 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM9 mRNA panobinostat results in increased expression of TRIM9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:50,975,266...51,095,105
Ensembl chr14:50,975,262...51,096,061
|
|
G |
TRNP1 |
TMF1 regulated nuclear protein 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA panobinostat results in increased expression of TRNP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,993,692...27,000,886
Ensembl chr 1:26,993,692...27,000,886
|
|
G |
TRPC2 |
transient receptor potential cation channel subfamily C member 2 (pseudogene) |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of TRPC2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr11:3,626,460...3,637,559
Ensembl chr11:3,616,679...3,637,549 Ensembl chr11:3,616,679...3,637,549
|
|
G |
TRPC4 |
transient receptor potential cation channel subfamily C member 4 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA panobinostat results in decreased expression of TRPC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:37,632,063...37,869,772
Ensembl chr13:37,632,063...37,869,802
|
|
G |
TRPC6 |
transient receptor potential cation channel subfamily C member 6 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA panobinostat results in increased expression of TRPC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:101,451,564...101,584,007
Ensembl chr11:101,451,564...101,872,562
|
|
G |
TRPS1 |
transcriptional repressor GATA binding 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA panobinostat results in increased expression of TRPS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:115,408,496...115,668,975
Ensembl chr 8:115,408,496...115,809,673
|
|
G |
TSHZ2 |
teashirt zinc finger homeobox 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:52,972,358...53,495,330
Ensembl chr20:52,972,358...53,495,330
|
|
G |
TSPO |
translocator protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA panobinostat results in increased expression of TSPO mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr22:43,151,559...43,163,242
Ensembl chr22:43,151,547...43,163,242
|
|
G |
TSPOAP1 |
TSPO associated protein 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of TSPOAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:58,301,231...58,328,795
Ensembl chr17:58,301,228...58,328,795
|
|
G |
TSPOAP1-AS1 |
TSPOAP1, SUPT4H1 and RNF43 antisense RNA 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA panobinostat results in decreased expression of TSPOAP1-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:58,325,450...58,353,727
Ensembl chr17:58,324,472...58,415,766
|
|
G |
TTC29 |
tetratricopeptide repeat domain 29 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA panobinostat results in increased expression of TTC29 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:146,706,617...146,945,864
Ensembl chr 4:146,706,617...146,945,882
|
|
G |
TTLL6 |
tubulin tyrosine ligase like 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:48,762,234...48,817,229
Ensembl chr17:48,762,234...48,817,229
|
|
G |
TUBA1A |
tubulin alpha 1a |
decreases expression |
ISO |
panobinostat results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr12:49,184,795...49,189,080
Ensembl chr12:49,184,686...49,189,324
|
|
G |
TUBB2A |
tubulin beta 2A class IIa |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA panobinostat results in increased expression of TUBB2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:3,153,666...3,157,544
Ensembl chr 6:3,153,497...3,157,544
|
|
G |
TULP4 |
TUB like protein 4 |
increases expression |
EXP |
Panobinostat results in increased expression of TULP4 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:158,232,195...158,511,828
Ensembl chr 6:158,232,236...158,511,828
|
|
G |
TVP23A |
trans-golgi network vesicle protein 23 homolog A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TVP23A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:10,757,318...10,818,794
Ensembl chr16:10,760,919...10,818,794
|
|
G |
TWIST1 |
twist family bHLH transcription factor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA panobinostat results in increased expression of TWIST1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:19,113,047...19,117,636
Ensembl chr 7:19,020,991...19,117,636
|
|
G |
UGT2B28 |
UDP glucuronosyltransferase family 2 member B28 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:69,280,475...69,295,050
Ensembl chr 4:69,280,475...69,295,050
|
|
G |
UGT3A1 |
UDP glycosyltransferase family 3 member A1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:35,951,006...36,001,022
Ensembl chr 5:35,951,006...36,001,028
|
|
G |
UGT8 |
UDP glycosyltransferase 8 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA panobinostat results in increased expression of UGT8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:114,598,402...114,678,225
Ensembl chr 4:114,598,770...114,678,225
|
|
G |
UNC5A |
unc-5 netrin receptor A |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of UNC5A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UNC5A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:176,810,559...176,880,898
Ensembl chr 5:176,810,519...176,880,898
|
|
G |
UNC5C |
unc-5 netrin receptor C |
multiple interactions increases expression affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of UNC5C mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5C mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of UNC5C mRNA] panobinostat results in increased expression of UNC5C mRNA panobinostat affects the expression of UNC5C mRNA |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 4:95,162,504...95,548,973
Ensembl chr 4:95,162,504...95,549,206
|
|
G |
UQCC2 |
ubiquinol-cytochrome c reductase complex assembly factor 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UQCC2 mRNA panobinostat results in decreased expression of UQCC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:33,696,764...33,711,700
Ensembl chr 6:33,694,293...33,711,727
|
|
G |
USP28 |
ubiquitin specific peptidase 28 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA panobinostat results in increased expression of USP28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:113,797,875...113,875,572
Ensembl chr11:113,797,874...113,875,572
|
|
G |
USP43 |
ubiquitin specific peptidase 43 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:9,645,260...9,729,687
Ensembl chr17:9,644,698...9,729,687
|
|
G |
USP49 |
ubiquitin specific peptidase 49 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP49 mRNA panobinostat results in decreased expression of USP49 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:41,789,896...41,895,375
Ensembl chr 6:41,789,896...41,895,375
|
|
G |
UST |
uronyl 2-sulfotransferase |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of UST mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:148,747,030...149,076,990
Ensembl chr 6:148,747,030...149,076,990
|
|
G |
UTF1 |
undifferentiated embryonic cell transcription factor 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA panobinostat results in increased expression of UTF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:133,230,217...133,231,558
Ensembl chr10:133,230,217...133,231,558
|
|
G |
VAMP7 |
vesicle associated membrane protein 7 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of VAMP7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:155,881,345...155,943,769 NCBI chr Y:57,067,865...57,130,289
Ensembl chr Y:57,067,865...57,130,289 Ensembl chr X:57,067,865...57,130,289
|
|
G |
VAMP8 |
vesicle associated membrane protein 8 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of VAMP8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:85,577,586...85,582,031
Ensembl chr 2:85,561,562...85,582,031
|
|
G |
VAPA |
VAMP associated protein A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA panobinostat results in decreased expression of VAPA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:9,914,016...9,960,021
Ensembl chr18:9,914,016...9,960,021
|
|
G |
VASH2 |
vasohibin 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA panobinostat results in increased expression of VASH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:212,950,541...212,991,585
Ensembl chr 1:212,950,520...212,992,037
|
|
G |
VCX |
variable charge X-linked |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of VCX mRNA |
CTD |
PMID:21791302 |
|
NCBI chr X:7,842,262...7,844,143
Ensembl chr X:7,842,262...7,844,143
|
|
G |
VCX3A |
variable charge X-linked 3A |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of VCX3A mRNA |
CTD |
PMID:21791302 |
|
NCBI chr X:6,533,618...6,535,118
Ensembl chr X:6,533,618...6,535,118
|
|
G |
VENTX |
VENT homeobox |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA panobinostat results in increased expression of VENTX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:133,237,855...133,241,928
Ensembl chr10:133,237,855...133,241,928
|
|
G |
VEPH1 |
ventricular zone expressed PH domain containing 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA panobinostat results in increased expression of VEPH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:157,259,742...157,503,605
Ensembl chr 3:157,259,742...157,533,619
|
|
G |
VGLL1 |
vestigial like family member 1 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA panobinostat results in increased expression of VGLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:136,532,215...136,556,799
Ensembl chr X:136,532,215...136,556,807
|
|
G |
VGLL3 |
vestigial like family member 3 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of VGLL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:86,937,973...86,991,149
Ensembl chr 3:86,876,388...86,991,149
|
|
G |
WDR72 |
WD repeat domain 72 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WDR72 mRNA panobinostat results in increased expression of WDR72 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:53,513,741...53,762,878
Ensembl chr15:53,513,741...53,762,878
|
|
G |
WFDC2 |
WAP four-disulfide core domain 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA panobinostat results in increased expression of WFDC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:45,469,753...45,481,532
Ensembl chr20:45,469,753...45,481,532
|
|
G |
WLS |
Wnt ligand secretion mediator |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WLS mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:68,098,459...68,232,546
Ensembl chr 1:68,098,473...68,233,120
|
|
G |
WNT10B |
Wnt family member 10B |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT10B mRNA panobinostat results in increased expression of WNT10B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:48,965,340...48,971,735
Ensembl chr12:48,965,340...48,971,735
|
|
G |
WNT3 |
Wnt family member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA Panobinostat results in increased expression of WNT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:46,762,506...46,818,692
Ensembl chr17:46,762,506...46,833,154
|
|
G |
WNT4 |
Wnt family member 4 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA panobinostat results in increased expression of WNT4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:22,117,313...22,143,097
Ensembl chr 1:22,117,313...22,143,969
|
|
G |
WNT5A |
Wnt family member 5A |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5A mRNA panobinostat results in decreased expression of WNT5A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539
|
|
G |
WNT5B |
Wnt family member 5B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA panobinostat results in decreased expression of WNT5B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:1,617,056...1,647,212
Ensembl chr12:1,529,891...1,647,212
|
|
G |
WNT6 |
Wnt family member 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:218,859,805...218,874,233
Ensembl chr 2:218,859,805...218,874,233
|
|
G |
WNT8A |
Wnt family member 8A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:138,077,367...138,092,365
Ensembl chr 5:138,083,990...138,092,365
|
|
G |
WWC1 |
WW and C2 domain containing 1 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of WWC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:168,291,645...168,472,303
Ensembl chr 5:168,291,645...168,472,303
|
|
G |
XCL1 |
X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of XCL1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:168,576,605...168,582,069
Ensembl chr 1:168,576,605...168,582,069
|
|
G |
XCL2 |
X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of XCL2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:168,540,768...168,543,997
Ensembl chr 1:168,540,768...168,543,997
|
|
G |
XKR4 |
XK related 4 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKR4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:55,102,028...55,542,054
Ensembl chr 8:55,102,028...55,542,054
|
|
G |
XKRX |
XK related X-linked |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XKRX mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:100,886,916...100,959,343
Ensembl chr X:100,913,445...100,929,433
|
|
G |
YAP1 |
Yes1 associated transcriptional regulator |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of YAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:102,110,447...102,233,424
Ensembl chr11:102,110,447...102,233,424
|
|
G |
YPEL1 |
yippee like 1 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr22:21,697,536...21,735,794
Ensembl chr22:21,697,536...21,735,794
|
|
G |
ZBTB1 |
zinc finger and BTB domain containing 1 |
decreases expression |
EXP |
Panobinostat results in decreased expression of ZBTB1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr14:64,503,716...64,533,693
Ensembl chr14:64,503,712...64,533,690
|
|
G |
ZBTB16 |
zinc finger and BTB domain containing 16 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA panobinostat results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:114,059,711...114,256,770
Ensembl chr11:114,059,041...114,256,765
|
|
G |
ZC3H12C |
zinc finger CCCH-type containing 12C |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ZC3H12C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:110,093,392...110,171,841
Ensembl chr11:110,093,392...110,171,841
|
|
G |
ZC3H6 |
zinc finger CCCH-type containing 6 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:112,275,597...112,340,059
Ensembl chr 2:112,275,597...112,340,059
|
|
G |
ZEB1 |
zinc finger E-box binding homeobox 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ZEB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814
|
|
G |
ZFHX4-AS1 |
ZFHX4 antisense RNA 1 |
increases expression |
EXP |
panobinostat results in increased expression of ZFHX4-AS1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:76,610,879...76,683,275
Ensembl chr 8:76,491,200...76,683,504
|
|
G |
ZFP14 |
ZFP14 zinc finger protein |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA panobinostat results in decreased expression of ZFP14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:36,334,453...36,379,201
Ensembl chr19:36,334,453...36,379,201
|
|
G |
ZFP2 |
ZFP2 zinc finger protein |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:178,895,913...178,933,212
Ensembl chr 5:178,895,898...178,933,212
|
|
G |
ZFP36L2 |
ZFP36 ring finger protein like 2 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA panobinostat results in increased expression of ZFP36L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:43,222,402...43,226,606
Ensembl chr 2:43,222,402...43,226,606
|
|
G |
ZFP42 |
ZFP42 zinc finger protein |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA panobinostat results in increased expression of ZFP42 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:187,995,771...188,005,246
Ensembl chr 4:187,995,771...188,005,046
|
|
G |
ZFY |
zinc finger protein Y-linked |
decreases expression |
EXP |
Panobinostat results in decreased expression of ZFY mRNA |
CTD |
PMID:33770205 |
|
NCBI chr Y:2,935,381...2,982,506
Ensembl chr Y:2,935,281...2,982,506
|
|
G |
ZIC1 |
Zic family member 1 |
multiple interactions |
EXP |
[Cisplatin co-treated with panobinostat] affects the expression of ZIC1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:147,409,365...147,416,719
Ensembl chr 3:147,393,422...147,510,293
|
|
G |
ZIC3 |
Zic family member 3 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA panobinostat results in increased expression of ZIC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:137,566,127...137,577,691
Ensembl chr X:137,566,127...137,577,691
|
|
G |
ZMYM2 |
zinc finger MYM-type containing 2 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZMYM2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:19,863,840...20,089,115
Ensembl chr13:19,958,677...20,091,829
|
|
G |
ZMYND8 |
zinc finger MYND-type containing 8 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZMYND8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZMYND8 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr20:47,209,214...47,356,699
Ensembl chr20:47,209,214...47,356,889
|
|
G |
ZNF165 |
zinc finger protein 165 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ZNF165 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:28,080,282...28,089,563
Ensembl chr 6:28,080,568...28,089,563
|
|
G |
ZNF280C |
zinc finger protein 280C |
increases expression |
EXP |
Panobinostat results in increased expression of ZNF280C mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:130,202,707...130,268,899
Ensembl chr X:130,202,707...130,268,899
|
|
G |
ZNF287 |
zinc finger protein 287 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:16,546,954...16,569,212
Ensembl chr17:16,546,954...16,569,204
|
|
G |
ZNF385B |
zinc finger protein 385B |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA panobinostat results in decreased expression of ZNF385B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:179,441,982...179,861,612
Ensembl chr 2:179,441,982...179,861,612
|
|
G |
ZNF385D |
zinc finger protein 385D |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA panobinostat results in decreased expression of ZNF385D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:21,412,218...22,372,763
Ensembl chr 3:21,412,218...22,373,321
|
|
G |
ZNF436 |
zinc finger protein 436 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA panobinostat results in decreased expression of ZNF436 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:23,359,448...23,369,836
Ensembl chr 1:23,359,448...23,369,836
|
|
G |
ZNF436-AS1 |
ZNF436 antisense RNA 1 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ZNF436-AS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:23,368,971...23,371,839
Ensembl chr 1:23,368,939...23,371,839
|
|
G |
ZNF462 |
zinc finger protein 462 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF462 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF462 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 9:106,860,158...107,013,634
Ensembl chr 9:106,863,166...107,013,634
|
|
G |
ZNF483 |
zinc finger protein 483 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF483 mRNA panobinostat results in decreased expression of ZNF483 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:111,525,179...111,578,136
Ensembl chr 9:111,525,159...111,577,844
|
|
G |
ZNF503 |
zinc finger protein 503 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA panobinostat results in decreased expression of ZNF503 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:75,279,725...75,401,916
Ensembl chr10:75,397,830...75,401,764
|
|
G |
ZNF503-AS2 |
ZNF503 antisense RNA 2 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA panobinostat results in decreased expression of ZNF503-AS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:75,401,528...75,408,982
Ensembl chr10:75,401,519...75,408,982
|
|
G |
ZNF519 |
zinc finger protein 519 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA panobinostat results in decreased expression of ZNF519 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:14,071,121...14,132,435
Ensembl chr18:14,057,457...14,132,490
|
|
G |
ZNF521 |
zinc finger protein 521 |
decreases expression multiple interactions |
EXP |
panobinostat results in decreased expression of ZNF521 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:25,061,924...25,352,166
Ensembl chr18:25,061,924...25,352,190
|
|
G |
ZNF600 |
zinc finger protein 600 |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ZNF600 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:52,764,164...52,833,645
Ensembl chr19:52,749,942...52,786,807
|
|
G |
ZNF750 |
zinc finger protein 750 |
multiple interactions increases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA panobinostat results in increased expression of ZNF750 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:82,829,434...82,840,022
Ensembl chr17:82,829,434...82,840,022
|
|
G |
ZNF785 |
zinc finger protein 785 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA panobinostat results in decreased expression of ZNF785 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:30,578,361...30,585,697
Ensembl chr16:30,573,740...30,585,769
|
|
G |
ZNF804A |
zinc finger protein 804A |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF804A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:184,598,529...184,939,492
Ensembl chr 2:184,598,529...184,939,492
|
|
G |
ZNF827 |
zinc finger protein 827 |
multiple interactions affects expression |
EXP |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF827 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF827 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 4:145,757,627...145,938,823
Ensembl chr 4:145,757,627...145,938,823
|
|
G |
ZNF93 |
zinc finger protein 93 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA panobinostat results in decreased expression of ZNF93 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:19,900,946...19,935,575
Ensembl chr19:19,900,913...19,963,464
|
|
G |
ZRANB3 |
zinc finger RANBP2-type containing 3 |
multiple interactions |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZRANB3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:135,196,969...135,531,218
Ensembl chr 2:135,136,916...135,531,218
|
|
G |
ZSCAN16-AS1 |
ZSCAN16 antisense RNA 1 |
multiple interactions decreases expression |
EXP |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA panobinostat results in decreased expression of ZSCAN16-AS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:28,121,795...28,137,316
Ensembl chr 6:28,015,122...28,137,313
|
|
G |
ZYG11A |
zyg-11 family member A, cell cycle regulator |
increases expression multiple interactions |
EXP |
panobinostat results in increased expression of ZYG11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:52,842,760...52,894,998
Ensembl chr 1:52,842,511...52,894,998
|
|